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Exploring the genetic landscape of complex diseases using the recessive model 
 
ABSTRACT 
 
 High-throughput sequencing technologies have changed the way we identify, study and 
understand the role of rare variation in Mendelian diseases. Sequencing in complex diseases have 
proven to be more challenging to interpret, but methods and approaches are being developed to 
aid in our understanding of variation in these diseases. 
 In this dissertation, we have sought to interpret and understand the role of rare (<1% 
allele frequency) and low-frequency (1-5% allele frequency) variants in the genetic etiologies of 
complex diseases such as autism. We compared the rates of rare 2-hit (homozygous and 
compound heterozygous) loss-of-function variants in ~1,000 autism cases and ~1,000 controls 
and discovered an excess of such events in the cases, suggesting that ~5% of cases might harbor 
a rare 2-hit loss-of-function variant that confers risk for their disorder. 
 Next, we developed a novel statistical method (RAFT) and discovered 3 individuals with 
autism and intellectual disability who harbor rare homozygous missense mutations in the 
cholesterol biosynthesis gene DHCR24. We adapted a yeast biochemical assay to understand the 
efficiency of cholesterol synthesis for these missense variants in DHCR24, as well as a 
population survey of all missense variants from 4,300 European Americans. 
 Finally, we utilized the unique genetic architecture as a result of bottlenecks by 
demonstrating that such populations are enriched for rare deleterious variants that might have 
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important medical consequences. By genotyping 83 loss-of-function variants in 36,000 Finns, we 
discovered several associations, including a strong protective association between LPA and 
coronary heart disease, suggesting that knocking out LPA might prove to be an effective drug 
target in humans. 
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CHAPTER 1 
Introduction 
 
  
2 
 
A PREAMBLE 
Genetic mapping in the 1980s 
In 1983, James Gusella and his colleagues first discovered a polymorphic DNA marker 
on 4p16.3 associated with Huntington’s disease through the use of a then-new technology called 
restriction fragment length polymorphism (RFLP) genotyping and linkage analysis in 2 families 
[1]. It took nearly a decade of research before scientists identified the gene (Huntingtin; HTT) 
and the trinucleotide repeat (CAG)n in HTT cause the disease [2]. Shortly thereafter, a series of 
genetic studies into various diseases using similar technologies soon discovered the mutations 
and causal genes involved in human diseases, such as ∆F508 in the Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) gene involved in cystic fibrosis [3]. The 
statistical evaluation for these linkage studies were laid decades earlier when Newton Morton 
derived a score for calculating the logarithm of the odds, or the LOD score for evaluating the 
significance of genetic discoveries from linkage studies in pedigrees in 1955 [4].  
The invention of new technologies is often quickly accompanied by a wave of new 
methods and approaches for genetic mapping and statistical evaluation of genetic discoveries. By 
1987, in anticipation of a complete RFLP linkage map of the human genome, Eric Lander and 
David Botstein introduced “homozygosity mapping” for mapping recessive genes in inbred 
families [5]. The concept behind the approach was to calculate the probability that an affected 
child with inbreeding coefficient F has homozygosity by descent at a disease allele with 
frequency q is 𝐹𝑞
𝐹𝑞+(1−𝐹)𝑞2. Subsequent papers by Eric Lander, Nicholas Schork and Leonid 
Kruglyak demonstrated that a LOD score of 3.3 instead of 3 is required to achieve a genome-
wide false positive rate of 5% [6,7]. However, the likelihood computations in traditional linkage 
calculations increase exponentially with the number of loci and haplotypes, so methods such as 
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the Elston–Stewart and Lander-Green algorithms were devised to calculating the likelihoods in 
pedigrees [8,9]. In 1995, a model for calculating recessive LOD score was also proposed and 
implemented [10]. To-date, tools such as homozygosity mapping, LOD score calculations and 
the genome-wide significance LOD score threshold of 3.3 have been widely adopted by human 
geneticists for mapping genes underlying recessive diseases in consanguineous populations 
[11,12,13]. 
 
Genetic mapping in the early 21th century 
 In 2005, shortly after the completion of the Human Genome Project, the HapMap Project 
was completed with several groups involved in characterizing naturally occurring human 
variation in diverse populations [14]. This resulted in the development and use of single 
nucleotide polymorphism (SNP) genotyping arrays, as well as copy number variant (CNV) 
genotyping arrays. As the development of the arrays proceeded with increasing density of the 
markers, as well as figuring out the optimal lengths of the oligonucleotides, the development of 
tools and methods for the discovery of variants associated with various diseases proceeded as 
well. One of the earliest genome-wide studies was a “transmission test for linkage 
disequilibrium” (TDT) performed using 290 autosomal microsatellite markers for a Mendelian 
disease Saguenay-Lac-Saint-Jean cytochrome oxidase deficiency and the authors discovered an 
genome-wide linkage disequilibrium region on chromosome 2p16 with a p-value of 1.2 × 10-5 
[15]. The first successful genome-wide association study (GWAS) in a complex disease was 
performed in 2005 using a chi-squared test on the allele frequencies of 116,204 SNPs in 96 
European cases with age-related macular degeneration and 50 controls [16]. The authors 
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discovered 2 significantly-associated SNPs in the intron of the complement factor H (CFH) gene 
that surpassed the study-wide significance threshold of 4.8 × 10-7.  
Several methodologies and standards such as the use of genomic control [17] to evaluate 
spurious associations driven by population stratification between cases and controls were 
developed and adopted for these GWAS. To-date, several case-control association studies have 
been performed for various common diseases and traits such as height [18]. An alternative 
approach was developed in 1993 by Spielman et al. called the TDT (as mentioned earlier) [19]. 
In short, TDT counts the number of transmitted and untransmitted alleles from heterozygous 
unaffected parents to heterozygous affected children and uses the McNemar’s chi-squared test 
statistic to evaluate probability. One advantage in performing TDT as compared to the case-
control GWAS tests is that TDT is not affected by population stratification – that is, systematic 
ancestry differences between cases and controls that can confound case-control association 
studies.  
An early GWAS performed in 2009 for schizophrenia with 3,322 cases and 3,587 
controls did not discover any loci with genome-wide significance [20], but a subsequent GWAS 
study in 2013 with 8,832 schizophrenia cases and 12,067 controls discovered 13 significant loci 
[21]. While GWAS using SNP genotyping arrays has been successful for several complex 
diseases and traits such as height where hundreds of loci have been discovered to contribute to 
the phenotype [18], GWAS has not yet worked for some complex disorders such as autism. To-
date, no single significant locus from GWAS in autism has been successfully replicated across 
different studies [22,23,24]. However, a recent study has estimated the contribution of common 
variants in autism to be ~40% for simplex families and ~60% for multiplex families [25], 
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suggesting that common variants associated with autism should be discovered with larger sample 
sizes.  
However, the widespread ease and use of the CNV genotyping arrays led to a series of 
groundbreaking discoveries on the importance of recurrent de novo deletions and duplications 
associated with autism [26]. In 2009, Jonathan Sebat and Michael Wigler performed a genome-
wide scan on 85,000 probes in 264 families and observed a 10-fold excess of de novo CNVs in 
individuals with sporadic autism (that is, there is only 1 affected individual in the family), and a 
3-fold excess of de novo CNVs in affected individuals with another affected first-degree relative. 
While the authors could not identify any specific CNV associated with risk for autism, they 
discovered the importance of de novo CNVs with autism (P = 0.0005). Recent studies using 
microarrays with more probes and larger sample sizes on >500 families have implicated specific 
de novo loci such as 16p11.2 with autism [27,28,29]. A subsequent study using CNV genotyping 
arrays on 104 Middle Eastern families has also implicated the role of rare recessive copy number 
variants with autism, although no specific locus could be identified with confidence [13]. While 
the role of de novo and rare inherited CNVs have been associated with increased risk for autism, 
some of these CNVs span across regions as large as several megabases long and across tens of 
genes. As such, it has been difficult to pinpoint specific genes underlying some of these CNVs 
that are associated with autism. 
 
Genetic mapping in post-2009 for Mendelian diseases 
More recently, in the era of post-GWAS performed using SNP and CNV arrays, human 
geneticists have recently adopted a range of methodologies for studying disease genetics through 
the use of whole-genome sequencing or whole-exome sequencing, which has revolutionized the 
6 
 
field of human genetics, especially for the discovery of rare variants with large effects. As an 
example, we revisit a landmark paper in 2009 when Ng et al. sequenced 8 control individuals 
from HapMap and 4 individuals with a dominant disease called Freeman-Sheldon syndrome, 
caused by mutations in MYH3 and as a proof-of-concept, demonstrated that they were able to re-
discover MYH3 as the causal gene using whole-exome sequencing [30]. Subsequently, more 
causal genes in various Mendelian diseases were identified [31,32]. To-date, whole-exome 
sequencing has been used routinely to identify novel genes that are involved in rare Mendelian 
diseases [33,34,35,36]. A pilot study to evaluate the utility of using whole-exome sequencing to 
diagnose 250 probands with a range of neuro-developmental phenotypes discovered that 
approximately 25% of the probands were able to obtain a genetic diagnosis [37], highlighting the 
potential importance of exome sequencing in the near future for clinical diagnosis of rare 
Mendelian diseases. We have been involved in helping clinical collaborators with mapping novel 
genes and variants for various recessive Mendelian diseases such as neuronal ceroid 
lipofuscinosis, where we found a novel causal gene in the potassium channel tetramerization 
domain-containing protein 7 (KCTD7) gene [34], diacylglycerol acyl transferase 1 (DGAT1) in 
infantile enteropathy [33], as well as digenic mutations in OTUD4 and RNF216 in ataxia and 
hypogonadism [35]. 
 
GENETIC MAPPING IN COMPLEX DISEASES AND TRAITS 
Initial studies using whole-exome sequencing in complex diseases and traits such as 
combined hypolipidemia, adopted similar screening and filtering strategies as those used for 
Mendelian diseases. This was motivated by the assumption that complex diseases might be 
driven by several rare variants and genes of large effects, similar to the causal variants and genes 
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found in Mendelian diseases. This assumption was supported by earlier work that discovered 
variants of large effects in complex diseases and traits, such as the proprotein convertase 
subtilisin/kexin type 9 (PCSK9) gene. A linkage study performed in 2003 on a large pedigree 
with 35 individuals discovered a missense mutation (S127R) in PCSK9 that was associated with 
hypercholesterolemia and increased risk for coronary heart disease [38]. In 2005, Cohen et al. 
tested the hypothesis if loss-of-function mutations in PCSK9 have a similar or opposite effect as 
the S127R mutation and sequenced the coding regions of the gene in 198 African-Americans, 
and discovered 2 nonsense mutations (Y142X and C679X) that were associated with reduced 
levels of circulating low-density lipoprotein (LDL), thus potentially reducing risk for coronary 
heart disease [39]. This was subsequently proven in a later study [40]. 
Similarly, in 2009, Musunuru et al. performed whole-exome sequencing on 2 probands 
from a large pedigree of 38 individuals with combined hypolipidemia, characterized by low 
levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides, and 
discovered compound heterozygous loss-of-function variants in the angiopoietin-like 3 protein 
(ANGPTL3), suggesting that similar to the loss-of-function variants in PCSK9, loss-of-function 
variants in ANGPTL3 might potentially reduce risk for coronary heart disease as well [41]. 
However, such studies proved to be extremely rare success stories in complex disease genetics. 
In reality, whole-exome sequencing has proven to be more challenging for discovering novel or 
causal genes and variants underlying risk for complex diseases such as autism and schizophrenia.  
 
Whole-exome sequencing to discover rare polygenic and de novo variants 
A recent study with whole-exome sequencing of ~2,500 schizophrenia cases and ~2,500 
controls conducted by Purcell et al. demonstrated that while there are certain sets of genes such 
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as activity-regulated cytoskeleton-associated scaffold protein and targets of the fragile X mental 
retardation protein (FMRP) that were enriched for mutations in the cases, they could not detect 
evidence for specific genes or rare alleles (0.5-1% allele frequencies) with large effects [42]. In a 
recent 2014 study by Yingleong Chan and Joel Hirschhorn, they developed a novel method for 
detecting rare polygenic signals from summary results obtained in GWAS of various common 
diseases [43]. The approach utilizes the observation that rare risk variants are easier to detect 
than rare protective variants in a case-control study. Using their approach, Chan et al. 
demonstrated that there are strong rare (<1% allele frequency) and low-frequency (1-5% allele 
frequency) polygenic signals involved in conferring risk for schizophrenia, consistent with the 
observation that schizophrenia is highly polygenic and that there are rare and low-frequency 
variants to be discovered in the future with larger sequencing studies. 
Similarly, a study involving whole-exome sequencing of ~1,000 autism cases and ~1,000 
controls did not uncover evidence for specific genes or variants involved in autism [44]. And 
subsequently, a larger study by Lee et al. with almost 5,000 autism cases and more than 10,000 
parental and population controls using exome chip genotyping, which involves genotyping a 
subset of variants discovered from whole-exome sequencing, did not uncover evidence for 
specific genes or variants either (unpublished). However, using the same method developed by 
Chan et al., the authors found a strong rare and low-frequency polygenic signal in autism, again 
suggesting that larger sample sizes are needed for gene and variant discovery. In epilepsy 
genetics, whole-exome sequencing in ~900 cases and ~2,000 controls did not identify rare 
variants of large effects as well [45]. 
On the other hand, an initial study in 2011 explored the role of de novo point mutations 
from whole-exome sequencing data on 20 trios with autism and discovered 4 potentially 
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interesting genes (GRIN2B, LAMC3, FOXP1, SCN1A) [46]. Subsequent studies with almost 
1,000 trios discovered a strong contribution from de novo loss-of-function variants in autism and 
provided evidence for specific genes such as SCN2A, CHD8, CTNNB1 and DYRK1A involved in 
autism risk [47,48,49,50]. Whole-exome sequencing to identify de novo point mutations 
involved in intellectual disability and epilepsy have also proven to be fruitful and have 
implicated several genes such as GABRB3, CACNA1A, CHD2, FLNA, GABRA1, GRIN1, 
GRIN2B, HNRNPU, IQSEC2, MTOR and NEDD4L [51,52]. On the other hand, whole-exome 
sequencing studies to identify de novo point mutations have not successfully identified specific 
genes in other complex diseases such as schizophrenia [53]. However, it is worth noting that for 
intellectual disability, autism and epilepsy, clear excesses of de novo point mutations have been 
identified in the cases compared to unaffected siblings or controls, whereas such an excess has 
not been observed for schizophrenia. 
 
AUTISM GENETICS 
Using autism genetics as an example, previous literature has demonstrated that de novo 
CNVs have been shown to contribute an estimated 10-15% risk to autism and specific loci such 
as 16p11.2 have been robustly associated with autism risk [28,29]. Homozygous CNVs have also 
been shown to play a role in autism [13], although Middle Eastern consanguineous families were 
used in the study and it is unclear how much these homozygous CNVs could account for in an 
out-bred European population. On the other hand, common SNPs have been estimated to 
contribute 40% risk to autism, although no single locus has been robustly discovered [25]. Rare 
polygenic inheritance have also been discovered to contribute to autism risk (unpublished), 
although no specific locus can be implicated and it is unclear what the contribution of such 
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variation is to autism. More recently, de novo point mutations discovered from whole-exome 
sequencing have been estimated to contribute 20-50% risk to autism and specific recurrent genes 
have been discovered [47,48,49,50]. 
 
Addressing heritability and gender bias in autism 
However, as we have learnt from Mendelian genetics, there are several modes of 
inheritance involved in disease etiologies, such as the de novo or dominant, recessive, as well as 
X-linked dominant and recessive models. These studies to identify de novo mutations in autism 
do not address a fundamental question about the high heritability of autism (h2 ~ 0.8) and that 
there are many families with multiple affected children. In addition, a second interesting 
observation is that there are typically 4 affected males for every affected female with autism, and 
this observation cannot be addressed by the de novo model in autism as such de novo point 
mutations and CNVs have been shown to occur in both genders equally [28,29,47,48,49,50]. In 
order to explore the role of inherited variation in autism, we tested the hypothesis if rare 
recessive variants have a significant role in autism (Chapter 2) and discovered that there is a ~2-
fold excess of rare (≤5% allele frequency) homozygous and compound heterozygous loss-of-
function variants on the autosomes in probands with autism and that this excess was present in 
genes found to be expressed in the brain. A similar excess was observed for rare (≤0.25%) 
hemizygous loss-of-function variants outside the pseudo-autosomal regions on the X-
chromosome in affected males compared to unaffected males. Collectively, we estimated a 
significant 5% contribution to autism from these “rare complete knockouts” of genes.  
Many of these genes were observed only once and we could not implicate specific genes 
in this study, similar to some of the earlier studies implicating the role of de novo CNVs and 
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point mutations. However, some of the candidate genes were reported as known disease-causing 
genes such as USH2A which causes deafness and blindness. We confirmed with the clinicians 
that the proband with compound heterozygous loss-of-function variants in USH2A had severe 
hearing problems, consistent with the phenotypic description for Usher Syndrome. The other 
genes were Fragile X E mental retardation syndrome protein (AFF2), KIAA2022 which was 
previously implicated in intellectual disability, Sushi-repeat containing protein, X-linked 2 
(SRPX2) involved in rolandic epilepsy and methyl CpG binding protein 2 (MECP2) involved in 
Rett Syndrome. It is worth noting that hemizygous loss-of-function mutations in MECP2 
typically result in death among males, so only females with Rett Syndrome are viable. However, 
the mutation we discovered in MECP2 truncates only the last 4 amino acids of the protein and is 
found to be heterozygous in the mother and hemizygous in the proband and his affected brother, 
potentially suggesting that this late-truncating mutation results in a largely functional protein and 
is viable in males. 
Our discovery of the autistic proband with compound heterozygous loss-of-function 
variants in USH2A also raised an interesting question regarding incidental discoveries through 
the use of whole-exome sequencing in research studies. The protocols and avenues for returning 
such findings from incidental discovery have yet to be defined and established. While the 
American College of Medical Genetics and Genomics (ACMG) has recently proposed a set of 
guidelines and genes for returning medically-actionable information to the patients [54], we note 
that USH2A is not among the list of genes listed by ACMG. However, given that the proband 
with the compound heterozygous loss-of-function variants in USH2A did have severe hearing 
loss, we reported the result back to the clinic that the patient had been enrolled at. Thereafter, the 
variants were confirmed in a CLIA lab and IRB was approached about returning information to 
12 
 
the primary care physician, and ultimately the patient, as the original consent for our research 
study had not included re-contacting or return of information to the participants. The finding was 
deemed actionable and ultimately, genetic counseling was provided to the family with respect to 
this genetic diagnosis. 
 
Other literature supporting the recessive model in autism 
 During the time when we were working on the manuscript for Chapter 2 and 
subsequently, other studies have also discovered an excess of runs of homozygosity in autism 
cases, further supporting a role for the recessive model in the disorder [55,56]. A pair of papers 
discovered initial evidence for specific genes that are potentially involved in conferring risk to 
autism in an autosomal recessive mode of inheritance, such as UBE3B, SYNE1 and AMT [11,12]. 
More recently, a paper provided conclusive evidence from 3 Middle Eastern families for the role 
of homozygous deleterious mutations in the branched chain ketoacid dehydrogenase kinase 
(BCKDK) with autism and epilepsy [57]. This work was of potential therapeutic interest as well, 
as the authors demonstrated that they were able to reverse the phenotype in mice with dietary 
supplementation. This provided evidence that a subset of individuals affected with autism can 
potentially benefit from a dietary treatment. However, recessive mutations in BCKDK are 
extremely rare outside the Middle Eastern families and no European individual with recessive 
mutations in BCKDK have been discovered thus far and this raises the question of whether such 
treatment can be generalized to help affected children outside the Middle Eastern populations. 
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The recessive model in other complex diseases 
 In collaboration with groups studying Type 2 diabetes and schizophrenia, we have also 
applied a similar approach to evaluate the contribution of the recessive model in these complex 
diseases. However, we did not observe any excess of rare or low-frequency recessive loss-of-
function variants in Type 2 diabetic cases or schizophrenia cases, even with larger sample sizes 
than our autism study (unpublished). This suggests that the recessive loss-of-function variants 
might not play a huge role in the genetic etiologies of such diseases, but these analyses do not 
rule out the possibility for some recessive variants or genes to confer risk in Type 2 diabetes or 
schizophrenia. 
 
Novel statistical test to identify rare recessive variants and genes 
In Chapter 3, we first developed a novel statistical test for identifying rare recessive 
variants in complex diseases. Power calculations showed that conventional statistical tests such 
as logistic regression or Fisher’s Exact Test on the homozygous counts were underpowered for 
detecting rare recessive variants <5% allele frequency. As such, we developed a test that 
increases the power for detection by utilizing the deviation from the expected probabilities of the 
homozygotes. The intuition behind the approach is that an observation of 5 cases that are 
homozygous for a rare variant with 0.1% allele frequency should be more unusual than an 
observation of 5 cases that are homozygous for a common variant with 10% allele frequency. We 
termed our statistical test as RAFT (for Recessive Allele Frequency-based Test). 
However, one issue with the RAFT test is that deviation from the expected probabilities 
is also indicative of genotyping errors (such as hybridization issues on SNP genotyping arrays) 
or misalignment errors from sequencing data, resulting in erroneous variant calls. As such, 
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stringent filtering and quality control steps are required and we have tested and developed a 
series of methodologies for identifying and removing such false positives. In addition, if the 
populations used in the study are of non-homogeneous populations (such as Finns and non-
Finnish Europeans), it can result in an excess of homozygosity for both rare and common 
variants. To address this, we have also formulated a series of analytic strategies for identifying 
such scenarios. 
 
Discovery of DHCR24 in autism 
We applied RAFT to an exome chip genotyping dataset comprising of ~1,000 unrelated 
probands with autism of European ancestry and ~2,000 unaffected parents as controls. In doing 
so, we discovered that the top hit was a rare (0.05% allele frequency) missense variant in the 24-
Dehydrocholesterol Reductase (DHCR24) gene that was highly conserved in 46 vertebrates and 
was predicted by PolyPhen2 to be deleterious, and that this rare missense variant segregated in 
an autosomal recessive manner in a family with 3 affected children. Subsequently, we discovered 
another 2 homozygous private missense variants in 2 Middle Eastern families with autism and 
intellectual disability. DHCR24 is a key enzyme involved in converting desmosterol into 
cholesterol in the liver and brain. In order to assess the pathogenicity of the missense variants, 
we adapted a yeast biochemical assay developed by Waterham et al. [58] and characterized the 
conversion rate of desmosterol to cholesterol for the 3 missense variants discovered from these 
families.  
These missense variants in DHCR24 were likely to result in loss-of-function for the gene 
and that we found fetal demises harboring nonsense and deleterious missense mutations, 
suggesting that knocking out both copies of DHCR24 is not tolerated in healthy humans. 
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However, it has been shown for a similar disorder Smith-Lemli-Opitz syndrome (SLOS) marked 
by low levels of cholesterol as a result of recessive mutations in the DHCR7 gene, that 
simvastatin or cholesterol supplementation such as egg yolks might aid in improving aberrant 
behavior [59]. However, a larger study has questioned the role of cholesterol supplementation in 
the treatment of individuals affected with SLOS, given that cholesterol supplementation does not 
typically cross the blood-brain barrier and that cholesterol synthesis in the brain occurs de novo 
[60]. 
 
Potentially treatable subsets of complex diseases 
 During the process of our work on the DHCR24 discovery, a notable paper on a 
suppressor screen in Rett Syndrome was published and highlighted a nonsense mutation in the 
Squalene monooxygenase (SQLE) gene that suppressed the Rett Syndrome phenotype in 
MECP2-null nice, thus presenting cholesterol-lowering drugs such as simvastatin as a potential 
treatment for individuals with Rett Syndrome [61]. Another important paper by Novarino et al. 
that discovered a potentially treatable subset of autism with recessive mutations in the BCKDK 
gene demonstrated that there might be a small number of individuals with deficiencies in key 
metabolic genes that result in severe to mild neuro-developmental disorders [57]. A third paper 
followed with Ruzzo et al. describing a rare form of intellectual disability caused by recessive 
mutations in the asparagine synthetase (ASNS) gene which catalyzes the synthesis of asparagine 
from glutamine and aspartate, suggesting that asparagine supplementation can potentially aid 
these affected individuals if treatment was performed early [62]. Together with our work on 
DHCR24, while these papers discovered potentially treatable subsets that account for only a 
small percentage of all individuals affected with autism and other neuro-developmental 
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disorders, they present a new and exciting research focus by utilizing new genomics technologies 
(such as whole-exome sequencing) for the rapid discovery of genetic causes underlying complex 
diseases, functional validation of the genes and variants discovered and potential treatment 
options for these affected individuals.  
 However, it should be cautioned that the path towards treatment or therapeutics even for 
such potentially treatable subsets might require several more decades of research. While it has 
been shown that cholesterol supplementation for children affected with SLOS might help to 
improve aberrant behavior, it has not been demonstrated convincingly that post-natal 
supplementation can help in improving the intellectual and cognitive abilities of these children. It 
will be important to assess and understand the impact of cholesterol deficiency temporally 
throughout the development of the human brain. One potential solution is for pregnant mothers 
who have fetuses that are at risk for cholesterol deficiency diseases might be placed on high 
cholesterol diet, although long-term assessment of such a diet on the mothers’ health will be 
required. Moreover, since cholesterol is produced in the brain de novo, it is unclear if cholesterol 
supplementation can aid in increasing the levels of cholesterol in the developing brain.  
 
FINNISH GENETICS 
 Traditionally, the genetic causes for several recessive Mendelian diseases were mapped 
in founder populations such as Ashkenazi Jewish and Finnish individuals [63,64,65] or 
consanguineous inbred populations such as the Middle Eastern individuals [66,67,68]. To further 
understand the role of recessive genetic factors in common diseases, we explored a unique 
founder population such as the Finns. We demonstrated in Chapter 4 that a variant that causes 
embryonic lethality in a dominant mode of inheritance will be virtually absent or can found at 
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extremely low allele frequencies in both the Finnish and out-bred European populations. 
However, this is not true for a recessive variant that results in embryonic lethality. Even in the 
worst case scenario where a recessive variant results in embryonic lethality, it can be present at 
~1% allele frequency in today’s Finnish population, given that the founding bottleneck in 
Finland occurred just ~100 generations ago. Moreover, out of the 36 Finnish heritage diseases 
(rare diseases that are relatively common in Finland), 32 of these diseases are autosomal 
recessive while 2 are autosomal dominant, supporting the hypothesis that deleterious recessive 
alleles might be enriched in Finland as a result of the bottleneck. 
 Traditionally, genetic mapping for recessive diseases have been successful in the Finnish 
population [63,69]. As we demonstrate in Chapter 4, this is both a result of founder alleles being 
increased in frequency from the bottleneck in Finland, as well as the reduced genetic diversity in 
rare variation found in founder populations since rare variation is lost as well when undergoing a 
bottleneck event. Similarly, when we performed genetic mapping in recessive diseases (neuronal 
ceroid lipofuscinosis and congenital diarrheal disorder) using whole-exome sequencing, we 
discovered the causal genes (KCTD7 and DGAT1 respectively) using founder populations 
(Mexicans and Ashkenazi Jewish respectively) relatively easily. 
 In 2001, a pair of papers first mapped a hexanucleotide repeat expansion in C9orf72 in 
the 9p21 region that was associated with risk for amyotrophic lateral sclerosis (ALS) using the 
Finnish population [70,71]. The authors discovered that the C9orf72 hexanucleotide repeat 
expansion accounted for ~46% of familial ALS and ~21% of sporadic ALS within Finland, while 
the same repeat expansion accounted for only ~6% of familial ALS and ~2% of sporadic ALS in 
Iranians [72]. This work demonstrated as well that genetic mapping in Finland for monogenic 
causes in complex diseases can be more fruitful given the reduced background rate of rare 
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variants in such founder populations. Recently, several papers on the discovery of rare and low-
frequency variants associated with complex diseases such as Type 2 diabetes, Alzheimer’s 
disease have also been discovered from other founder populations such as the Icelandic 
population [73,74,75], highlighting the utility of discovering rare and low-frequency variants in 
complex diseases from such founder population. 
 
Genetic architecture of the Finns from whole-exome sequencing data 
We explored the genetic architecture of the Finns using whole-exome sequencing data in 
Chapter 4 and showed that Finns are enriched for low-frequency variants with 0.5-5% allele 
frequency and depleted for extremely rare variants (<0.5% allele frequency). However, across all 
allele frequency spectrum except for common variants, there are proportionally more loss-of-
function variants versus missense and synonymous variants in Finns. In fact, there are almost 
twice as many low-frequency homozygous loss-of-function variants in an average Finnish 
individual compared to a non-Finnish European individual. This motivated our large targeted 
genotyping experiment of 83 low-frequency loss-of-function variants across ~36,000 Finnish 
individuals in order to discover associations of these low-frequency loss-of-function with a set of 
quantitative measurements and traits, as well as disease outcomes defined using the medical 
record system in Finland. 
 
Low-frequency loss-of-function variants in complex diseases and traits 
 Among the results from our association study, we discovered 2 rare and low-frequency 
splice variants in the LPA gene that lower circulating lipoprotein(a) levels. Previously, increased 
lipoprotein(a) levels have been associated with increased risk for coronary heart disease [76] and 
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risk variants in LPA have been associated with increased risk for coronary heart disease [77]. 
However, as in the case of PCSK9, it was only until later when compound heterozygous loss-of-
function mutations in PCSK9 were found in a healthy African American individual that 
suggested knocking out or down the protein levels was suitable as a therapeutic target and did 
not result in lethality or severe consequences in humans. In our study, we demonstrated that loss-
of-function mutations that lower lipoprotein(a) levels are protective against coronary heart 
disease and that similar to PCSK9, we observed several individuals with a complete knockout of 
the gene but are otherwise healthy. This shows that knocking out or down LPA might similar 
prove to be an effective drug target for coronary heart disease. 
 
SUMMARY 
 In terms of genetic discoveries for human diseases, this is an incredibly exciting era for 
geneticists, given the rapid revolutions in technologies, methodologies and approaches for 
understanding the role of rare variation in diseases. In terms of Mendelian diseases, it is now 
possible to identify novel genes and variants involved with the use of whole-exome or whole-
genome sequencing. And for complex diseases such as autism where genetic discoveries had 
been extremely difficult, it is now possible to discover specific genes and variants associated 
with whole-exome sequencing or genotyping. 
  
20 
 
REFERENCES 
1. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, et al. (1983) A 
polymorphic DNA marker genetically linked to Huntington's disease. Nature 306: 234-
238. 
2. HDCRG (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable 
on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research 
Group. Cell 72: 971-983. 
3. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, et al. (1989) Identification of the 
cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 
1066-1073. 
4. Morton NE (1955) Sequential tests for the detection of linkage. Am J Hum Genet 7: 277-318. 
5. Lander ES, Botstein D (1987) Homozygosity mapping: a way to map human recessive traits 
with the DNA of inbred children. Science 236: 1567-1570. 
6. Lander ES, Schork NJ (1994) Genetic dissection of complex traits. Science 265: 2037-2048. 
7. Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting 
and reporting linkage results. Nat Genet 11: 241-247. 
8. Lander ES, Green P (1987) Construction of multilocus genetic linkage maps in humans. Proc 
Natl Acad Sci U S A 84: 2363-2367. 
9. Elston RC, Stewart J (1971) A general model for the genetic analysis of pedigree data. Hum 
Hered 21: 523-542. 
10. Kruglyak L, Daly MJ, Lander ES (1995) Rapid multipoint linkage analysis of recessive traits 
in nuclear families, including homozygosity mapping. Am J Hum Genet 56: 519-527. 
21 
 
11. Yu TW, Chahrour MH, Coulter ME, Jiralerspong S, Okamura-Ikeda K, et al. (2013) Using 
whole exome sequencing to identify inherited causes of autism. Neuron. 
12. Chahrour MH, Yu TW, Lim ET, Ataman B, Coulter ME, et al. (2012) Whole-exome 
sequencing and homozygosity analysis implicate depolarization-regulated neuronal genes 
in autism. PLoS Genet 8: e1002635. 
13. Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, et al. (2008) Identifying autism loci and 
genes by tracing recent shared ancestry. Science 321: 218-223. 
14. HapMap (2005) A haplotype map of the human genome. Nature 437: 1299-1320. 
15. Lee N, Daly MJ, Delmonte T, Lander ES, Xu F, et al. (2001) A genomewide linkage-
disequilibrium scan localizes the Saguenay-Lac-Saint-Jean cytochrome oxidase 
deficiency to 2p16. Am J Hum Genet 68: 397-409. 
16. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. (2005) Complement factor H 
polymorphism in age-related macular degeneration. Science 308: 385-389. 
17. Devlin B, Bacanu SA, Roeder K (2004) Genomic Control to the extreme. Nat Genet 36: 
1129-1130; author reply 1131. 
18. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, et al. (2010) Hundreds of 
variants clustered in genomic loci and biological pathways affect human height. Nature 
467: 832-838. 
19. Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission test for linkage disequilibrium: 
the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum 
Genet 52: 506-516. 
22 
 
20. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. (2009) Common 
polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460: 
748-752. 
21. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, et al. (2013) Genome-wide 
association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45: 1150-
1159. 
22. Weiss LA, Arking DE, Daly MJ, Chakravarti A (2009) A genome-wide linkage and 
association scan reveals novel loci for autism. Nature 461: 802-808. 
23. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, et al. (2009) Common genetic variants on 
5p14.1 associate with autism spectrum disorders. Nature 459: 528-533. 
24. Anney R, Klei L, Pinto D, Regan R, Conroy J, et al. (2010) A genome-wide scan for 
common alleles affecting risk for autism. Hum Mol Genet 19: 4072-4082. 
25. Klei L, Sanders SJ, Murtha MT, Hus V, Lowe JK, et al. (2012) Common genetic variants, 
acting additively, are a major source of risk for autism. Mol Autism 3: 9. 
26. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, et al. (2007) Strong association of 
de novo copy number mutations with autism. Science 316: 445-449. 
27. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, et al. (2008) Association between 
microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 358: 667-675. 
28. Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, et al. (2011) Multiple recurrent 
de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are 
strongly associated with autism. Neuron 70: 863-885. 
29. Levy D, Ronemus M, Yamrom B, Lee YH, Leotta A, et al. (2011) Rare de novo and 
transmitted copy-number variation in autistic spectrum disorders. Neuron 70: 886-897. 
23 
 
30. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, et al. (2009) Targeted capture 
and massively parallel sequencing of 12 human exomes. Nature 461: 272-276. 
31. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, et al. (2010) Exome sequencing 
identifies the cause of a mendelian disorder. Nat Genet 42: 30-35. 
32. Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, et al. (2010) Exome 
sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 42: 
790-793. 
33. Haas JT, Winter HS, Lim E, Kirby A, Blumenstiel B, et al. (2012) DGAT1 mutation is linked 
to a congenital diarrheal disorder. J Clin Invest 122: 4680-4684. 
34. Staropoli JF, Karaa A, Lim ET, Kirby A, Elbalalesy N, et al. (2012) A homozygous mutation 
in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system. Am J 
Hum Genet 91: 202-208. 
35. Margolin DH, Kousi M, Chan YM, Lim ET, Schmahmann JD, et al. (2013) Ataxia, 
dementia, and hypogonadotropism caused by disordered ubiquitination. N Engl J Med 
368: 1992-2003. 
36. Mannstadt M, Harris M, Bravenboer B, Chitturi S, Dreijerink KM, et al. (2013) Germline 
mutations affecting Galpha11 in hypoparathyroidism. N Engl J Med 368: 2532-2534. 
37. Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, et al. (2013) Clinical whole-exome 
sequencing for the diagnosis of mendelian disorders. N Engl J Med 369: 1502-1511. 
38. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, et al. (2003) Mutations in PCSK9 
cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156. 
24 
 
39. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, et al. (2005) Low LDL 
cholesterol in individuals of African descent resulting from frequent nonsense mutations 
in PCSK9. Nat Genet 37: 161-165. 
40. Kathiresan S (2008) A PCSK9 missense variant associated with a reduced risk of early-onset 
myocardial infarction. N Engl J Med 358: 2299-2300. 
41. Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, et al. (2010) Exome sequencing, 
ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 363: 2220-
2227. 
42. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, et al. (2014) A polygenic burden 
of rare disruptive mutations in schizophrenia. Nature. 
43. Chan Y, Lim ET, Sandholm N, Wang SR, McKnight AJ, et al. (2014) An excess of risk-
increasing low-frequency variants can be a signal of polygenic inheritance in complex 
diseases. Am J Hum Genet 94: 437-452. 
44. Liu L, Sabo A, Neale BM, Nagaswamy U, Stevens C, et al. (2013) Analysis of rare, exonic 
variation amongst subjects with autism spectrum disorders and population controls. PLoS 
Genet 9: e1003443. 
45. Heinzen EL, Depondt C, Cavalleri GL, Ruzzo EK, Walley NM, et al. (2012) Exome 
sequencing followed by large-scale genotyping fails to identify single rare variants of 
large effect in idiopathic generalized epilepsy. Am J Hum Genet 91: 293-302. 
46. O'Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, et al. (2011) Exome sequencing in 
sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 43: 
585-589. 
25 
 
47. Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, et al. (2012) Patterns and rates of exonic 
de novo mutations in autism spectrum disorders. Nature 485: 242-245. 
48. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, et al. (2012) De novo 
mutations revealed by whole-exome sequencing are strongly associated with autism. 
Nature. 
49. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, et al. (2012) Sporadic autism 
exomes reveal a highly interconnected protein network of de novo mutations. Nature. 
50. Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, et al. (2012) De novo gene disruptions in 
children on the autistic spectrum. Neuron 74: 285-299. 
51. Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, et al. (2013) De novo mutations in 
epileptic encephalopathies. Nature 501: 217-221. 
52. de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, et al. (2012) Diagnostic 
exome sequencing in persons with severe intellectual disability. N Engl J Med 367: 1921-
1929. 
53. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, et al. (2014) De novo 
mutations in schizophrenia implicate synaptic networks. Nature. 
54. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, et al. (2013) ACMG recommendations 
for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 
15: 565-574. 
55. Lin PI, Kuo PH, Chen CH, Wu JY, Gau SS, et al. (2013) Runs of homozygosity associated 
with speech delay in autism in a taiwanese han population: evidence for the recessive 
model. PLoS One 8: e72056. 
26 
 
56. Gamsiz ED, Viscidi EW, Frederick AM, Nagpal S, Sanders SJ, et al. (2013) Intellectual 
disability is associated with increased runs of homozygosity in simplex autism. Am J 
Hum Genet 93: 103-109. 
57. Novarino G, El-Fishawy P, Kayserili H, Meguid NA, Scott EM, et al. (2012) Mutations in 
BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science 338: 
394-397. 
58. Waterham HR, Koster J, Romeijn GJ, Hennekam RC, Vreken P, et al. (2001) Mutations in 
the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal 
recessive disorder of cholesterol biosynthesis. Am J Hum Genet 69: 685-694. 
59. Svoboda MD, Christie JM, Eroglu Y, Freeman KA, Steiner RD (2012) Treatment of Smith-
Lemli-Opitz syndrome and other sterol disorders. Am J Med Genet C Semin Med Genet 
160C: 285-294. 
60. Tierney E, Conley SK, Goodwin H, Porter FD (2010) Analysis of short-term behavioral 
effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome. Am J 
Med Genet A 152A: 91-95. 
61. Buchovecky CM, Turley SD, Brown HM, Kyle SM, McDonald JG, et al. (2013) A 
suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett 
syndrome. Nat Genet 45: 1013-1020. 
62. Ruzzo EK, Capo-Chichi JM, Ben-Zeev B, Chitayat D, Mao H, et al. (2013) Deficiency of 
asparagine synthetase causes congenital microcephaly and a progressive form of 
encephalopathy. Neuron 80: 429-441. 
27 
 
63. Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander ES, et al. (1998) CLN5, a 
novel gene encoding a putative transmembrane protein mutated in Finnish variant late 
infantile neuronal ceroid lipofuscinosis. Nat Genet 19: 286-288. 
64. Visapaa I, Fellman V, Vesa J, Dasvarma A, Hutton JL, et al. (2002) GRACILE syndrome, a 
lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L. 
Am J Hum Genet 71: 863-876. 
65. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, et al. (2004) Familial combined 
hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36: 
371-376. 
66. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, et al. (1997) Congenital leptin 
deficiency is associated with severe early-onset obesity in humans. Nature 387: 903-908. 
67. Barak T, Kwan KY, Louvi A, Demirbilek V, Saygi S, et al. (2011) Recessive LAMC3 
mutations cause malformations of occipital cortical development. Nat Genet 43: 590-594. 
68. Bitner-Glindzicz M, Lindley KJ, Rutland P, Blaydon D, Smith VV, et al. (2000) A recessive 
contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness 
identifies the Usher type 1C gene. Nat Genet 26: 56-60. 
69. Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, et al. (1995) Mutations in the 
palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. 
Nature 376: 584-587. 
70. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al. (2011) A 
hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked 
ALS-FTD. Neuron 72: 257-268. 
28 
 
71. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. (2011) 
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes 
chromosome 9p-linked FTD and ALS. Neuron 72: 245-256. 
72. Alavi A, Nafissi S, Rohani M, Shahidi G, Zamani B, et al. (2014) Repeat expansion in 
C9ORF72 is not a major cause of amyotrophic lateral sclerosis among Iranian patients. 
Neurobiol Aging 35: 267 e261-267. 
73. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, et al. (2012) A mutation in APP 
protects against Alzheimer's disease and age-related cognitive decline. Nature 488: 96-99. 
74. Steinthorsdottir V, Thorleifsson G, Sulem P, Helgason H, Grarup N, et al. (2014) 
Identification of low-frequency and rare sequence variants associated with elevated or 
reduced risk of type 2 diabetes. Nat Genet. 
75. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, et al. (2013) Variant of 
TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107-116. 
76. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. (2009) Lipoprotein(a) 
concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. 
JAMA 302: 412-423. 
77. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, et al. (2009) Genetic variants 
associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361: 2518-
2528. 
 
 
29 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
Rare complete knockouts in humans: population distribution and significant role in autism 
spectrum disorders 
 
 
  
30 
 
Rare complete knockouts in humans: population distribution and significant role in autism 
spectrum disorders 
 
Elaine T. Lim1,4,5,6,7, Soumya Raychaudhuri4,6,9, Stephan J. Sanders10, Christine Stevens4, Aniko 
Sabo11, Daniel G. MacArthur1,4,6, Benjamin M. Neale1,4,5,6, Andrew Kirby1,4,6, Douglas M. 
Ruderfer1,3,4,5,6,8,12, Menachem Fromer1,3,4,5,6,8,12, Monkol Lek1,4,6, Li Liu18, Jason Flannick1,2,4,6, 
Stephan Ripke1,4,5, Uma Nagaswamy11, Donna Muzny11, Jeffrey G. Reid11, Alicia Hawes11, Irene 
Newsham11, Yuanqing Wu11, Lora Lewis11, Huyen Dinh11, Shannon Gross11, Li-San Wang19, 
Chiao-Feng Lin19, Otto Valladares19, Stacey B. Gabriel4, Mark dePristo4, David M. 
Altshuler1,2,4,6, Shaun M. Purcell1,3,4,5,6,8,12, NHLBI Exome Sequencing Project, Matthew W. 
State10, Eric Boerwinkle11,21, Joseph D. Buxbaum13,14,15,16,17, Edwin H. Cook22, Richard A. 
Gibbs11, Gerard D. Schellenberg20, James S. Sutcliffe23, Bernie Devlin24, Kathryn Roeder18, and 
Mark J. Daly1,4,5,6,* 
 
1 Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, 
USA. 
2 Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA. 
3 Psychiatric & Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, 
MA 02114, USA. 
4 Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA. 
5 Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA 02142, USA. 
6 Departments of Genetics and Medicine, Harvard Medical School, Boston, MA 02115, USA. 
31 
 
7 Program in Genetics and Genomics, Biological and Biomedical Sciences, Harvard Medical 
School, Boston, MA 02115, USA. 
8 Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA. 
9 Division of Immunology, Allergy, and Rheumatology, Brigham and Women’s Hospital, 
Boston, MA 02115, USA. 
10 Departments of Psychiatry and Genetics, Yale University School of Medicine, New Haven, 
CT 06520, USA. 
11 Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA. 
12 Division of Psychiatric Genomics, Mount Sinai School of Medicine, New York, NY 10029, 
USA. 
13 Seaver Autism Center for Research and Treatment, Mount Sinai School of Medicine, New 
York, NY 10029, USA. 
14 Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA. 
15 Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, 
NY 10029, USA. 
16 Department of Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA. 
17 Friedman Brain Institute, Mount Sinai School of Medicine, New York, NY 10029, USA. 
18 Department of Statistics and Lane Center for Computational Biology, Carnegie Mellon 
University, Pittsburgh, PA 15213, USA. 
19 Penn Center for Bioinformatics, University of Pennsylvania, Philadelphia, PA 19104, USA. 
20 Pathology and Laboratory Medicine, Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, PA 19104, USA. 
32 
 
21 Human Genetics Center, University of Texas Health Science Center at Houston, TX 77030, 
USA. 
22 Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612, USA. 
23 Departments of Molecular Physiology & Biophysics and Psychiatry, Vanderbilt Brain 
Institute, Vanderbilt University, Nashville, TN 37232, USA. 
24 Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, 
USA. 
* Correspondence: mjdaly@atgu.mgh.harvard.edu 
 
Originally published as: 
Lim ET et al. Rare complete knockouts in humans: population distribution and significant role in 
autism spectrum disorders. Neuron, 2013. 77(2): p.235-42. 
 
  
33 
 
ABSTRACT 
To characterize the role of rare complete human knockouts in autism spectrum disorders 
(ASD), we identify genes with homozygous or compound heterozygous loss-of-function (LoF) 
variants (defined as nonsense and essential splice sites) from exome sequencing of 933 cases and 
869 controls. We identify a two-fold increase in complete knockouts of autosomal genes with 
low rates of LoF variation (≤5% frequency) in cases and estimate a 3% contribution to ASD risk 
by these events, confirming this observation in an independent set of 563 probands and 4,605 
controls. Outside the pseudo-autosomal regions on the X-chromosome, we similarly observe a 
significant 1.5-fold increase in rare hemizygous knockouts in males, contributing to another 2% 
of ASDs in males. Taken together these results provide compelling evidence that rare autosomal 
and X-chromosome complete gene knockouts are important inherited risk factors for ASD. 
 
INTRODUCTION 
Autism spectrum disorder (ASD) is a highly heritable, common disorder that affects ~1 in 
88 individuals [1]. Previous studies have shown a reproducible contribution of de novo copy 
number variants (CNVs) [2,3,4,5,6] and de novo single nucleotide variants (SNVs) [7,8,9,10] to 
ASD risk - though these effects provide little explanation for the widely recognized high 
heritability [11]. An early segregation analysis on 46 multiplex families (each with multiple 
affected children) suggested evidence for an autosomal recessive (or ‘2-hit’) model in ASD [12] 
with a subsequent study showing that ASD is unlikely to fit a model with a major gene effect 
[13]. Further to this point, the most recent results from de novo CNVs and SNVs point to a 
model in which hundreds of genes are likely to contribute to autism risk. Building from these 
observations, as a means of providing insight into the heritable component of ASD risk, we 
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sought to test the hypothesis that 2-hit etiologies exist in ASD and that these events, like the de 
novo CNVs and SNVs, are most likely to be distributed over many genes. Supporting this 
hypothesis are historical segregation analyses [12,14], the successful use of homozygosity 
mapping in consanguineous populations [15], as well as recent studies showing that ASD 
probands had a significant excess of homozygous haplotype sharing, suggesting that there are 
recessive loci in these risk-conferring haplotypes [16,17]. Other studies have also implicated the 
role of a 2-hit or oligogenic model for rare CNVs in ASD [18]. 
It has been shown that there are relatively few homozygous or compound heterozygous 
LoF variants (i.e., complete gene knockouts) in healthy individuals. Most of these complete 
knockouts found are common (MAF>5%) and are distributed across a very small number (~100-
200) of genes, such as the olfactory receptors, that are apparently inessential and do not result in 
any obvious phenotype or severe medical consequence [19]. We similarly observe in these ASD 
datasets that an average individual harbors ~5 common complete knockouts (from nonsense and 
essential splice site variants) distributed across a small subset of genes on the autosomes. In 
striking contrast, if we consider only LoF variants with frequency ≤5%, fewer than 5% of 
individuals harbor even a single rare complete knockout (Table 2.1). While heterozygous LoF 
mutations are seen in thousands of genes, the very low frequency and paucity of observed 
complete knockouts suggests a broad pool of genes (including many Mendelian disorders) where 
2-hit variants may give rise to severe and reproductively deleterious phenotypes. While genes 
with common complete knockouts are more likely to be benign (or unlikely to result in severe 
phenotypes with high penetrance), genes with rare complete knockouts are more likely to be 
disease-causing [20] simply because selection prevents deleterious recessive-acting variants from 
reaching even moderate allele frequencies. 
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Table 2.1: Population Distribution of Rare and Common LoFs 
The average number of rare (≤5%) and common (>5%) homozygous LoF variants, as well as the 
average number of such variants calculated from the BI case-control dataset. 
 Average number 
of homozygous 
variants 
Number of unique 
genes with a 
homozygous 
variant 
Average number 
of heterozygous 
variants 
Number of 
unique genes 
with a 
heterozygous 
variant 
Rare (≤5%) 
LoFs 
0.05 variant per 
individual 
33 genes 13 variants per 
individual 
3,409 genes 
Common (>5%) 
LoFs 
5 variants per 
individual 
96 genes 36 variants per 
individual 
99 genes 
 
 
If a subset of ASD cases were caused by rare 2-hit events with large effects (e.g. odds 
ratios of >5) distributed across many different genes, then family-based linkage or GWAS would 
have little power to detect such events, as each locus individually would explain a very small 
fraction of all cases given the commonness of the outcome and the large number of ASD genes. 
To evaluate evidence for such 2-hit etiologies in ASD, we studied the distribution and patterns of 
rare complete knockouts from whole-exome sequence data across two case-control studies 
comprised of 1,802 European subjects to identify events in which individuals carried 2 LoF 
autosomal variants in a single gene in trans. In this study, we show that rare complete knockouts 
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on the autosomes (variant allele frequencies of ≤5%) are significantly enriched in cases, 
suggesting that these events contribute to the genetic etiology of ASD.  
A variant with a diploid allele frequency of 5% on the autosomes results in a complete 
knockout in 0.25% of the individuals. Outside the pseudo-autosomal regions on the X-
chromosome in males, a single LoF variant with 0.25% allele frequency also results in a 
complete knockout in 0.25% of males. Similarly, we found that rare complete knockouts on the 
X-chromosome (variant allele frequencies of ≤0.25%) are also significantly enriched in male 
cases, further reinforcing the role of rare complete knockouts as risk factors for ASD. 
 
RESULTS 
Exome Capture and Sequencing 
To assess the contribution of rare complete knockouts to ASD, we analyzed data from an 
ethnically-matched case-control population. We selected 933 cases and 869 controls sequenced 
in this study by matching them with multi-dimensional scaling (MDS) of common variants 
genotyped on Illumina 1M, Affymetrix 5.0, or 6.0 arrays [21] to reduce potential confounding by 
population stratification. The exomes were sequenced at two different sequencing centers – the 
Broad Institute (BI) and the Baylor College of Medicine (BCM). A total of 428 ASD cases 
selected from the Autism Genetic Resource Exchange (AGRE) and 378 NIMH controls (a total 
of 806 individuals) were sequenced at BI, and another 505 ASD cases selected from the Autism 
Simplex Collection (TASC) and 491 NIMH controls (a total of 996 individuals) were sequenced 
at BCM, resulting in 1,802 individuals across the two case-control datasets. All controls were 
selected from an NIMH control repository and were ascertained for not having schizophrenia or 
bipolar mood disorder. Another 563 probands were added into the final analyses (388 
37 
 
trios/quartets from the Simons Simplex Collection (SSC) [8,10], 175 trios from the Boston 
Autism Consortium sequenced at BI (104 from [9]) and together with 4,605 additional European 
controls from the NHLBI exome sequencing project and the 1000 Genomes Project, this resulted 
in a total of >6,000 exomes used in this study (Table 2.2). The metrics for the case-control 
datasets are described in Table 2.3. 
 
Enrichment of Rare Complete Knockouts in ASD 
Given that rare complete knockouts consist of both compound heterozygous and 
homozygous variants on the autosomes, we adapted a statistical phasing approach similar to the 
four-haplotype test to eliminate instances in which multiple LoF variants may segregate in cis 
(Figure 2.1). There are a total of 91 such rare complete knockouts in the case-control datasets, 
with 62 of these found in the cases compared to 29 in the controls (Table 2.4), representing a 
roughly 2-fold enrichment of these events in the cases (odds ratio (OR) = 2.0, 95% CI = [1.5, 
2.5], one-sided permutation P = 0.0017). Based on the difference between cases and controls 
(6% of the cases versus 3.3% of the controls have a rare complete knockout), we estimate a ~3% 
contribution by rare complete knockouts to ASD. While different capture and sequencing 
technologies were employed at the two sequencing centers, and different depths of sequencing 
achieved (Liu et al., personal communication), the excess in cases was consistent in the two 
datasets (ORs = 2.1, 95% CI = [1.5, 2.7] and 1.8, 95% CI = [1.1, 2.5]). 
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Table 2.2: Description of Available Datasets 
The case-control datasets comprise of cases and controls that were well-matched for their 
common variants and sequenced at the BI and BCM were used to assess the enrichment of rare 
complete knockouts (Datasets 1 and 2). For the final analyses, probands from 200 quartets 
sequenced at Yale University, 188 quartets sequenced at Cold Spring Harbor Laboratory 
(CSHL), 104 published trios and 71 new trios from BI were compared to another 4,605 controls 
from the NHLBI Exome Sequencing Project and the 1000 Genomes Project (Datasets 3-8), 
resulting in a total of 1,496 cases and 5,474 controls in this study. 
 Type Sequencing Center Number of cases Number of controls 
Dataset 1 Case-control BI 
(unpublished) 
428 cases 378 controls 
Dataset 2 Case-control BCM 
(unpublished) 
505 cases 491 controls 
Total for case-control datasets 933 cases 869 controls 
Dataset 3 Quartets Yale 
[10] 
200 probands - 
Dataset 4 Quartets CSHL  
[8] 
188 probands - 
Dataset 5 Trios BI  
[9] 
104 probands - 
Dataset 6 Trios BI 
(unpublished) 
71 probands - 
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Table 2.2: Description of Available Datasets (Continued) 
 Type Sequencing Center Number of cases Number of controls 
Dataset 7 Controls Multiple centers - 4419 controls 
(NHLBI Exome 
Sequencing Project) 
Dataset 8 Controls Multiple centers - 186 controls 
(1000 Genomes 
Project) 
Total numbers for final analyses 1496 cases 5474 controls 
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Table 2.3: Metrics for BI and BCM Case-Control Datasets 
(A) The number of genes, variants and average coverage in the BI and BCM case-control 
datasets. 
(B) Number of variants and the distribution of the variants in both the BI and BCM case-control 
datasets. 
A 
 # Genes Average minor allele 
frequency 
# Variants per gene Average depth 
BCM 15759 0.021 11.28 62.41 
BI 17900 0.024 18.49 140.22 
 
B 
 # 
Variants 
# 
Missense 
variants 
# 
Nonsense 
variants 
# 
Synonymous 
variants 
# 
Singletons 
Common 
variants 
(>5% 
MAF) 
Rare 
variants 
(≤5% 
MAF) 
BCM 177699 95522 2190 61720 111766 18231 159468 
BI 330985 198070 4149 128766 171813 40080 290897 
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Figure 2.1: LD-based Phasing Approach To Predict Compound Heterozygous Variants 
(A) If both the red and blue variants within the same gene are in trans (they occurred on different 
chromosomes in Persons 1 and 2), we will observe some individuals in the population with only 
the red variant (G1) and some individuals with only the blue variant (G2). 
(B) If the blue variant occurred on the same chromosome as the red variant within the same gene 
at some point in time and is in cis with the red variant, we will observe some individuals in the 
population with only the red variant (G7), but will not observe any individual with only the blue 
variant (G2). In addition, there might be some individuals with 3 or 4 copies of alleles across 
both variants (G10 and G11), suggesting that both variants are more likely to be in cis. 
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Figure 2.1: LD-based Phasing Approach To Predict Compound Heterozygous Variants 
(Continued) 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Person 1 
Person 3 
G8. Individuals with 
homozygous A 
Person 2 
G11. Individuals with 
homozygous A and B 
G7. Individuals with 
heterozygous A 
G9. Individuals with 
both alleles 
G10. Individuals with 
homozygous A and 
heterozygous B 
G12. Individuals with 
neither allele 
Person 1 
Person 2 
Person 3 
G3. Individuals with 
homozygous A 
G4. Individuals with 
homozygous B 
G2. Individuals with 
heterozygous B 
G1. Individuals with 
heterozygous A 
G6. Individuals with 
neither allele 
G5. Individuals with 
compound heterozygotes 
AB 
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Table 2.4: Number of 2-hit Events Observed in the Cases and Controls 
 (A) Number of 2-hit events observed in the cases compared to controls for the various allele 
frequencies and various functional categories: LoF, non-synonymous (NS) and synonymous 
(SYN) and the numbers in brackets indicate the number of homozygous events. The difference 
between the total number of 2-hit events and the homozygous events are the compound 
heterozygous events. 
(B) Number of heterozygous variants observed in the cases compared to controls for the various 
allele frequencies and various functional categories: LoF, non-synonymous (NS) and 
synonymous (SYN). 
A 
Allele 
Freq 
# 2-hit LoF 
in cases 
# 2-hit LoF 
in controls 
# 2-hit NS 
in cases 
# 2-hit NS  
in controls 
# 2-hit 
SYN in 
cases 
# 2-hit SYN 
in controls 
≤5% 62 
(42) 
29 
(19) 
18857 
(3465) 
15365 
(2783) 
13417 
(3513) 
10034 
(2548) 
≤10% 172 
(142) 
149 
(121) 
38115 
(12345) 
32199 
(10283) 
31743 
(13261) 
25943 
(10900) 
≤20% 617 
(585) 
538 
(505) 
90237 
(43948) 
78646 
(38339) 
88421 
(51844) 
76202 
(45036) 
≤30% 1024 
(988) 
876 
(840) 
158175 
(93604) 
139520 
(82719) 
176497 
(119533) 
155521 
(106061) 
≤40% 1645 
(1603) 
1418 
(1378) 
242024 
(162019) 
215878 
(144892) 
287349 
(214735) 
255106 
(191552) 
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Table 2.4: Number of 2-hit Events Observed in the Cases and Controls (Continued) 
A 
Allele 
Freq 
# 2-hit LoF 
in cases 
# 2-hit LoF 
in controls 
# 2-hit NS 
in cases 
# 2-hit NS  
in controls 
# 2-hit SYN 
in cases 
# 2-hit SYN 
in controls 
≤50% 3331 
(3240) 
3029 
(2953) 
315502 
(245761) 
280425 
(220735) 
395881 
(317715) 
351109 
(283265) 
 
B 
Allele 
Freq 
# LoF 
variants 
in cases 
# LoF 
variants in 
controls 
# NS 
variants in 
cases 
# NS 
variants in 
controls 
# SYN 
variants in 
cases 
# SYN 
variants in 
controls 
≤5% 9365 8400 517337 451650 428510 367373 
≤10% 12479 11230 817404 728463 747665 660771 
≤20% 19472 17664 1396259 1262890 1437932 1294969 
≤30% 24355 20386 1981964 1803775 2218066 2015026 
≤40% 29198 26749 2567749 2342964 3409983 2748908 
≤50% 35087 32289 3133619 2863937 3821090 3486579 
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Using the results from a previous study of expression patterns of post-mortem brains 
[22], we observed the enrichment in rare complete knockouts in cases was particularly 
pronounced in genes found to be expressed in the brain, with 37 events in cases compared to 
only 13 in the controls (OR = 2.7, 95% CI = [2.1, 3.3], one-sided permutation P = 0.002), 
although this enrichment in brain-expressed genes was not significantly different from the global 
enrichment observed (one-sided permutation P = 0.13, Figure 2.2). 
To confirm that this excess was not an artifact of any residual uncertainty in statistical 
phasing, we examined the subset of rare complete knockouts that were homozygous LoF variants 
alone and found that these events were also significantly enriched by 2-fold (42 in cases and 19 
in controls, OR = 2.1, 95% CI = [1.6, 2.6], one-sided permutation P = 0.0059, Table 2.4). We 
further ensured that the excess was not driven by inaccuracies in phasing ‘singleton’ variants 
(variants that were observed only once in a single individual) and found that rare complete 
knockouts excluding the singleton variants were also significantly enriched (48 in cases and 24 
in controls, OR = 1.9, 95% CI = [1.4, 2.4], one-sided permutation P = 0.0081). Since an excess 
in 2-hit LoF could arise trivially if there was a significant overall difference in rates of LoF 
variants between cases and controls, we evaluated the total number of single-copy losses (i.e., 
heterozygous LoF carriers) with variant allele frequencies ≤5% found in cases compared to 
controls and saw no enrichment (OR = 1.0, 95% CI = [0.9, 1.1], Table 2.5).  
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Figure 2.2: Expression Patterns of the Complete Knockouts 
(A) The enrichment of rare complete knockouts in cases versus controls. 
(B) The enrichment observed in rare complete knockouts is not observed in the common 
complete knockouts. 
The x-axis indicates the average number of events per individual in cases and controls and the 
numbers above the barplots indicate the total number of such events in cases and controls, with 
the odds ratios (OR) shown above. 
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Table 2.5: Control Experiments for the Enrichment Observed in Rare Complete 
Knockouts 
(A) The ratio of rare complete knockouts found in cases versus controls is significantly different 
from the ratio of rare 2-hit synonymous variants in cases versus controls. 
(B) The ratio of rare complete knockouts found in cases versus controls is also significantly 
different from the ratio of common complete knockouts in cases versus controls. 
The hypergeometric probabilities reflect the probabilities of the enrichment observed in rare 
complete knockouts after correcting for the enrichment in rare 2-hit synonymous and common 
complete knockouts. 
A 
 Not expressed 
in brain 
Expressed in 
brain 
Unknown Total 
Cases 1,172 10,894 1,351 13,417 
Controls 873 8,196 965 10,034 
Odds ratio of rare 
2-hit synonymous 
events 
1.3 1.2 1.3 1.3 
Odds ratio of rare 
2-hit LoF events 
1.5 2.7 1.4 2 
Hypergeometric P 0.47 0.01 0.49 0.021 
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Table 2.5: Control Experiments for the Enrichment Observed in Rare Complete 
Knockouts (Continued) 
B 
 Not expressed 
in brain 
Expressed in 
brain 
Unknown Total 
Cases 994 1,653 684 3,331 
Controls 950 1,419 660 3,029 
Odds ratio of 
common 2-hit LoF 
events 
1 1.1 1 1 
Odds ratio of rare 
2-hit LoF events 
1.5 2.7 1.4 2 
Hypergeometric P 0.27 0.0025 0.24 0.0015 
 
 
 
 
 
  
49 
 
Finally, we validated all variants by ensuring that they were either present in dbSNP, the 
NHLBI Exome Sequencing Project and/or were confirmed using Fluidigm genotyping, Sanger 
sequencing or Fluidigm PCR with MiSeq sequencing with 94% of these variants validating as 
true polymorphisms (Table 2.6, Table 2.7). Even conservatively assuming all validation failures 
were false positive SNPs (rather than genotyping assay failures), removing the three events in 
cases and two in controls from the overall tallies has no impact on the results. As a final check, 
we used rare homozygous and compound heterozygous (or ‘2-hit’) synonymous events, as well 
as common complete knockouts, as internal controls and confirmed the enrichment of rare 
complete knockouts was far greater and significantly different compared to both of these (Table 
2.5).  
Knockouts via homozygosity of rare LoF sites could arise from hemizygous LoF variants 
that were exposed through the deletion of the other copy in the gene region. Using a CNV-
calling algorithm for exome sequencing (XHMM) [23], we found that 2 of the homozygous LoFs 
observed in cases (E201X in KRT83 and E211X in PRAMEF2) were, in fact, LoF variants 
unmasked by deletions spanning across the regions (11kb and 183kb deletions respectively), 
although this does not change the fact that they are complete gene knockouts.  
To confirm these observations, we examined an independent set of cases (N = 563) from 
recent trio sequencing efforts (where 2-hit knockout status was certain from the existence of 
parental sequence data) and compared to a broader population dataset (N = 4,605) from the 
NHLBI exome sequencing project and 1000 Genomes Project (Table 2.2). The enrichment (7.6% 
in cases to 5.5% in controls, hypergeometric test P = 0.016) was replicated in this comparison as 
well – further confirming the veracity of this observation. 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
C1orf127 G->A G->A 1 0 Y Y Y Y 1 - - 
PRAMEF2 E211* E211* 1 0 Y Y Y Y 1 - - 
PGM1 G->A G->A 0 1 Y Y Y Y 0 - - 
FAM71A K555* K555* 1 0 Y Y Y Y 0 - - 
C2orf53 S78* S78* 0 1 
N N N N 
Did not 
validate 
- - 
C2orf63 A->T A->T 0 1 Y Y Y Y 0 - - 
VWA3B E372* E372* 1 0 Y Y Y Y 1 - - 
DPP4 T->C T->C 2 1 Y Y Y Y 2 - - 
IFIH1 C->G C->G 1 0 Y Y Y Y 1 - - 
PTH2R S82* S82* 1 0 Y N Y N 1 - - 
ATP13A5 Q355* Q355* 0 1 Y Y Y Y 0 - - 
CC2D2A R88* R88* 0 1 Y Y Y Y 0 - - 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts (Continued) 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
UGT2A1 Y192* Y192* 1 0 Y Y Y Y 1 - - 
C1orf127 G->A G->A 1 0 Y Y Y Y 1 - - 
PRAMEF2 E211* E211* 1 0 Y Y Y Y 1 - - 
PGM1 G->A G->A 0 1 Y Y Y Y 0 - - 
FAM71A K555* K555* 1 0 Y Y Y Y 0 - - 
C2orf53 S78* S78* 0 1 
N N N N 
Did not 
validate 
- - 
C2orf63 A->T A->T 0 1 Y Y Y Y 0 - - 
VWA3B E372* E372* 1 0 Y Y Y Y 1 - - 
DPP4 T->C T->C 2 1 Y Y Y Y 2 - - 
IFIH1 C->G C->G 1 0 Y Y Y Y 1 - - 
PTH2R S82* S82* 1 0 Y N Y N 1 - - 
ATP13A5 Q355* Q355* 0 1 Y Y Y Y 0 - - 
CC2D2A R88* R88* 0 1 Y Y Y Y 0 - - 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts (Continued) 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
UGT2A1 Y192* Y192* 1 0 Y Y Y Y 1 - - 
AGXT2 C->T C->T 1 0 Y Y Y Y 0 - - 
FAM81B Q144* Q144* 1 1 Y Y Y Y 0 - - 
SLC17A4 Q433* Q433* 0 1 Y Y Y Y 0 - - 
PNPLA1 Y488* Y488* 1 1 Y Y Y Y 0 - - 
USP45 A->G A->G 0 1 Y Y Y Y 0 - - 
KIAA1919 L182* L182* 1 0 Y N Y N 1 - - 
TAAR2 W168* W168* 1 0 Y Y Y Y 1 - - 
LPA T->C T->C 1 0 Y Y Y Y 1 - - 
UNC93A G->C G->C 1 0 Y Y Y Y 1 - - 
RNF32 T->C T->C 2 0 Y Y Y Y 2 - - 
LRRC69 T->A T->A 1 0 Y Y Y Y 0 - - 
PKHD1L1 G->A G->A 0 1 Y Y Y Y 0 - - 
ZNF883 R341* R341* 0 1 Y Y Y Y 0 - - 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts (Continued) 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
OR10V1 Q123* Q123* 1 0 Y Y Y Y 1 - - 
RAD52 Y415* Y415* 1 0 Y Y Y Y 1 - - 
KRT83 E201* E201* 1 1 Y Y Y Y 1 - - 
OAS3 R812* R812* 1 0 N N N N 1 - - 
OLFM4 R214* R214* 0 1 Y Y Y Y 0 - - 
CLYBL R259* R259* 2 0 Y Y Y Y 0 - - 
C14orf105 Q183* Q183* 1 0 Y Y Y Y 1 - - 
NPC2 C->T C->T 0 1 Y Y Y Y 0 - - 
SERPINA10 R88* R88* 1 0 Y Y Y Y 0 - - 
RAGE R94* R94* 0 1 Y Y Y Y 0 - - 
ABCC12 W1024* W1024* 2 1 Y Y Y Y 1 - - 
DBF4B G->T G->T 1 0 Y Y Y Y 0 - - 
C17orf57 R211* R211* 1 0 Y Y Y Y 0 - - 
ABCA10 R1322* R1322* 4 0 Y Y Y Y 4 - - 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts (Continued) 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
FLJ35220 A->G A->G 1 1 Y Y Y Y 1 - - 
STARD6 R19* R19* 5 0 Y Y Y Y 3 - - 
ZNF77 Q100* Q100* 1 0 Y Y Y Y 1 - - 
UNC13A G->A G->A 1 0 Y Y Y Y 1 - - 
ZNF780B T->C T->C 1 0 Y Y Y Y 1 - - 
LAIR2 R76* R76* 0 1 Y Y Y Y 0 - - 
ZIM3 K438* K438* 0 1 Y Y Y Y 0 - - 
KIAA1755 R510* R510* 0 1 Y Y Y Y 0 - - 
C1orf168 T->C K198* 1 0 Y Y N N 1 1 N 
DNAH14 L286* E3391* 0 1 N N N Y 1 1 - 
VWA3B E372* A->T 1 0 
Y Y N N 
1 Did not 
validate 
- 
DNAH7 Y3978* R1009* 1 0 Y Y N Y 1 1 - 
GBE1 A->G Q46* 0 1 Y Y N N 1 1 - 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts (Continued) 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
ATP13A5 A->G Q355* 1 0 N N Y Y 1 1 - 
CC2D2A R88* A->T 0 1 
Y Y N N 
1 Did not 
validate 
- 
WDR17 A->T A->T 1 0 
N N N N 
Did not 
validate 
Did not 
validate 
- 
INTS8 A->T A->T 1 0 
N Y N N 
Did not 
validate 
Did not 
validate 
- 
SLC22A25 T->C W120* 1 0 Y Y N N 1 1 Y 
MMP1 C->T A->G 0 1 Y Y Y Y 0 0 - 
RAD52 Y415* S346* 1 0 Y Y Y Y 1 1 - 
C12orf64 G->T R1808* 1 0 N N N N 1 1 - 
ZSCAN29 Q669* C645* 1 0 N N N N 1 1 - 
TMC3 S1045* R736* 1 0 Y Y N Y 0 0 - 
C17orf57 R211* G->A 1 0 Y Y Y Y 1 1 Y 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts (Continued) 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
C17orf57 R211* K433* 0 1 Y Y Y Y 0 0 - 
C17orf57 R211* Y546* 2 0 Y Y Y Y 0 0 - 
C17orf57 R236* G->A 0 1 Y Y Y Y 0 0 - 
C17orf57 G->A K433* 1 1 Y Y Y Y 1 1 Y 
KLK14 A->G C->T 0 1 N N Y Y 1 1 - 
LILRA3 E54* C->G 1 0 Y Y Y Y 1 1 N 
C20orf71 S109* C165* 1 0 Y Y Y Y 0 0 - 
SLC17A9 G->T T->C 1 0 Y N Y N 1 1 N 
FLG R501* R501* 1 0 Y Y Y Y 0 0 - 
CFHR2 E199* E199* 1 0 Y Y Y Y 0 0 - 
NT5C1B S118* S118* 1 0 Y Y Y Y 0 0 - 
SULT1C3 W36* W36* 1 0 Y Y Y Y 0 0 - 
THSD7B C->T C->T 1 0 Y Y Y Y 0 0 - 
DPP4 T->C T->C 2 0 Y Y Y Y 0 0 - 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts (Continued) 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
SLC22A14 A->C A->C 2 0 Y Y Y Y 0 0 - 
TGM4 W269* W269* 1 0 Y Y Y Y 0 0 - 
KNG1 R412* R412* 1 0 N N N N 0 0 - 
ATP13A5 Q355* Q355* 1 0 Y Y Y Y 0 0 - 
UGT2A1 Y192* Y192* 1 0 Y Y Y Y 0 0 - 
MICB R193* R193* 1 0 Y Y Y Y 0 0 - 
LPA C->T C->T 1 0 Y Y Y Y 0 0 - 
ABCB5 G->C G->C 2 0 Y Y Y Y 0 0 - 
CCL26 R44* R44* 1 0 Y Y Y Y 0 0 - 
ACTR3C Q121* Q121* 1 0 N N N N 0 0 - 
PLAT R561* R561* 1 0 Y Y Y Y 0 0 - 
PKHD1L1 G->C G->C 2 0 Y Y Y Y 0 0 - 
OR1J1 C235* C235* 1 0 Y Y Y Y 0 0 - 
PTCHD3 R476* R476* 1 0 Y Y Y Y 0 0 - 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts (Continued) 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
CYP2C18 Y68* Y68* 1 0 Y Y Y Y 0 0 - 
OR8K3 Q260* Q260* 1 0 Y Y Y Y 0 0 - 
PZP Q598* Q598* 1 0 Y N Y N 0 0 - 
SPERT C71* C71* 1 0 Y Y Y Y 0 0 - 
CLYBL R225* R225* 1 0 Y Y Y Y 0 0 - 
OR4M2 R128* R128* 1 0 Y Y Y Y 0 0 - 
SPTBN5 R1848* R1848* 2 0 Y Y Y Y 0 0 - 
LRRC29 W6* W6* 1 0 Y Y Y Y 0 0 - 
KRTAP4-8 C30* C30* 1 0 Y Y Y Y 0 0 - 
KRT31 C->T C->T 1 0 Y Y Y Y 0 0 - 
HAP1 S616* S616* 1 0 Y Y Y Y 0 0 - 
C17orf57 R236* R236* 1 0 Y Y Y Y 0 0 - 
C17orf57 G->A G->A 1 0 Y Y Y Y 0 0 - 
ENDOV A->G A->G 1 0 Y Y Y Y 0 0 - 
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Table 2.6: List of Autosomal Genes with Rare Complete Knockouts (Continued) 
Gene Variant 1 
Annotation 
Variant 2 
Annotation 
# 
Cases 
# 
Controls 
Variant 
1 found 
in 
dbSNP? 
Variant 
1 found 
in 
NHLBI 
ESP? 
Variant 
2 found 
in 
dbSNP? 
Variant 
2 found 
in 
NHLBI 
ESP? 
# 
Individuals 
validated 
for Variant 
1 
# 
Individuals 
validated 
for Variant 
2 
In 
trans? 
LILRA3 E54* E54* 1 0 Y Y Y Y 0 0 - 
LILRA3 C->G C->G 1 0 Y Y Y Y 0 0 - 
USH2A Y4238* W2075* 1 0 N N N N 0 0 Y 
ZAN G->A G->A 1 0 Y Y Y Y 0 0 Y 
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Table 2.7: List of X-chromosome Genes with Rare Complete Knockouts 
Gene Chr Variant 
Position 
Variant 
Annotation 
# 
Male 
cases 
# Male 
controls 
# Female 
cases 
# Female 
controls 
Variant 
found in 
dbSNP? 
Variant 
found in 
NHLBI 
ESP? 
# Validated males 
GYG2 X 2795295 Q431* 1 0 0 0 N N 1 
ARSH X 2931214 G->T 1 0 0 0 N N 0 
FAM9C X 13061246 C->A 1 0 0 0 N N 0 
PIR X 15415636 Q210* 1 0 0 0 N N 0 
BEND2 X 18221904 Y208* 1 0 0 0 N N 1 
MAP3K15 X 19387332 R1136* 3 2 0 0 Y Y 0 
MAP3K15 X 19389113 R1122* 0 0 1 0 Y Y 0 
MAP3K15 X 19416381 R677* 0 1 0 0 Y N 0 
MAP3K15 X 19433376 C->A 0 1 0 0 Y Y 0 
MAP3K15 X 19482459 C197* 1 0 0 0 N N 1 
KLHL34 X 21675102 Q269* 0 1 0 0 Y Y 0 
PRDX4 X 23700511 A->G 1 0 0 0 N N 0 
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Table 2.7: List of X-chromosome Genes with Rare Complete Knockouts (Continued) 
Gene Chr Variant 
Position 
Variant 
Annotation 
# 
Male 
cases 
# Male 
controls 
# Female 
cases 
# Female 
controls 
Variant 
found 
in 
dbSNP? 
Variant 
found in 
NHLBI 
ESP? 
# Validated males 
GYG2 X 2795295 Q431* 1 0 0 0 N N 1 
ARSH X 2931214 G->T 1 0 0 0 N N 0 
FAM9C X 13061246 C->A 1 0 0 0 N N 0 
PIR X 15415636 Q210* 1 0 0 0 N N 0 
BEND2 X 18221904 Y208* 1 0 0 0 N N 1 
MAP3K15 X 19387332 R1136* 3 2 0 0 Y Y 0 
MAP3K15 X 19389113 R1122* 0 0 1 0 Y Y 0 
MAP3K15 X 19416381 R677* 0 1 0 0 Y N 0 
MAP3K15 X 19433376 C->A 0 1 0 0 Y Y 0 
MAP3K15 X 19482459 C197* 1 0 0 0 N N 1 
KLHL34 X 21675102 Q269* 0 1 0 0 Y Y 0 
PRDX4 X 23700511 A->G 1 0 0 0 N N 0 
FTHL17 X 31089629 E148* 0 1 0 0 Y Y 0 
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Table 2.7: List of X-chromosome Genes with Rare Complete Knockouts (Continued) 
Gene Chr Variant 
Position 
Variant 
Annotation 
# 
Male 
cases 
# Male 
controls 
# Female 
cases 
# Female 
controls 
Variant 
found 
in 
dbSNP? 
Variant 
found in 
NHLBI 
ESP? 
# Validated males 
DUSP21 X 44703448 Q24* 0 1 0 0 N N 1 
ZNF157 X 47272856 R462* 1 0 0 0 N N 1 
SSX1 X 48125772 Q173* 0 1 0 0 N N 1 
GAGE8 X 49236822 G->T 1 0 0 0 N Y Failed primer design 
ITIH5L X 54815083 C->T 1 0 0 0 N N 1 
PFKFB1 X 54987256 C->T 1 0 0 0 N N Failed primer design 
FAAH2 X 57475022 E432* 3 1 1 0 Y Y 2 
MTMR8 X 63565059 T->G 1 0 0 0 N N 1 
VSIG4 X 65242332 R325* 2 0 0 0 Y Y 1 
DGAT2L6 X 69420288 R151* 1 0 0 0 Y Y 1 
DGAT2L6 X 69421907 Q214* 1 0 0 0 N Y 1 
CXCR3 X 70837390 Q25* 1 0 0 0 Y Y 0 
KIAA2022 X 73959981 Q1471* 1 0 0 0 N N 1 
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Table 2.7: List of X-chromosome Genes with Rare Complete Knockouts (Continued) 
Gene Chr Variant 
Position 
Variant 
Annotation 
# 
Male 
cases 
# Male 
controls 
# Female 
cases 
# Female 
controls 
Variant 
found 
in 
dbSNP? 
Variant 
found in 
NHLBI 
ESP? 
# Validated males 
SATL1 X 84349207 Y601* 1 0 0 0 Y Y 1 
PCDH11X X 91137905 G->A 1 0 0 0 Y Y 0 
SRPX2 X 99921931 G->A 1 0 0 0 N N 1 
DRP2 X 100503119 E432* 1 0 0 0 N N 1 
GLRA4 X 102979868 R54* 1 0 0 0 Y Y 0 
VSIG1 X 107316600 G->A 1 0 0 0 N N 1 
GUCY2F X 108673541 E596* 1 1 0 0 N N 1 
ZCCHC16 X 111698851 R299* 1 0 0 0 N N 1 
LUZP4 X 114540908 R161* 1 0 0 0 N N 1 
LUZP4 X 114540914 R163* 1 0 0 0 N N 1 
KIAA1210 X 118220508 C->T 1 0 0 0 Y N 1 
SLC25A43 X 118544221 R196* 1 0 0 0 Y N 1 
SLC25A43 X 118586969 R323* 1 0 0 0 Y Y 1 
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Table 2.7: List of X-chromosome Genes with Rare Complete Knockouts (Continued) 
Gene Chr Variant 
Position 
Variant 
Annotation 
# 
Male 
cases 
# Male 
controls 
# Female 
cases 
# Female 
controls 
Variant 
found 
in 
dbSNP? 
Variant 
found in 
NHLBI 
ESP? 
# Validated males 
ATP1B4 X 119510234 G->C 1 0 0 0 Y N 0 
ZNF75D X 134421668 Q312* 1 2 0 0 Y Y 0 
MMGT1 X 135047209 R124* 0 1 0 0 N Y 0 
MAP7D3 X 135328223 C->A 0 1 0 0 N N 1 
GPR112 X 135428491 Q876* 1 0 0 0 N N 1 
MCF2 X 138664615 S857* 1 0 0 0 Y Y 0 
MAGEC3 X 140969250 Q193* 1 0 0 0 Y Y 1 
AFF2 X 147744095 Q283* 1 0 0 0 N N 1 
MAMLD1 X 149638986 R381* 0 1 0 0 N N 1 
MECP2 X 153295832 E495* 1 0 0 0 N N 1 
TMLHE X 154743928 T->C 1 0 0 0 N N 1 
ARSF X 2994704 R93* 1 0 0 0 Y Y 0 
FAM9C X 13058887 Q107* 0 1 0 0 N Y 0 
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Table 2.7: List of X-chromosome Genes with Rare Complete Knockouts (Continued) 
Gene Chr Variant 
Position 
Variant 
Annotation 
# 
Male 
cases 
# Male 
controls 
# Female 
cases 
# Female 
controls 
Variant 
found 
in 
dbSNP? 
Variant 
found in 
NHLBI 
ESP? 
# Validated males 
DMD X 31196048 C->T 1 0 0 0 Y Y 0 
SSX1 X 48116655 A->T 1 0 0 0 N Y 0 
ITIH6 X 54777550 E1206* 0 1 0 0 Y Y 0 
VSIG4 X 65244866 C->T 0 1 0 0 N N 0 
DGAT2L6 X 69397495 W21* 1 0 0 0 N N 0 
P2RY4 X 69479172 W101* 0 1 0 0 Y Y 0 
ERCC6L X 71424992 E1086* 0 1 0 0 N N 0 
ZCCHC13 X 73524146 W15* 1 0 0 0 Y Y 0 
SATL1 X 84362650 W255* 2 2 0 0 Y Y 0 
SYTL4 X 99946207 C->T 0 1 0 0 N N 0 
TMEM31 X 102968546 Q43* 0 1 0 0 N N 0 
GLRA4 X 102979868 R54* 1 1 0 0 Y Y 0 
RNF128 X 105937343 Y37* 1 0 0 0 N N 0 
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Table 2.7: List of X-chromosome Genes with Rare Complete Knockouts (Continued) 
Gene Chr Variant 
Position 
Variant 
Annotation 
# 
Male 
cases 
# Male 
controls 
# Female 
cases 
# Female 
controls 
Variant 
found 
in 
dbSNP? 
Variant 
found in 
NHLBI 
ESP? 
# Validated males 
TEX13B X 107224898 C->T 1 1 0 0 Y Y 0 
SLC25A43 X 118540640 R165* 0 1 0 0 Y Y 0 
OR13H1 X 130678702 R219* 1 0 0 0 N Y 0 
CT45A5 X 134947910 R139* 1 0 0 0 Y Y 0 
MAP7D3 X 135312997 C->G 1 0 0 0 N Y 0 
CDR1 X 139865915 W206* 0 1 0 0 N N 0 
MAGEC3 X 140969250 Q193* 1 0 0 0 Y Y 0 
HAUS7 X 152720388 R362* 1 0 0 0 N N 0 
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Similar Enrichment of Rare Complete Knockouts Observed on the X-chromosome 
Given the gender bias in ASD, with roughly 4 times as many affected males than females 
[24], we asked analogously whether rare gene knockouts outside the pseudo-autosomal regions 
on the X-chromosome (arising from hemizygous LoFs in males) were enriched in male cases 
versus male controls. To further increase the sample sizes, we included the male probands and 
their unaffected fathers from the trios and quartets. The nucleotide diversity on the X-
chromosome is estimated to be between half to three-quarters that of the autosomes and 
deleterious LoF variants on the X-chromosome are under stronger negative selection given the 
smaller effective population size and constant exposure in hemizygous males [25]. To match the 
baseline knockout rate to the autosomes, where we examined variants with ≤5% minor allele 
frequency (MAF) and therefore ≤0.25% homozygosity, we examined LoF variants with 
population frequency (assessed in female control samples) of ≤0.25%. On average, we observed 
less than 1 such rare LoF variant on the X-chromosome in both males and females (Table 2.8). 
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Table 2.8: Population Distribution of LoF variants on the X-chromosome 
The average number of rare (≤0.25%) and common (>0.25%) LoFs outside the pseudo-
autosomal regions on the X-chromosome in males, as well as the average number of rare and 
common LoFs outside the pseudo-autosomal regions on the X-chromosome in females is shown. 
 Average 
number of 
hemizygous 
variants in 
males 
Number of 
unique genes 
with a 
hemizygous 
variant in males 
in the datasets 
Average 
number of 
heterozygous 
and 
homozygous 
variants in 
females 
Number of 
unique genes 
with a variant 
in females in the 
datasets 
Rare (≤0.25%) 
LoFs 
0.02 variant per 
individual 
28 genes 0.04 variant per 
individual 
41 genes 
Common 
(>0.25%) LoFs 
0.23 variant per 
individual 
11 genes 0.21 variant per 
individual 
13 genes 
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Similar to the autosomes, we observed a significant enrichment of rare hemizygous LoFs 
in male cases (Table 2.9), with 88 such events observed – 60 of them were found in male cases 
and 28 of them were found in male controls (OR = 1.5, 95% CI = [1.1, 2.0], one-sided 
hypergeometric test P = 0.034). No enrichment was seen in the internal controls of this 
comparison - rare hemizygous synonymous variants were not enriched in male cases compared 
to male controls (OR = 1.0, 95% CI = [0.9, 1.1]), indicating the observed enrichment is specific 
to rare complete knockouts on the X-chromosome in male ASD cases. Based on the difference 
between cases and controls, we further estimate another 1.7% contribution by rare complete 
knockouts on the X-chromosome in male cases. In addition, we found 2 of 170 female cases 
bearing a rare complete knockout on the X-chromosome and 0 of 452 female controls. As with 
the autosomes, we attempted validation for 44 of 50 rare X-chromosome LoF variants and all 44 
validated. 
We screened the list of rare complete knockouts observed on the autosomes and X-
chromosome for instances where a knockout was observed only in cases and not in any of the 
controls (Table 2.10) and performed a screen for enrichment of pathways and microRNA targets 
using WebGestalt [26]. The top pathway (“Complement and coagulation cascades”) was driven 
by 2 genes (KNG1 and PLAT; corrected P = 0.0027). Scanning predicted targets of microRNAs, 
we found one (mir-328) predicted to target 3 genes from the list (HAP1, AFF2 and MECP2; 
corrected P = 0.0013; Table 2.11). Additional siblings (affected = 30, unaffected = 17) were 
available for 31 probands who were genotyped to examine segregation of a proposed recessive 
model (Table 2.12). We observed 25 (expected 20) instances where segregation was consistent 
with a fully penetrant recessive model, including 4 genes with rare complete knockouts (PTH2R, 
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MECP2, VSIG1 and ZCCHC16) observed in cases only and not in a single control in any wave 
of our study. 
 
Gender and IQ 
It has been shown that the male gender bias is stronger in high-functioning ASD cases, 
and the gender bias is reduced for syndromic cases [27]. We found that there was a higher rate of 
rare complete knockouts in females (5.4%) compared to males (4%). Although 16% of the cases 
sequenced were female, 25% of the cases harboring rare complete knockouts were female (OR = 
1.7, 95% CI = [1.3, 2.1], one-sided Fisher’s P = 0.076). While not statistically significant, this 
trend is similar to previous observations that de novo CNVs and SNVs show a higher fraction of 
female cases with such events [4,5,8] and consistent with the model that females need a higher 
dose of genetic risk to manifest a diagnosis of ASD. We also observed a trend in IQ scores from 
18 of these cases with rare complete knockouts to another 133 cases (mean Z-score = -0.26 in 
probands with rare complete knockouts versus 0.035 in other cases), but it was not statistically 
significant (one-sided Wilcox P = 0.11). 
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Table 2.9: Number of Rare LoF and Synonymous Variants on the X-chromosome 
The number of rare hemizygous LoF and synonymous variants outside the pseudo-autosomal 
regions on the X-chromosome in males, as well as the number of rare heterozygous LoF and 
synonymous variants in females are shown, together with the respective odds ratios. 
 Rare hemizygous / 
heterozygous LoF variants 
Rare hemizygous / heterozygous 
synonymous variants 
Hemizygous LoFs in males (N = 2,144) 
Cases (N = 1,245) 60 events 2,114 events 
Controls (N = 899) 28 events 1,516 events 
OR [95% CI] 1.5 [1.1, 2.0] 1.0 [0.9, 1.1] 
Heterozygous LoFs in females (N = 622) 
Cases (N = 170) 21 events 641 events 
Controls (N = 452) 56 events 1,256 events 
OR [95% CI] 1.0 [0.5, 1.5] 1.4 [1.2, 1.6] 
 Rare homozygous LoF 
variants 
Rare homozygous synonymous 
variants 
Homozygous LoFs in females (N = 622) 
Cases (N = 170) 2 events 5 events 
Controls (N = 452) 0 events 0 events 
OR [95% CI] - - 
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Table 2.10: List of Rare Complete Knockouts on Autosomes and X-chromosome Found in 
Cases Only 
A summary of the list of genes with rare complete knockouts observed only in the cases and not 
in controls - genes found to be involved in known diseases have been marked with “*”, and 
genes found in CNVs regions previously implicated in ASD risk have been marked with “+”. 
Gene Chr # Cases # Controls Expressed in the brain? 
DGAT2L6 X 3 0 No 
SLC22A14 3 2 0 No 
LUZP4 X 2 0 No 
MAGEC3 X 2 0 Unknown 
CFHR2 1 1 0 Yes 
USH2A* 1 1 0 No 
PTH2R 2 1 0 Yes 
KNG1 3 1 0 No 
TGM4 3 1 0 No 
AGXT2 5 1 0 No 
KIAA1919 6 1 0 Yes 
MICB 6 1 0 Yes 
ACTR3C 7 1 0 Unknown 
LRRC69 8 1 0 Unknown 
PLAT 8 1 0 Yes 
CYP2C18 10 1 0 Yes 
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Table 2.10: List of Rare Complete Knockouts on Autosomes and X-chromosome Found in 
Cases Only (Continued) 
A summary of the list of genes with rare complete knockouts observed only in the cases and not 
in controls - genes found to be involved in known diseases have been marked with “*”, and 
genes found in CNVs regions previously implicated in ASD risk have been marked with “+”. 
C12orf64 12 1 0 Unknown 
PZP 12 1 0 Unknown 
LRRC29 16 1 0 No 
DBF4B 17 1 0 Unknown 
HAP1 17 1 0 Yes 
AFF2* X 1 0 Yes 
ARSF X 1 0 Yes 
ARSH X 1 0 Unknown 
ATP1B4 X 1 0 No 
BEND2 X 1 0 No 
CT45A5 X 1 0 Yes 
CXCR3 X 1 0 Yes 
DMD X 1 0 Yes 
DRP2 X 1 0 Yes 
GPR112 X 1 0 Unknown 
GYG2 X 1 0 Yes 
HAUS7 X 1 0 Yes 
ITIH5L X 1 0 No 
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Table 2.10: List of Rare Complete Knockouts on Autosomes and X-chromosome Found in 
Cases Only (Continued) 
A summary of the list of genes with rare complete knockouts observed only in the cases and not 
in controls - genes found to be involved in known diseases have been marked with “*”, and 
genes found in CNVs regions previously implicated in ASD risk have been marked with “+”. 
KIAA1210 X 1 0 Unknown 
KIAA2022* X 1 0 Unknown 
MCF2 X 1 0 Yes 
MECP2* X 1 0 Yes 
MTMR8 X 1 0 Yes 
PCDH11X+ X 1 0 Yes 
PIR X 1 0 Yes 
PRDX4 X 1 0 Yes 
RNF128 X 1 0 Yes 
SRPX2* X 1 0 Yes 
TMLHE+ X 1 0 Yes 
VSIG1 X 1 0 Yes 
ZCCHC13 X 1 0 No 
ZCCHC16 X 1 0 No 
ZNF157 X 1 0 Yes 
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Table 2.11: List of microRNAs and the Enrichment of Targets in the Gene List Found in 
Table 2.10 
MicroRNA Raw P-value Corrected P-value 
MIR-328 6.28e-05 0.0013 
MIR-361 0.0031 0.0163 
MIR-504 0.0030 0.0163 
MIR-124A 0.0020 0.0163 
MIR-194 0.0049 0.0175 
MIR-452 0.0050 0.0175 
MIR-143 0.0090 0.0270 
MIR-494 0.0105 0.0276 
MIR-518A-2 0.0166 0.0349 
MIR-369-3P 0.0166 0.0349 
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Table 2.12: Segregation Patterns within Multiplex Families 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
C1orf127 Proband F Affected 
 
AA - Y - N 
 
Sibling F Unaffected 
 
AA - 
   
 
Sibling M Affected 
 
GA - 
   
 
Dad M Unaffected 
 
AA - 
   
 
Mum F Unaffected 
 
GA - 
   PRAMEF2 Proband M Affected   T T - Y - N 
  Sibling M Affected   GG -       
  Sibling M Unaffected   GT -       
  Dad M Unaffected   GT -       
  Mum F Unaffected   GG -       
C1orf168 Proband M Affected 
 
TC TA Y N - 
 
Sibling F Affected 
 
TT TT 
   
 
Dad M Unaffected 
 
TT TT 
   
 
Mum F Unaffected 
 
TC TA 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
VWA3B Proband M Affected   TT - Y - N 
  Sibling M Affected   GT -       
  Dad M Unaffected   TT -       
  Mum F Unaffected   GT -       
VWA3B Proband M Affected 
 
GT AA N - - 
 
Sibling M Affected 
 
GT AA 
   
 
Dad M Unaffected 
 
GT AA 
   
 
Mum F Unaffected 
 
GG AA 
   PTH2R Proband M Affected   AA - Y - Y 
  Sibling M Affected   AA -       
  Sibling M Unaffected   CA -       
  Sibling M Unaffected   CC -       
  Dad M Unaffected   CA -       
  Mum F Unaffected   CA -       
DPP4 Proband M Affected 
 
CC - Y - Y 
 
Sibling M Affected 
 
CC - 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
 
Sibling F Unaffected 
 
TT - 
   
 
Dad M Unaffected 
 
TC - 
   
 
Mum F Unaffected 
 
TC - 
   DPP4 Proband F Affected   CC - Y - N 
  Sibling F Unaffected   TC -       
  Sibling M Affected   CC -       
  Dad M Unaffected   CC -       
  Mum F Unaffected   TC -       
IFIH1 Proband M Affected 
 
GG - Y - N 
 
Sibling M Affected 
 
CC - 
   
 
Sibling M Unaffected 
 
CC - 
   
 
Dad M Unaffected 
 
CG - 
   
 
Mum F Unaffected 
 
CG - 
   UGT2A1 Proband M Affected   TT - Y - N 
  Sibling M Affected   AA -       
  Sibling M Unaffected   AT -       
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
  Dad M Unaffected   AT -       
  Mum F Unaffected   AT -       
WDR17 Proband F Affected 
 
AA AA N - - 
 
Sibling F Affected 
 
AA AA 
   
 
Dad M Unaffected 
 
AA AA 
   
 
Mum F Unaffected 
 
AA AA 
   KIAA1919 Proband F Affected   AA - Y - N 
  Sibling F Affected   TT -       
  Sibling M Unaffected   TA -       
  Dad M Unaffected   TA -       
  Mum F Unaffected   TA -       
TAAR2 Proband F Affected 
 
TT - Y - Y 
 
Sibling F Affected 
 
TT - 
   
 
Dad M Unaffected 
 
CT - 
   
 
Mum F Unaffected 
 
CT - 
   UNC93A Proband M Affected   CC - Y - N 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
  Sibling M Affected   GC -       
  Sibling M Affected   GC -       
  Dad M Unaffected   GC -       
  Mum F Unaffected   GC -       
RNF32 Proband M Affected 
 
CC - Y - N 
 
Sibling M Affected 
 
TT - 
   
 
Sibling F Affected 
 
CC - 
   
 
Dad M Unaffected 
 
TC - 
   
 
Mum F Unaffected 
 
TC - 
   RNF32 Proband F Affected   CC - Y - N 
  Sibling F Affected   TT -       
  Dad M Unaffected   TC -       
  Mum F Unaffected   TC -       
INTS8 Proband F Affected 
 
AA AA N - - 
 
Sibling F Affected 
 
AA AA 
   
 
Dad M Unaffected 
 
AA AA 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
 
Mum F Unaffected 
 
AA AA 
   OR10V1 Proband M Affected   AA - Y - N 
  Sibling F Affected   AA -       
  Dad M Unaffected   AA -       
  Mum F Unaffected   AA -       
SLC22A25 Proband M Affected 
 
TC CT Y Y Y 
 
Sibling M Affected 
 
TC CT 
   
 
Dad M Unaffected 
 
TC TT 
   
 
Mum F Unaffected 
 
TT CT 
   RAD52 Proband F Affected   AC - Y - Y 
  Sibling F Affected   CC -       
  Dad M Unaffected   AC -       
  Mum F Unaffected   AC -       
RAD52 Proband M Affected 
 
AC GT Y - N 
 
Sibling M Affected 
 
CC GG 
   
 
Sibling F Unaffected 
 
CC GG 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
 
Dad M Unaffected 
 
AC TT 
   
 
Mum F Unaffected 
 
AC GG 
   KRT83 Proband M Affected   AA - Y - N 
  Sibling M Unaffected   CA -       
  Sibling M Unaffected   AA -       
  Dad M Unaffected   AA -       
  Mum F Unaffected   CA -       
OAS3 Proband F Affected 
 
CT CT Y Y N 
 
Sibling F Affected 
 
CT CC 
   
 
Dad M Unaffected 
 
CT CC 
   
 
Mum F Unaffected 
 
CC CT 
   C14orf105 Proband M Affected   AA - Y - N 
  Sibling M Affected   GA -       
  Dad M Unaffected   GA -       
  Mum F Unaffected   GA -       
ABCC12 Proband F Affected 
 
TT - Y - N 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
 
Sibling M Affected 
 
CT - 
   
 
Sibling M Unaffected 
 
CT - 
   
 
Dad M Unaffected 
 
CT - 
   
 
Mum F Unaffected 
 
CT - 
   C17orf57 Proband M Affected   GA AT Y Y Y 
  Sibling F Unaffected   GA AA       
  Dad M Unaffected   GA AA       
  Mum F Unaffected   GG AT       
ABCA10 Proband M Affected 
 
AA - Y - Y 
 
Sibling F Affected MZ AA - 
   
 
Sibling F Affected MZ AA - 
   
 
Dad M Unaffected 
 
GA - 
   
 
Mum F Unaffected 
 
GA - 
   ABCA10 Proband M Affected   AA - Y - N 
  Sibling M Affected   GA -       
  Sibling M Unaffected   GG -       
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
  Dad M Unaffected   GA -       
  Mum F Unaffected   GA -       
ABCA10 Proband M Affected 
 
AA - Y - Y 
 
Sibling M Affected 
 
AA - 
   
 
Sibling M Unaffected 
 
GA - 
   
 
Dad M Unaffected 
 
GA - 
   
 
Mum F Unaffected 
 
GA - 
   ABCA10 Proband M Affected   AA - Y - N 
  Sibling M Affected   GA -       
  Sibling F Affected   GA -       
  Dad M Unaffected   GA -       
  Mum F Unaffected   GA -       
FLJ35220 Proband M Affected 
 
GG - Y - N 
 
Sibling M Affected 
 
AG - 
   
 
Dad M Unaffected 
 
GG - 
   
 
Mum F Unaffected 
 
AG - 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
STARD6 Proband M Affected   AA - Y - N 
  Sibling M Affected   GA -       
  Dad M Unaffected   GA -       
  Mum F Unaffected   AA -       
STARD6 Proband F Affected 
 
AA - Y - N 
 
Sibling F Unaffected 
 
AA - 
   
 
Sibling M Affected 
 
GG - 
   
 
Dad M Unaffected 
 
GA - 
   
 
Mum F Unaffected 
 
GA - 
   STARD6 Proband M Affected   AA - Y - Y 
  Sibling M Unaffected   GA -       
  Sibling M Affected   AA -       
  Dad M Unaffected   GA -       
  Mum F Unaffected   GA -       
ZNF77 Proband M Affected 
 
AA - Y - N 
 
Sibling M Affected 
 
GA - 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
 
Dad M Unaffected 
 
GA - 
   
 
Mum F Unaffected 
 
GA - 
   UNC13A Proband M Affected   AA - Y - N 
  Sibling M Affected   GA -       
  Dad M Unaffected   GA -       
  Mum F Unaffected   AA -       
LILRA3 Proband M Affected 
 
CA CG Y N N 
 
Sibling M Affected 
 
CA CG 
   
 
Sibling M Unaffected 
 
CA CG 
   
 
Dad M Unaffected 
 
CC CC 
   
 
Mum F Unaffected 
 
CA CG 
   SLC17A9 Proband F Affected   GT TC Y N - 
  Sibling F Unaffected   GG TT       
  Sibling F Unaffected   GG TT       
  Sibling M Affected   GT TC       
  Dad M Unaffected   GG TT       
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
  Mum F Unaffected   GT TC       
MAP3K15 Proband M Affected 
 
TT - Y - N 
 
Sibling M Unaffected 
 
TT - 
   
 
Dad M Unaffected 
 
GG - 
   
 
Mum F Unaffected 
 
GT - 
   ZNF157 Proband M Affected   TT - Y - N 
  Sibling M Affected   CC -       
  Dad M Unaffected   CC -       
  Mum F Unaffected   CT -       
MTMR8 Proband M Affected 
 
GG - Y - N 
 
Sibling M Affected 
 
TT - 
   
 
Sibling M Unaffected 
 
TT - 
   
 
Sibling F Unaffected 
 
TT - 
   
 
Sibling F Unaffected 
 
TT - 
   
 
Dad M Unaffected 
 
TT - 
   
 
Mum F Unaffected 
 
TG - 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
VSIG4 Proband M Affected MZ AA - Y - Y 
  Sibling M Affected MZ AA -       
  Sibling M Unaffected   TT -       
  Dad M Unaffected   TT -       
  Mum F Unaffected   TA -       
VSIG1 Proband M Affected 
 
AA - Y - Y 
 
Sibling M Affected 
 
AA - 
   
 
Sibling M Unaffected 
 
GG - 
   
 
Dad M Unaffected 
 
GG - 
   
 
Mum F Unaffected 
 
GA - 
   ZCCHC16 Proband M Affected   TT - Y - Y 
  Sibling M Affected   TT -       
  Sibling F Unaffected   CC -       
  Dad M Unaffected   CC -       
  Mum F Unaffected   CT -       
LUZP4 Proband M Affected 
 
TT - Y - N 
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Table 2.12: Segregation Patterns within Multiplex Families (Continued) 
Gene Status Gender Affected_status MZ/DZ Genotype1 Genotype2 Validated? In trans? Recessive inheritance? 
 
Sibling M Affected MZ CC - 
   
 
Sibling M Affected MZ CC - 
   
 
Dad M Unaffected 
 
CC - 
   
 
Mum F Unaffected 
 
CT - 
   SLC25A43 Proband M Affected   TT - Y - N 
  Sibling M Unaffected   TT -       
  Dad M Unaffected   CC -       
  Mum F Unaffected   CT -       
MECP2 Proband M Affected 
 
AA - Y - Y 
 
Sibling M Affected 
 
AA - 
   
 
Dad M Unaffected 
 
CC - 
   
 
Mum F Unaffected 
 
AC - 
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DISCUSSION 
As shown previously, de novo copy number variants (CNVs) are extremely rare events in 
a control population and they occur at 1-2% in controls. Given the rarity of such events, 
discovery of a global enrichment of these de novo CNVs at a much higher rate of 6-8% in ASD 
individuals suggested a 6% contribution to ASD by these de novo CNVs [2,4,5]. This 
highlighted the significance of such events as risk factors for ASD and subsequent association 
and replication studies of such events with larger sample sizes pinpointed to specific de novo 
CNVs that have since been significantly associated with ASD, such as deletions and duplications 
on chromosome 16p11.2 [3]. 
Similar to the de novo CNV studies, as well as emerging de novo SNV studies, we 
observed that rare complete knockouts in the human exome are found in only 3% of a control 
population, but are present at a 2-fold enrichment in ASD cases. Given that these rare complete 
knockouts are not found in a single gene but, like the de novo CNVs and SNVs, are distributed 
across many different genes, these events would have been missed through previous association 
or linkage studies. As with any genetic screen, population stratification can confound these 
results. However, the samples selected for sequencing were of European ancestry and 
individually matched in case-control pairs based on principal component analyses and selected 
from a much larger pool of potential samples. Owing to occasional sample failure, ultimately 
88% of the final samples were matched one-to-one for ancestry and a similar 2-fold enrichment 
was observed in the subset of matched cases and controls for the rare complete knockouts (49 
events in cases versus 25 events in controls, OR = 2, 95% CI = [1.5, 2.5]). 
Interestingly, we observed a 1.5-fold enrichment of hemizygous LoF variants on the X-
chromosome in male cases compared to male controls, but did not observe a significant global 
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enrichment of heterozygous LoF variants on the X-chromosome in female cases compared to 
female controls. There are genes on the X-chromosome that can cause ASD-related disorders 
like Rett Syndrome in an X-linked dominant mode of inheritance such as CDKL5 and MECP2. 
However, we found that while there is a significant 1.5-fold enrichment in hemizygous LoFs in 
male cases, we did not observe a significant enrichment in single-copy losses in female cases, 
consistent with the observation that we did not see an overall difference in single-copy 
(heterozygous) losses on the autosomes. Given that males have only a single copy of the X-
chromosome and would be more susceptible to a complete knockout on the X-chromosome than 
females, these rare complete knockouts on the X-chromosome can also explain a small part of 
the male gender bias observed in ASD. 
 
Candidate genes 
Among our list of consolidated genes with rare complete knockouts that were observed 
only in cases, we discovered a known autosomal recessive gene in one of the probands from the 
trios – Usher syndrome 2A (USH2A), which has been reported to cause a known autosomal 
recessive disease Usher Syndrome Type II, characterized by mild to severe hearing loss and 
sometimes retinitis pigmentosa [28]. We found and confirmed the bilinieal inheritance of two 
previously unreported compound heterozygous nonsense mutations (W2075X and Y4238X) in 
USH2A from both parents. Clinical follow-up confirmed an Usher Syndrome Type II diagnosis – 
a potential confounder in the diagnosis of ASD [29]. 
 When we cross-compared the list of genes harboring rare complete knockouts with 
previously published literature on de novo SNVs [7,8,9,10], we found 3 genes that were common 
between the rare complete knockouts and de novo SNVs – IFIH1 (where a de novo missense 
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variant was found in a proband), ABCC12 (where a de novo silent variant was found in a 
proband) and PKHD1L1 (where a de novo upstream variant was found in a proband).  
We further compared the list of X-chromosome genes with previously published CNVs 
and found that there are 2 genes that have been previously associated with rare CNVs. We found 
an affected male with a rare hemizygous splice variant (c.359-2T>C) in the trimethyllysine 
hydroxylase, epsilon protein – TMLHE, which is involved in the biosynthesis of carnitine [30]. 
Recently, TMLHE deficiency resulting in dysregulation of carnitine metabolism has also been 
proposed as a risk factor for ASD [31,32]. Another affected male was found to harbor a 
hemizygous splice variant (c.3034-1G>A) in the protocadherin 11 X-linked protein – PCDH11X. 
An inherited deletion in PCDH11X, as well as a de novo deletion in PCDH11Y was previously 
reported in a child with severe language delay, suggesting a potential role for PCDH11X in 
language development [33]. 
There were 3 genes with at least 2 male cases harboring rare complete knockouts on the 
X-chromosome and no controls were found to harbor rare complete knockouts in these genes 
(SLC22A14, LUZP4, DGAT2L6). In addition, among a list of genes known to be involved in 
intellectual disability [9], we found 4 genes from our list with rare complete knockouts in 4 male 
cases. One affected male has a nonsense variant Q283X in the Fragile X E mental retardation 
syndrome protein (AFF2), which causes non-syndromic mental retardation and this nonsense 
variant results in more than 80% of the protein to be truncated. Another male case has a nonsense 
variant resulting in Q1471X in an uncharacterized gene KIAA2022 and mouse studies revealed 
that the protein is expressed in the developing brain and plays a role in neurite outgrowth [34]. A 
third male case has a splice variant c.961+1G>A in Sushi-repeat containing protein, X-linked 2 
(SRPX2), a protein that is found to be expressed in neurons. Mutations in SRPX2 have been 
93 
 
reported to be associated with rolandic epilepsy with speech and cognition impairment [35] and 
FOXP2, a gene which is involved in speech and language disorders, has been shown to regulate 
SRPX2 [36]. A fourth male with ASD harbored an E495X nonsense variant in methyl CpG 
binding protein 2 (MECP2). Complete knockouts in MECP2 are lethal in males and 
heterozygous LoFs in MECP2 cause Rett Syndrome in females. Interestingly, the hemizygous 
nonsense mutation that was observed in this male case truncates only the last four amino acids of 
the MECP2 protein and this potentially generates a protein product, which explains why the 
hemizygous LoF observed in this gene is viable in a male. Late-truncating mutations in MECP2 
have been reported to cause the Zappella variant of Rett Syndrome, which is a milder form of 
Rett Syndrome and autistic behavior is often observed in affected individuals [37]. 
 
Total Contribution to ASD From de novo and Inherited Factors 
As described previously in various studies, there is an estimated 6% contribution to ASD 
risk from de novo CNVs [4,5,38]. Recent studies have estimated another 10% contribution to 
ASD risk by de novo SNVs [7,8,9,10]. In this study, we estimate a 3% contribution to ASD risk 
by rare complete knockouts on the autosomes and another 2% contribution by rare complete 
knockouts on the X-chromosome, resulting in another 5% contribution to ASD risk. Because a 
comparably reliable and validated set of insertion and deletion variants are not yet available 
across our entire dataset, we have not fully evaluated the contribution of frameshifts. Given that 
there is likely a similar number of frameshift mutations as single nucleotide LoF variants [8,19], 
the addition of frameshifts will likely increase this contribution further. 
The global enrichment of rare complete knockouts in cases highlights the significance of 
such events in the overall genetic etiology of ASD. In addition, these events provide further 
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insight into the heritable component of ASD, which have not yet been accounted for by de novo 
CNVs and SNVs. However, many of these rare complete knockouts are distributed across many 
different genes. This agrees with our current understanding of ASD genetics to date: that this 
complex disorder follows a multigenic model where hundreds of genes are involved and that 
each individual gene accounts for a small fraction of ASD. Together with the ongoing de novo 
CNV and SNV studies, our study and that of another study in this issue [39], demonstrate 
convincing evidence of a rare recessive contribution to the heritability of ASD. 
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MATERIALS AND METHODS 
The institutional review board of all participating institutions approved this study and 
written informed consent from all subjects was obtained. The datasets and detailed information 
for the samples have been deposited into dbGAP (accession ID: phs000298.v1.p1). 
 
Exome capture and sequencing 
Exome capture and sequencing at BI was performed as follows. Genomic DNA was 
sheared to 200-300 bp using a Covaris Acoustic Adaptor. Fragments were end-repaired, dA-
tailed, and sequencing adaptor oligonucleotides ligated using reagents from New England 
BioLabs. Libraries were barcoded using the Illumina index read strategy, which uses six-base 
sequences within the adapter that are sequenced separately from the genomic DNA insert. The 
DNA library was subsequently enriched for sequences with 5' and 3' adapters by PCR 
amplication using with primers complementary to the adapter sequences (ligation-mediated PCR, 
LM-PCR). Exons were captured using the Agilent 38Mb SureSelect v2. In some cases, barcoded 
libraries from 2-4 subjects were mixed prior to hybridization with the capture reagent. After 
capture, another round of LM-PCR was performed to generate enough DNA to sequence. 
Libraries were sequenced using an IlluminaHiSeq2000. 
At BCM, genomic DNA was sheared into fragments of approximately 120 base pairs 
with the Covaris S2 or E210 system. Fragments were processed through DNA End-Repair and 
A-tailing, and the resulting fragments were ligated with BCM-HGSC-designed Truncated-TA 
(TrTA) P1 and TA-P2 adapters with the NEB Quick Ligation Kit. Solid Phase Reversible 
Immobilization bead cleanup was used to purify the adapted fragments, after which nick 
translation and Ligation-Mediated PCR was performed using Platinum PCR Supermix HIFi. The 
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pre-capture libraries were hybridized to NimbleGen EZ Exome v2, VCRome v1, or VCRome 
v2.1 probes, either in solution or with solid-phase capture chips, and then amplied. In some 
cases, barcoded capture libraries were pooled in sets of 4 samples after postcapture amplication. 
Libraries were sequenced on the Life Technologies SOLiD platform using both 50bp fragment 
and 50x35bp paired-end run formats. 
 
Data quality control and filtering 
BI data was processed with Picard (http://picard.sourceforge.net/), which utilizes base 
quality score recalibration and local realignment at known indels and BWA for mapping reads to 
hg19. SNPs were called using GATK [40]. BCM data was processed with Picard and reads 
mapped to hg18 using Bfast [41]. The quality score recalibration and indel realignment was 
performed using GATK, followed by SNV identification using AtlasSNP 2 software [42]. 
Genotyping data from Affymetrix 5.0 and 6.0 was filtered using an MAF threshold of ≥5% and 
missing genotypes with ≤2% using PLINK and concordance checks were performed on the 
variant calls from the sequencing and genotyping arrays. 3 samples with low concordance 
between the exome sequencing and genotyping arrays (≤90%) were detected in the BI case-
control dataset and discarded from further analyses.  
The variants used in this study were restricted to sites that passed the standard GATK 
filters to eliminate SNPs with strand-bias, low quality for the depth of sequencing achieved, 
homopolymer runs, and SNPs near indels. And variants were required had an average read depth 
of ≥10x and a quality score of ≥30. Homozygous calls were required to have less than 10% of 
the alternate allele and heterozygous calls to have an allele balance of between 30% and 70%. A 
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HWE threshold of ≥0.05 was used as well. A set of 160 rare variants was selected for Sequenom 
validation and the validation rate using these filters was 99.5%.  
 
Annotation and analyses 
For the case-control datasets, we annotated each variant according to the longest 
transcript from the RefSeq database. The trio and quartet datasets were annotated using a custom 
pipeline that was built on top of the Variant Effect Predictor [43] to allow more stringent filtering 
of annotation artifacts from the 1000 Genomes Project [19]. The cases and controls in the BI 
dataset was compared separately from the cases and controls in the BCM dataset before 
combining the results, to ensure that differences in sequencing technologies and platforms did 
not affect the results. Variants on the autosomes were filtered using MAF≤5% in the controls 
from each dataset. 
Variants on the X-chromosome were filtered using similar thresholds as the autosomal 
variants. In addition, variants that were found to be heterozygous in males were removed from 
the analyses as such inconsistencies were most likely to have resulted from mis-alignment errors. 
To increase the number of observations for the X-chromosome analyses, male probands from the 
trios/quartets were added as additional cases to the overall counts from the case-control datasets 
and their fathers were added as additional controls, since male offspring do not inherit their X-
chromosomes from their fathers and the X-chromosomes in their fathers would serve as perfect 
normal controls. In addition, the MAF for rare variants on the X-chromosome were calculated 
from a large set of control females from the NHLBI exome sequencing study. 
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Fluidigm genotyping 
96 PCR primer pairs and probes were designed by Fluidigm Corporation to amplify 
candidate mutations with a target amplicon size of 200 bp. Using the Fluidigm microfluidic 
platform, 96 multiplex-PCR reactions were performed using 96 DNA samples. Genotyping and 
clustering of calls were performed by manufacturer instructions for the Fluidigm Dynamic Array 
system in which assays are based on allele-specific PCR SNP detection chemistry and integrated 
fluidic circuits (IFCs). 
 
Sanger sequencing 
We designed primers and amplified regions around the candidate LoF sites according to 
standard protocols. PCR products were sequenced using traditional Sanger fluorescent dideoxy 
method on ABI 3730 capillary sequencers. Resulting sequences were analyzed and SNVs 
detected using SNPdetector software [44]. 
 
Sample preparation and pooling for Fluidigm PCR and MiSeq sequencing 
The baseline concentration of genomic DNA was quantified by Quant-iT PicoGreen 
dsDNA reagent and detected on the Thermo Scientific Varioskan Flash. All DNAs were 
normalized to 50ng/μl and repeat quantification was performed to assess accuracy of the 
normalization step.  The quantification and normalization was repeated again to ensure that all 
samples fell within the desired concentration range. A 10% variance was allowed, as that is the 
limit of quantitation of PicoGreen detection system. The normalization steps were done with 
robotic automation using the Packard Multiprobe II HT EX and Caliper LabChip GX system. 
Equimolar amounts of each DNA in a pool of samples is essential thus the same robotic 
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automation was used to guarantee a uniform pipetting error across all samples in all steps. Once 
each individual sample was normalized to 50ng/ul, 2 parental samples from different families 
were pooled together using a Multiprobe or Packard Robotic to total 25 pools (50 people). These 
pools along with individual probands were sent for Fluidigm PCR and MiSeq sequencing efforts 
described below. 
 
Fluidigm PCR and MiSeq sequencing 
Validation of selected variants was performed by targeted resequencing using 
microﬂuidic PCR (Access array system, Fluidigm) and the MiSeq sequencing system (Illumina). 
Father, mother and probands from each family with a LoF mutation were selected based on the 
presence of the indicated variant by whole exome sequencing. Target speciﬁc primers were 
designed to ﬂank sites of interest and produce amplicons of 150-200 bp ± 20 bp. Molecularly 
barcoded, Illumina-compatible speciﬁc oligos, containing sequences complementary to the 
primer tails were added to the access array chip in the same well as the genomic DNA samples 
(20–50 ng of input) such that all amplicons for a given genomic sample share the same index. 
PCR was performed on the Fluidigm access array according to the manufacturer’s instructions. 
Indexed libraries were recovered for each sample in a single collection well from the Fluidigm 
chip, quantiﬁed using PicoGreen, and then normalized for uniformity across libraries. Resulting 
normalized libraries were loaded on the MiSeq instrument and sequenced using paired end 150 
bp sequencing reads. Paired-end sequencing was carried out by using MiSeq sequencing 
instruments; the resulting data were analyzed with the current Illumina pipeline. Standard quality 
control metrics, including error rates, percentage passing ﬁlter reads, and total Gb produced, 
were used to characterize process performance before downstream analysis. The Illumina 
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pipeline generates data ﬁles (BAM ﬁles) that contain the reads together with quality parameters. 
Detection of the presence of the targeted variants in each sample was done using the mpileup 
option in Samtools and were visually inspected using the tview option [45]. 
 
Linkage disequilibrium-based phasing of variant pairs 
We adopted a linkage disequilibrium (LD) based method, similar to the four-haplotype 
test used to detect a recombination event, to phase pairs of variants within the same gene and 
applied this approach to predict compound heterozygous variants in the case-control datasets. A 
pair of variants (A and B) was predicted to occur on different chromosomes if: 
1. We observed at least 1 individual who is heterozygous for variant A; and, 
2. we observed at least 1 individual who is heterozygous for variant B; and, 
3. we did not observe any individual who is homozygous at 1 variant and has at least 1 copy of 
the second variant (Figure 2.1). 
In addition, since we cannot accurately phase singletons, we included all pairs of variants if at 
least one of them is a singleton. 
 
Statistical analyses for global enrichment 
For each variant, we calculated the MAF of the variant in the controls. The MAF of a 
variant pair is the maximum MAF of either variant in the pair. Multiple variant pairs within the 
same gene in the same individual were counted as a single complete knockout event. We 
calculated the normalized enrichment ratio as the (total number of events in cases/total number 
of events in controls)×(number of controls/number of cases) to handle the imbalance in the 
number of cases and controls that were sequenced. We assessed the statistical significance of the 
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global enrichment by shuffling the case-control labels for 10,000 permutations. For the 
enrichment analyses on the X-chromosome, one-sided hypergeometric probabilities were 
calculated assuming that hemizygous synonymous variants in male cases and controls are largely 
neutral variants. All the analyses were performed within each case-control dataset separately 
before combining the results, to ensure that the observations were not driven by a single dataset. 
 
Copy number variant calling from exome sequencing data 
The XHMM exome sequencing CNV discovery and genotyping pipeline [23] was run on 
these samples to detect exon-level copy number variation and assign CNV quality metrics. 
Stringent call-level QC was performed by removing all sex chromosome CNV and low-quality 
XHMM calls (XHMM SQ<60). This was followed by removal of outlier samples (those with no 
CNV, >50 CNV calls, or >5 MB of total CNV length). 
 
Normalization of IQ scores from Raven’s Colored Progressive Matrices (CPM) 
To obtain a normalized IQ score, we performed linear regression on the CPM total scores 
for 151 cases between the ages of 4 to 11 who were part of this exome sequencing study, 
corrected for their ages (β = 1.34, SE = 0.31, P = 3.48×10-5). 
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ABSTRACT 
We describe the development of a novel population-based methodology (named RAFT for 
Recessive Allele Frequency-based Test) for discovering rare recessive variants and genes in 
complex diseases using whole-exome sequencing or genotyping technologies. We demonstrate 
that our approach is better powered than conventional population-based recessive tests. In 
applying our methodology to a set of exome chip and exome sequencing studies, we discovered 
evidence for rare recessive missense variants in the cholesterol synthesis gene 3-β-
Hydroxysteroid-Δ 24 Reductase (DHCR24) in autism and intellectual disability. We further 
performed a series of site-directed mutagenesis and desmosterol-to-cholesterol conversion assays 
to evaluate and characterize the functionality of these missense variants in cholesterol synthesis. 
 
INTRODUCTION 
Identifying the genetic causes of rare recessive Mendelian diseases using whole-exome 
sequencing has proven extremely successful [1]. Recent reports have also suggested a significant 
role for recessive alleles in the genetic architecture of complex diseases such as schizophrenia 
and autism spectrum disorders or ASDs [2,3,4,5]. However, identifying such rare recessive 
subtypes in complex diseases has been challenging, given the genetic heterogeneity and 
polygenicity of complex diseases [3]. Demonstrated approaches for screening rare recessive 
alleles in complex diseases include the use of unique populations such as consanguineous 
populations [4,6] or founder populations such as the Icelandic, Ashkenazi Jewish and Finnish 
populations [7,8] by identifying rare homozygous variants in regions with long runs of 
homozygosity [2,9]. Evaluation of the significance of the homozygous variants discovered from 
these screens has typically relied upon linkage calculations, or population-based approaches such 
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as chi-squared test, logistic regression or Fisher’s Exact Test. Here, we utilize a population-based 
approach (which we named RAFT for “Recessive Allele Frequency-based Test”) to prioritize 
homozygous variants in a common disease based on their rarity of these variants in terms of their 
allele frequencies (Materials and Methods). We have also adapted this population-based 
approach to family-based datasets to increase the power for discovering rare recessive genes in 
ASD. In applying our approach, we discovered a cholesterol biosynthesis gene (DHCR24) where 
milder missense variants in the gene contribute to ASD in a recessive mode of inheritance while 
more severe missense variants contribute to intellectual disability (ID), as well as brain 
malformations and fetal death. 
 
RESULTS 
Evaluating power for existing tests on simulated monogenic and polygenic diseases 
We first considered a monogenic recessive disease where there is a single causal gene involved, 
for instance cystic fibrosis transmembrane conductance regulator (CFTR) in cystic fibrosis (CF). 
If we were to sequence 40 individuals with CF and observed that half of them were homozygous 
for the ∆F508 deletion in CFTR, and that none in 4,000 unaffected controls were homozygous 
for ∆F508, the p-value obtained for this observation using Fisher’s Exact Test on the 
homozygous counts (Hom-FET) is highly significant (<1×10-15). Next, we consider an 
oligogenic recessive disease where there are several causal genes involved, for instance Usher 
Syndrome where there are 20 causal genes known to-date. Now if we were to sequence 40 cases 
we might only observe 2 cases who are recessive (either homozygous or compound 
heterozygous) for LoF variants in one of the genes, for instance Usher Syndrome 2A (USH2A). 
The p-value obtained from Fisher’s Exact Test is far more modest (9.6×10-5) for this observation 
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(Figure 3.1). Given the polygenicity involved in a complex disease such as ASD where we 
expect hundreds of genes and several modes of inheritance to be involved, we would have very 
little power to detect individual recessive genes contributing to a small percentage of cases, even 
if they were fully penetrant.  
 To further illustrate the effect of polygenicity on recessive gene discovery, we used a 
previously published instance where 2 independent families of Middle Eastern ancestry with 
ASD, intellectual disability and epilepsy were reported to harbor rare LoF variants in the 
BCKDK gene [10]. Given the background where ~200 families of Middle Eastern ancestry with 
ASD have been sequenced to-date [4], the p-value obtained using Fisher’s Exact Test for 
observing 2 independent probands with recessive LoF variants in BCKDK out of 200 ASD cases 
of Middle Eastern ancestry, compared to none with recessive variants in BCKDK among the 400 
parents, is only 0.11 – an unremarkable result in an exome-wide screen of all genes. However, 
we demonstrate later on that we would have identified BCKDK from an exome-wide screen for 
recessive genes using our population-based approach. 
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Figure 3.1: Power Calculations to Illustrate Decreased Power in Complex Diseases 
(A) P-values obtained when performing Fisher’s Exact Test on the homozygous counts (Hom-
FET) if there are 1, 2, 4, 8, 20 or 40 genes with complete penetrance that are causal for the 
disease. (B) P-values obtained using Hom-FET with different percentages of variance explained 
by the homozygotes (aa) in the cases, assuming complete penetrance. This is an ideal scenario 
and the power for detection will be lower if the variants exhibit incomplete penetrance or if there 
are fewer controls available. 
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Figure 3.1: Power Calculations to Illustrate Decreased Power in Complex Diseases 
(Continued) 
A 
 
B 
Example % variance 
explained 
E(Case 
aa) 
E(Case 
Aa or AA) 
E(Control 
aa) 
E(Control 
Aa or AA) 
Hom-FET 
E(p-value) 
CFTR 
in cystic fibrosis 
50% 20 20 0 4,000 <1×10-15 
USH2A  
in Usher Syndrome 
5% 2 38 0 4,000 9.6×10-5 
Gene X  
in ASD 
2.5% 1 39 0 4,000 1.0×10-2 
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RAFT test statistics 
It has been proposed previously that incorporating the departure from Hardy-Weinberg 
equilibrium (HWE) can improve the power to detect such rare recessives [11,12,13]. As such, we 
developed a likelihood-based association test (RAFT) to evaluate jointly the significance of the 
excess homozygosity from the expected under HWE, as well as the significance of the case-
control deviation. Using conventional case-control recessive tests, an observation of 5 cases and 
0 controls being homozygous for a variant of 0.5% allele frequency is no more significant than 
the same 5 to 0 observation for a variant of 5% allele frequency. However, the intuition behind 
our test is to assess how unusual is an observation with N number of recessives in the cases given 
the expected number of recessives based on the allele frequency. As such, we would expect the 
observation of 5 cases being homozygous for a variant of 0.5% allele frequency to be far more 
significant than 5 cases being homozygous for a variant of 5% allele frequency.  
 However, for particularly rare variants, it is expected that many recessive cases are 
compound heterozygotes rather than homozygous in nature. Following our previous analysis [3], 
we modified the RAFT statistic using the composite allele frequency of variants in a target class 
within the same gene, for instance, all LoF variants, or all non-synonymous (missense and LoF) 
variants. We used this composite allele frequency to estimate the probability that a single 
chromosome drawn from a population carries an alternate allele in the gene and this can be used 
to estimate the probability under a recessive mode of inheritance (homozygous and compound 
heterozygous) using the modified RAFT statistic. While this will very likely be an effective 
screening strategy for LoF variants, it is possible that for rare missense variants, the inevitable 
inclusion of neutral variants will reduce the power [14].  
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Using the previous example with the 2 recessive LoF observations in BCKDK, the 
composite allele frequency (or sum of the allele frequencies) of all LoF variants in BCKDK is 
0%, i.e. there are no LoF variants found in 207 unrelated Middle Eastern individuals. The p-
value calculated using RAFT for these 2 recessive observations in BCKDK is 2.0×10-9 
(Supplementary Methods), which is exome-wide significant at an α threshold of 0.05 after 
Bonferroni correction for 17,974 genes (P-value threshold = 2.8×10-6). Moreover, this 
observation is even more significant after including each additional affected sibling in those 2 
families who are homozygous for the LoF variants as replication (P×0.25 for each additional 
sibling). 
 
Application of RAFT to autism datasets 
We first applied our approach to a whole-exome genotyping dataset comprising of 1,069 
unrelated individuals of European ancestry with ASD as “cases” and another 2,141 unrelated 
parents of matched ancestry without ASD as “controls” from the Autism Genetic Resource 
Exchange (AGRE) collection by first ensuring that the cases and controls were from a 
homogeneous population of European ancestry (Figure 3.2). In the process, we discovered a rare 
missense variant (P244L) that is found at 0.05% allele frequency (Table 3.1, Figure 3.2) 
segregating perfectly in an autosomal recessive mode of inheritance within a single family of 3 
affected children (OR>4000, P = 7.8×10-6, Figure 3.3A). Given the allele frequency for the 
missense variant, we expected to observe a single homozygote in 4 million individuals. 
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Figure 3.2: The first 2 dimensions using MDS for the individuals in the exome chip study 
The MDS plot for the probands (one unrelated affected child from each family) and both parents 
from each family of European ancestry from the exome chip genotyping data. 
119 
 
Table 3.1: Top hits from the exome chip scan 
The odds ratio, LOD score and P-values calculated using RAFT, as well as the p-value calculated using Fisher’s Exact Test on the 
allele counts (FET P-value) and Fisher’s Exact Test on the homozygous counts (Hom-FET P-value) shown. For the DHCR24 P244L 
variant, there are another 2 affected children in the same family who are homozygous for the same rare variant, so the final p-value 
was multiplied by another 0.25 × 0.25 = 7.8×10-6. 
Chr Position Case 
AA 
Case 
Aa 
Case 
aa 
Control 
AA 
Control 
Aa 
Control 
aa 
Case 
Allele 
Freq 
Control 
Allele 
Freq 
Odds 
Ratio 
LOD score P-value Gene Variant Amino 
Acid 
FET 
P-value 
Hom-FET 
P-value 
16 17228363 1067 1 1 2140 1 0 0.0014 0.0002 9636 3.55 0.00005 XYLT1 missense p.T665M 0.11 0.33 
1 32087170 1067 1 1 2139 2 0 0.0014 0.0005 4281 3.20 0.00013 HCRTR1 missense p.F239L 0.34 0.33 
1 55337168 1067 1 1 2137 2 0 0.0014 0.0005 4276 3.20 0.00013 DHCR24 missense p.P244L 0.34 0.33 
22 41077895 1057 2 1 2121 1 0 0.0019 0.0002 4243 3.19 0.00013 MCHR1 missense p.T411M 0.05 0.33 
11 69490001 1066 2 1 2139 2 0 0.0019 0.0005 2408 2.95 0.00023 ORAOV1 missense p.G3S 0.1 0.33 
12 14577265 1067 1 1 2138 3 0 0.0014 0.0007 2408 2.95 0.00023 ATF7IP missense p.L139R 0.41 0.33 
15 72030269 1067 1 1 2138 3 0 0.0014 0.0007 2408 2.95 0.00023 THSD4 missense p.P610L 0.41 0.33 
2 242312656 1065 1 1 2133 3 0 0.0014 0.0007 2402 2.95 0.00023 FARP2 missense p.H45R 0.41 0.33 
11 47311032 1067 1 1 2137 4 0 0.0014 0.0009 1540 2.75 0.00037 MADD missense p.S892C 0.69 0.33 
15 78572759 1066 2 1 2138 3 0 0.0019 0.0007 1540 2.75 0.00037 WDR61 downstream NA 0.23 0.33 
16 49671518 1066 2 1 2138 3 0 0.0019 0.0007 1540 2.75 0.00037 ZNF423 silent p.N515N 0.23 0.33 
21 34897281 1067 1 1 2137 4 0 0.0014 0.0009 1540 2.75 0.00037 GART missense p.L365V 0.69 0.33 
2 97279225 1067 1 1 2137 4 0 0.0014 0.0009 1540 2.75 0.00037 KANSL3 silent p.P265P 0.69 0.33 
2 170366485 1067 1 1 2137 4 0 0.0014 0.0009 1540 2.75 0.00037 KBTBD10 missense p.I66T 0.69 0.33 
4 155254512 1067 1 1 2137 4 0 0.0014 0.0009 1540 2.75 0.00037 DCHS2 missense p.V451L 0.69 0.33 
2 67630980 550 406 113 1115 859 167 0.3 0.28 1.4 2.65 0.00048 ETAA1 missense p.S389N 0.16 0.01 
1 89123443 414 461 194 805 1019 317 0.4 0.39 1.3 2.64 0.00048 - - - 0.4 0.02 
11 45949745 1067 1 1 2136 5 0 0.0014 0.0012 1069 2.60 0.00055 GYLTL1B missense p.R591Q 0.73 0.33 
11 102076653 1067 1 1 2136 5 0 0.0014 0.0012 1069 2.60 0.00055 YAP1 missense p.P278S 0.73 0.33 
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Figure 3.2: Intensity plot for the DHCR24 P244L variant discovered in the Boston family 
The intensities for the probands (unrelated cases) are colored in green, affected siblings colored 
in red and parents in blue. 
 
  
121 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Pedigrees for the 3 families with autism and intellectual disability and 
homozygous variants in DHCR24 
(A) Pedigree for the first European family with ASD, (B) pedigree for the second Middle Eastern 
family with ASD and (C) pedigree for the third Middle Eastern family with intellectual 
disability. 
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Figure 3.3: Pedigrees for the 3 families with autism and intellectual disability and 
homozygous variants in DHCR24 (Continued) 
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B 
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Figure 3.3: Pedigrees for the 3 families with autism and intellectual disability and 
homozygous variants in DHCR24 (Continued) 
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This prompted us to scan additional exome sequencing datasets, including 207 Middle 
Eastern families with a broad range of neuro-developmental disorders including autism and 
intellectual disability. We discovered two additional families, both of Middle Eastern ancestry, 
with rare homozygous missense variants in DHCR24 that segregated perfectly in a recessive 
mode of inheritance within the families. Given that the composite allele frequency of LoF and 
missense variants in DHCR24 in European Americans is 0.44% and 0.48% in Middle Eastern 
individuals, the RAFT p-value obtained for these 3 recessive observations is 7.64×10-10 
(Supplementary Methods), which is exome-wide significant. 
The second family was a Pakistani family with a pair of monozygotic twins diagnosed 
with autism (recruited as part of the AGRE collection), both of whom were homozygous for a 
R478Q missense change (Figure 3.3B). The third family was a large consanguineous pedigree 
from Saudi Arabia and had with four children diagnosed with intellectual disability (Figure 
3.3C). The affected children in this family were homozygous for a R103H missense change. 
Both the R478Q and R103H variants were not found in 400 independent individuals of Middle 
Eastern ancestry. 
The three missense variants discovered in these three families with ASD and intellectual 
disability (P244L, R478Q and R103H) all affect amino acid residues that are highly conserved in 
46 vertebrates, and all are predicted by PolyPhen2 to be “probably damaging”. A lookup in 6,500 
control individuals from the Exome Variant Server, as well as 1,000 individuals of Middle 
Eastern ancestry with exome sequencing data and an exome sequencing dataset comprising of 
26,000 individuals revealed no other individuals homozygous for these variants, nor any other 
rare (<1% allele frequency), protein-altering (missense, nonsense, splice site, or frameshift) 
variants in DHCR24 (Fisher’s Exact Test P = 1.8×10-4).  
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The 24-dehydrocholesterol reductase gene (DHCR24), a gene involved in cholesterol 
synthesis by converting desmosterol into cholesterol. Rare recessive missense variants in 
DHCR24 had been previously reported in 4 independent families affected by a rare disorder 
called desmosterolosis, which resulted in a variety of recognizable phenotypic manifestations 
such as microcephaly, agenesis or thinning of the corpus callosum and polydactyly 
[15,16,17,18]. Overlapping physical manifestations are seen in other disorders of cholesterol 
biosynthesis such as Smith-Lemli-Optiz Syndrome (SLOS), but the key distinguishing 
characteristic seen in the affected individuals was unusually high levels of desmosterol compared 
to total cholesterol in their serum. In one of these families, recessive missense variants in 
DHCR24 resulted in infant death shortly after birth [18], and by analogy to SLOS, many severe 
LoF variants in the gene are likely to be inviable in humans. Post-mortem analysis of the 
percentage of accumulated desmosterol in this case was measured across three different tissues 
(liver, kidney and brain) and found to be the highest in the brain, reaffirming the importance of 
cholesterol in the developing brain.  
In addition, we discovered a family with two fetal demises and both fetuses harbored 
compound heterozygous variants in DHCR24 (C36X and P443L). This observation confirmed 
that complete loss of DHCR24 (such as from the C36X variant) confers recessive lethality in 
humans and in some instances, severe missense variants such as the P443L variant, as well as the 
N294T, K306N and Y471S variants that were previously reported, can similarly result in 
recessive lethality. All 5 variants were not found in 33,500 control individuals and are likely to 
be private to the families studied. Interestingly, we found a rare protein-truncating variant 
(Y237X) that is found at 0.03% in European Americans from the Exome Variant Server and 
estimate that at least 1 in 1,700 individuals harbor a LoF variant in DHCR24 and this translates 
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to a recessive lethality rate of at least 1 in 11 million from a complete loss of DHCR24. Notably, 
the missense variant discovered in these two fetal demises (P443L) is in close proximity with the 
3 previously reported missense variants that resulted in fetal death and these variants are located 
near the p53 binding domain in DHCR24, and that region in the protein has been proposed to be 
involved in binding to desmosterol [19], suggesting that there might be a yet undiscovered 
domain in that region of the gene that is critical for human viability. 
 
Functional evidence for DHCR24 variants 
Since DHCR24 is likely to influence disease manifestations in a recessive manner, we performed 
an allelic screen of all the 16 missense variants and 1 LoF variant found in DHCR24 from the 
European Americans in the Exome Variant Server (Figure 3.4), in order to assess the distribution 
of cholesterol synthesis for the variants, as well as to estimate the carrier rate of European 
Americans harboring a LoF variant or a missense variant predicted to be deleterious from the 
allelic screen. We performed the allelic screen by creating mutants of all the 17 variants, as well 
as the 2 additional variants from the families with ASD and intellectual disability, the 2 variants 
from the fetal demises and 3 reported variants from previous desmosterolosis cases, resulting in a 
total of 24 variants tested. As controls, we included yeast transformed with wildtype DHCR24 
and yeast transformed with the plasmid alone. We have performed site-directed mutagenesis for 
all mutants and are currently inducing protein expression for all the DHCR24 mutants and 
optimizing a desmosterol-to-cholesterol biochemical assay adapted from Waterham et al. [20], in 
order to evaluate and assess the functionality of the variants discovered in the cases with autism 
and intellectual disability, as well as a population-based survey of missense variants in the gene. 
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Figure 3.4: Variants in DHCR24 discovered to-date 
(A) The previously reported disease-causing variants in patients with desmosterolosis 
highlighted in red and shown on top; the variants discovered in the individuals with autism and 
intellectual disability are highlighted in green; and the variants discovered to result in human 
lethality highlighted in orange or marked by orange arrows. 
(B) Diagram of the variants found in the 4,300 European Americans from the Exome Variant 
Server with the allele frequencies of the variants shown for European Americans (EA AF) and 
African Americans (AA AF). The variants colored in red are predicted by PolyPhen2 to be 
“probably damaging”, the variants colored in purple are predicted to be “possibly damaging”, the 
variants colored in blue are predicted to be “benign” and loss-of-function (LoF) variants are 
colored in orange. 
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Figure 3.4: Variants in DHCR24 discovered to-date (Continued) 
 
A 
 
B 
 
 
 
 
  
129 
 
DISCUSSION 
Cholesterol is known to be important for the formation of myelin sheaths and membrane lipid 
rafts, and is a signaling molecule involved in developmental pathways such as the Sonic 
Hedgehog signaling pathway that regulates limb development. Recessive mutations in several 
genes that affect the precursors for cholesterol synthesis have been implicated in various neuro-
developmental diseases, such as Smith–Lemli–Opitz syndrome, desmosterolosis and 
lathosterolosis [21]. DHCR24 (also known as Selective Alzheimer's Disease Indicator-1 or 
Seladin-1) is gene that encodes a 516-amino acid long protein and is found on 1p32.3, where 2 
rare duplications and one de novo deletion were previously reported in individuals with ASD 
[22]. The gene was also named Seladin-1 based on the initial discoveries that DHCR24 was 
down-regulated in parts of the brain known to be important in Alzheimer’s Disease [23,24], 
although this association has been debated recently [25,26]. The proportion of individuals with 
ASD and low cholesterol levels has been estimated to be as high as 20% [27] and a recent study 
in an ASD-related disorder (Rett Syndrome) has also highlighted the importance of the 
cholesterol synthesis pathway in neuro-developmental disorders [28].  
In this study, we present evidence for rare recessive variants in a critical gene involved in 
cholesterol synthesis (DHCR24) contributing to ASD and intellectual disability, as well as 
provide additional evidence that complete loss or severe missense variants in DHCR24 can result 
in recessive lethality in humans. In addition to describing a novel statistical screen (RAFT) to 
identify such rare recessive variants in a complex disorder such as ASD, we are evaluating 
functional evidence for the pathogenicity of the 3 new variants discovered in families with ASD 
and intellectual disability (R103H, P244L and R478Q) using a cholesterol synthesis assay in 
yeast. In addition, we also surveyed the missense variants found in a large control population of 
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4,300 Europeans and estimate that approximately 1 in 150 individuals are carriers for a 
pathogenic variant in DHCR24 and that approximately 1 in 86,000 individuals carry recessive 
pathogenic variants in DHCR24, although the rate of recessive carriers is much higher in ASD 
and intellectual disability (given that we discovered 3 independent families with recessive 
variants in DHCR24 among approximately 3,000 families).  
We discovered that knocking out DHCR24 has severe consequences on fetal lethality and 
drugs that target the gene are likely to result in serious side effects. However, cholesterol 
supplements, such as egg yolks, have been shown to aid improvements in children with epilepsy 
and other brain disorders such as Smith-Lemli-Opitz syndrome, and such dietary treatment can 
potentially help these individuals with ASD and intellectual disability as well. There are likely to 
be other genes that are directly involved in the cholesterol synthesis pathway, or are involved in 
regulating and modulating the cholesterol synthesis pathway, that can similarly confer a 
significant risk to ASD and intellectual disability. The identification and understanding of such 
genes, as well as the identification of individuals affected by cholesterol deficiency or 
accumulation of the precursor substrates, can help provide immediate dietary treatment for these 
individuals, as well as further our understanding of the different components involved in 
regulating cholesterol synthesis for therapeutic development. 
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MATERIALS AND METHODS 
Exome chip quality control and analyses 
Genotyping was conducted using the Illumina HumanExome bead chip at the Broad Institute on 
2,471 affected children and 3,018 unaffected parents. In order to select the children and parents 
of European ancestry, we performed multi-dimensional scaling (MDS) in PLINK [29] with the 
samples from the 1000 Genomes Project as reference, and matched based on the first 10 
dimensions. To reduce genotyping errors, variants with HWE p-values of ≤1×10-3 in the controls 
were removed. We performed Fisher’s Exact Test on the allele counts for common (>5%), low-
frequency (1-5%) and rare (<1%) variants to ensure that there is no global inflation and that we 
had a homogeneous European population for our study. The variants were then annotated using 
Variant Effect Predictor [30]. 
 
Exome sequencing quality control and analyses 
Whole-exome sequencing on the Middle Eastern individuals with autism and intellectual 
disability were performed at the Broad Institute [4]. Given the expected higher rate of 
consanguinity in these families, we selected 1 unaffected individual (parent or sibling) from each 
family to evaluate the allele frequencies of the variants. Variants that passed the standard GATK 
filters, had read depth of ≥10, Phred quality score of ≥30, and alternate heterozygous reads of 30-
70% or alternate homozygous reads of >90% were kept for analyses. In addition, variants with 
>10% missing genotypes after filtering were discarded as these are likely to be found in regions 
of the exome with poor coverage and can result in inaccurate estimates of the allele frequencies. 
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RAFT test statistic 
Let 𝑎 denote the minor or non-reference allele while 𝐴 is the reference or major allele. Let the 
probability of the expected number of individuals with the homozygous minor allele be 𝑃(𝑎𝑎). 
There are a few ways to estimate 𝑃(𝑎𝑎), such as using the heterozygotes in cases and controls 
for the estimation. One approach for estimating 𝑃(𝑎𝑎) is to calculate 𝑃(𝑎|𝑐𝑎𝑠𝑒) and 
𝑃(𝑎|𝑐𝑜𝑛𝑡𝑟𝑜𝑙) separately and we can estimate:  
𝑃(𝑎𝑎|𝑐𝑎𝑠𝑒) = 𝑃(𝑎|𝑐𝑎𝑠𝑒) × 𝑃(𝑎|𝑐𝑎𝑠𝑒) 
𝑃(𝑎𝑎|𝑐𝑜𝑛𝑡𝑟𝑜𝑙) = 𝑃(𝑎|𝑐𝑜𝑛𝑡𝑟𝑜𝑙) × 𝑃(𝑎|𝑐𝑜𝑛𝑡𝑟𝑜𝑙) 
 
An alternative approach is to estimate 𝑃(𝑎𝑎) = 𝑃(𝑎) × 𝑃(𝑎) by using the observed allele counts 
for the heterozygotes in cases and controls, which is the maximum likelihood estimate for the 
allele frequency:  
𝑃(𝑎) =  𝑛𝑐𝑎𝑠𝑒𝐴𝑎 +  𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝐴𝑎
𝑛𝑐𝑎𝑠𝑒𝐴𝑎 +  2𝑛𝑐𝑎𝑠𝑒𝐴𝐴 + 𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝐴𝑎 + 2𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝐴𝐴 
 
Then we performed an expectation maximization (EM) step to calculate the probability of 
observing 𝑛𝑎𝑎 number of alternate homozygotes in the controls, 𝑃(𝑛𝑎𝑎|𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠) 
and the probability of observing 𝑛𝑎𝑎���� number of heterozygotes and reference homozygotes in the 
controls, 𝑃(𝑛𝑎𝑎����│𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠) given a genotypic risk ratio in the controls (𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠).  
The binomial probability for such an observation can be calculated using 
𝑃(𝑛𝑎𝑎|𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠) × 𝑃(𝑛𝑎𝑎����│𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠), which is equivalent to [𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠×𝑃(𝑎𝑎)]𝑛𝑎𝑎[1−𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠×𝑃(𝑎𝑎)]𝑛𝑎𝑎����
𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠×𝑃(𝑎𝑎)+(1−𝑃(𝑎𝑎)) . Essentially, if there are variants with excessive 
homozygosity in the controls and deviate from the squared of the allele frequencies (which are 
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the expected probabilities for the homozygotes), this can be an indication of a common copy 
number polymorphism unmasking a rare variant in the controls, or variants in poorly covered 
regions with inaccurate variant calls, or misalignments with the human reference sequence. In 
such instances, 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 will be greater than 1, otherwise 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 will be equal to 1. 
Next, we performed a second EM step to estimate the equivalent 𝛾𝑐𝑎𝑠𝑒𝑠 in the cases and 
the formulation for the RAFT test statistic is a log-likelihood ratio between the observed and 
expected probabilities of recessives in the cases with respect to the controls: 𝑅𝐴𝐹𝑇 = 𝑙𝑜𝑔10 � 𝑃(𝑛𝑎𝑎|𝑐𝑎𝑠𝑒,𝛾=𝛾cases)𝑃(𝑛𝑎𝑎����|𝑐𝑎𝑠𝑒,𝛾=𝛾𝑐𝑎𝑠𝑒𝑠)𝑃(𝑛𝑎𝑎|𝑐𝑜𝑛𝑡𝑟𝑜𝑙,𝛾=𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)𝑃(𝑛𝑎𝑎����|𝑐𝑜𝑛𝑡𝑟𝑜𝑙,𝛾=𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)�. This evaluates any homozygosity in the 
cases in excess of the homozygosity found in the controls. In addition, we multiplied the 
probability by a global correction factor f to account for any excess of homozygosity in the 
exome (see Supplementary Methods). For instance, in consanguineous populations, we expect 
more rare homozygous variants than in out-bred populations, so the correction factor will result 
in a global reduction in the significance of a single rare homozygous variant in a consanguineous 
family. 
 
Mutagenesis and molecular cloning in yeast 
The human DHCR24 cDNA clones (BC004375 and BC01169) were ordered from Thermo 
Scientific and Sanger sequencing was performed on the cDNA clones to verify the sequences. 
We performed EcoRI and XhoI restriction enzyme digests on the 2 cDNA clones, as well as 
EcoRI digest on the FB1533 or p426 GAL vector to ligate the DHCR24 cDNA clones into the 
FB1533 vector. This resulted in a final plasmid that is 8.8kb long: 6.4kb for the vector and 2.4kb 
for the cDNA. We performed transformation using TOP10 competent cells from Life 
Technologies and cultured the E. coli for mutagenesis, which was done using the Agilent 
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QuikChange II site-directed mutagenesis kit. The primers used for mutagenesis are listed in 
Table 3.2 and Sanger sequencing was performed to confirm the mutants. The mutant plasmids 
were then transformed into the FY1856 yeast strain lacking the URA3 gene and colonies were 
selected on media lacking uracil. 
 
Yeast cell lysis and cholesterol synthesis biochemical assay 
Yeast cells were grown overnight to saturation (OD ~1.5), spun down and washed with 5mM 
Tris/HCl (pH 7.5) and 50 mM NaCl buffer, before re-suspending in 500μl of NaCl buffer. The 
cells were flash freezed and glass beads (0.40 to 0.60mm) from Jencons Scientific were added. 
Cell lysis was performed using a Beadbeater for 1 minute at 4°C and the resultant lysates were 
placed on ice for 2 minutes before extracting the supernatant. Using a previously described 
protocol, we incubated 25μl of the supernatant with 225μl of assay buffer comprising of 
desmosterol for 4 hours at 37°C before performing the sterol analyses [20]. 
 
Sterol analyses 
The assay mixes were sent overnight on dry ice to the Clinical Mass Spectrometry Laboratory at 
Kennedy Krieger Institute to measure the amounts of desmosterol, cholesterol and ergosterol. 
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Table 3.2: Primer sequences used for mutagenesis in DHCR24 
Mutant Primer Names Primer Sequences (5' to 3') Variant 
1 g1522a_sense cttccccgaggtgtacaacaagatctgcaaggc p. D508N or c.1522G>A 
 g1522a_antisense gccttgcagatcttgttgtacacctcggggaag  
2 g1353c_sense acactttgaagccagctcctgcatgaggcag p. R451S or c.1353G>C 
 g1353c_antisense ctgcctcatgcaggagctggcttcaaagtgt  
3 a1301g_sense aaatgaggcagagctctgcatcgacattggagcat p.Y434C or c.1301A>G 
 a1301g_antisense atgctccaatgtcgatgcagagctctgcctcattt  
4 g1140c_sense agctgtacgagcaccaccacgtggtgc p.Q380H or c.1140G>C 
 g1140c_antisense gcaccacgtggtggtgctcgtacagct  
5 g1135a_sense tgcgcaagctgtacaagcagcaccacgtg p.E379K or c.1135G>A 
 g1135a_antisense cacgtggtgctgcttgtacagcttgcgca  
6 a815c_sense ggaagggctgctctcctccctggatgagg p.Y272S or c.815A>C 
 a815c_antisense cctcatccagggaggagagcagcccttcc  
7 g737a_sense cgagccagtgcagggcctggagg p.R246Q or c.737G>A 
 g737a_antisense cctccaggccctgcactggctcg  
8 c736t_sense ttcgagccagtgtggggcctggagg p.R246W or c.736C>T 
 c736t_antisense cctccaggccccacactggctcgaa  
9 c711a_sense gcatcatccctgccaagaagtaagtcaagctgcgt p.Y237X or c.711C>A 
 c711a_antisense acgcagcttgacttacttcttggcagggatgatgc  
 
136 
 
Table 3.2: Primer sequences used for mutagenesis in DHCR24 (Continued) 
Mutant Primer Names Primer Sequences (5' to 3') Variant 
10 g689a_sense gccgctgagatccacatcatccctgcc p.R230H or c.689G>A 
 g689a_antisense ggcagggatgatgtggatctcagcggc  
11 g616a_sense gcgatgcactccgtccaaaaactcagacctgtt p.E206K or c.616G>A 
 g616a_antisense aacaggtctgagtttttggacggagtgcatcgc  
12 c566g_sense caacacatctgcactggttacgagctggtcctg p.A189G or c.566C>G 
 c566g_antisense caggaccagctcgtaaccagtgcagatgtgttg  
13 c519g_sense catgggcacaggcatggagtcatcatccca p.I173M or c.519C>G 
 c519g_antisense tgggatgatgactccatgcctgtgcccatg  
14 c403t_sense attgtccgtgtggagtccttggtgaccatgg p.P135S or c.403C>T 
 c403t_antisense ccatggtcaccaaggactccacacggacaat  
15 c394t_sense ccaagaaacagattgtctgtgtggagcccttggtg p.R132C or c.394C>T 
 c394t_antisense caccaagggctccacacagacaatctgtttcttgg  
16 g236a_sense ccagaagcaggtgcaggaatggaaggagc p.R79Q or c.236G>A 
 g236a_antisense gctccttccattcctgcacctgcttctgg  
17 a881c_sense agagcccagcaagctgactagcattggcaattact p.N294T or c.881A>C 
 a881c_antisense agtaattgccaatgctagtcagcttgctgggctct  
18 g918t_sense caattactacaagccgtggttctttaatcatgtggagaactat p.K306N or c.918G>T 
 g918t_antisense atagttctccacatgattaaagaaccacggcttgtagtaattg  
19 c731t_sense ctgcgtttcgagctagtgcggggcctg p.P244L or c.731C>T 
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Table 3.2: Primer sequences used for mutagenesis in DHCR24 (Continued) 
Mutant Primer Names Primer Sequences (5' to 3') Variant 
 c731t_antisense caggccccgcactagctcgaaacgcag  
20 g308a_sense gctcactgtctcactacatgtcgggaagtacaaga p.R103H or c.G308A 
 g308a_antisense tcttgtacttcccgacatgtagtgagacagtgagc  
21 a1412c_sense catggcttccagatgctgtctgccgactgc p.Y471S or c.A1412C 
 a1412c_antisense gcagtcggcagacagcatctggaagccatg  
22 g1433a_sense gactgctacatgaaccaggaggagttctgggag p.R478Q or c.1433G>A 
 g1433a_antisense ctcccagaactcctcctggttcatgtagcagtc  
23 c108t_sense tgggtgttcgtgtgtctcttcctcctgcc p.C36X or c.108C>T 
 c108t_antisense ggcaggaggaagagacacacgaacaccca  
24 c1328t_sense ggagcatatggggagctgcgtgtgaaacacttt p.P443L or c.1328C>T 
 c1328t_antisense aaagtgtttcacacgcagctccccatatgctcc  
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SUPPLEMENTARY MATERIALS AND METHODS 
Supplementary Methods 
Evaluating the RAFT test statistic on a simulated Finnish dataset 
To evaluate the distribution of our test statistic, we obtained a whole-exome sequencing dataset 
comprising of 3,000 individuals of Finnish ancestry and 3,000 non-Finnish Europeans (NFEs) 
(Lim et al., unpublished). There are a total of 590,003 coding variants in 3,000 Finns and 3,000 
NFEs from whole exome sequencing data, and for each variant, we randomly generated 5,000 
cases and 5,000 controls using the allele frequencies derived from only the Finns. When we ran 
RAFT on the simulated Finnish dataset with 5,000 cases and 5,000 controls, we found that across 
all allele frequency bins (common ≥5%, low-frequency 1-5% or rare ≤1%), we obtained similar 
numbers of observed compared to expected variants in the various p-value bins and the ratios of 
the expected compared to observed are approximately 1 or less than 1 (Table 3.3).  
 
Evaluating the RAFT test statistic on a simulated Finnish and NFE dataset with 
substructure 
There are 2 confounding factors in applying RAFT – first, population stratification where the 
cases are from an ethnically different population compared to the controls, can result in deviation 
from HWE. However, similar to existing genome-wide association studies, this can be easily 
detected using existing methods such as genomic control to identify if the cases are well-matched 
to the controls in terms of ancestry. The second confounding factor is population substructure 
where the cases and controls are equally sampled from two or more heterogeneous populations. 
For instance, if the cases and controls are derived from Finns and NFEs, this can result in the 
Wahlund effect where there is excessive homozygosity and reduced heterozygosity. Unlike 
139 
 
direct case-control comparisons, such heterogeneity can inflate the statistic above. To further 
evaluate the effect of population sub-structure on RAFT (where the cases and controls are well-
matched for ancestry but contain ethnically different subpopulations in both cases and controls), 
we randomly generated 5,000 cases and 5,000 controls using equal proportions of Finns and 
NFEs in the cases and controls. However, when we ran the test statistic on the simulated data, we 
observed an unusually high inflation among the common variants (Table 3.4). Even in a study in 
which cases and controls are perfectly matched exome-wide, departures from HWE may occur at 
sites if the population is not of homogeneous ancestry (such as the Wahlund effect). As such, 
careful analyses have to be performed to ensure that there is no excessive substructure in the 
cases and controls when applying RAFT. 
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Table 3.3: Distribution of variants from running RAFT on the simulated Finnish dataset 
The observed median number of variants and the lower and upper values from 100 simulations 
are shown in the brackets. 
 
Number of common (≥5%) variants = 26,368 
 P≤1×10-5 P≤1×10-4 P≤1×10-3 P≤1×10-2 P≤1×10-1 
Observed 0 [0-3] 3 [0-9] 17 [7-29] 117 [96-139] 765 [704-844] 
Expected 0.26 2.6 26 264 2637 
Ratio 
(Obs/Exp) 
0 [0-11.4] 1.14 [0-3.41] 0.64 [0.27-1.1] 0.44 [0.36-0.53] 0.29 [0.27-0.32] 
      
Number of low-freq (1-5%) variants = 15,665 
 P≤1×10-5 P≤1×10-4 P≤1×10-3 P≤1×10-2 P≤1×10-1 
Observed 0 [0-1] 0 [0-3] 5 [0-12] 91 682 
Expected 0.16 1.57 16 157 1567 
Ratio 
(Obs/Exp) 
0 [0-6.38] 0 [0-1.92] 0.32 [0-0.76] 0.29 [0.17-0.39] 0.28 [0.25-0.31] 
      
Number of rare (≤1%) variants = 161,291 
 P≤1×10-5 P≤1×10-4 P≤1×10-3 P≤1×10-2 P≤1×10-1 
Observed 0 [0-2] 6 [1-17] 43 [28-59] 196 [162-232] 881 [785-948] 
Expected 1.61 16 161 1613 16,129 
Ratio 
(Obs/Exp) 
0 [0-1.24] 0.37 [0.06-1.05] 0.27 [0.17-
0.37] 
0.12 [0.1-0.14] 0.05 [0.05-0.06] 
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Table 3.4: Distribution of variants from running RAFT on the simulated Finnish and NFE 
dataset 
The observed median number of variants and the lower and upper values from 100 simulations 
are shown in the brackets. 
 
Number of common (≥5%) variants = 25,184 
 P≤1×10-5 P≤1×10-4 P≤1×10-3 P≤1×10-2 P≤1×10-1 
Observed 3 [0-7] 10 [4-17] 44 [33-65] 217 [189-242] 1101 [1041-1163] 
Expected 0.25 2.52 25 252 2518 
Ratio 
(Obs/Exp) 
11.9 [0-27.8] 3.97 [1.59-6.75] 1.75 [1.31-2.58] 0.86 [0.75-0.96] 0.44 [0.41-0.46] 
      
Number of low-freq (1-5%) variants = 15,165 
 P≤1×10-5 P≤1×10-4 P≤1×10-3 P≤1×10-2 P≤1×10-1 
Observed 0.5 [0-4] 4 [0-9] 18 [8-29] 108 [87-130] 684 [609-748] 
Expected 0.15 1.52 15 152 1517 
Ratio 
(Obs/Exp) 
3.3 [0-26.4] 2.64 [0-5.93] 1.19 [0.53-1.91] 0.71 [0.57-0.86] 0.45 [0.4-0.49] 
      
Number of rare (≤1%) variants = 270,458 
 P≤1×10-5 P≤1×10-4 P≤1×10-3 P≤1×10-2 P≤1×10-1 
Observed 1 [0-3] 28 [18-47] 120.5 [94-143] 419 [379-485] 1561.5 [1462-1650] 
Expected 2.7 27 270 2705 27046 
Ratio 
(Obs/Exp) 
0.37 [0-1.11] 1.04 [0.67-1.74] 0.45 [0.35-0.53] 0.15 [0.14-0.18] 0.06 [0.05-0.06] 
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Calculating correction factor to detect substructure 
To estimate the amount of substructure or homozygosity by descent, we fitted a regression model 
on all coding variants with the intercept set to 0, where q is the allele frequency of the alternate 
allele: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 ℎ𝑜𝑚𝑜𝑧𝑦𝑔𝑜𝑡𝑒𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙𝑠 =  𝛽1 𝑞 + 𝛽2 𝑞2 
Using the whole-exome sequencing data for the 3,000 NFEs, we estimated the parameters: 
𝛽1 = 0.00898 
𝛽2 = 0.991 
Using the whole-exome sequencing data for the 3,000 Finns, we estimated the parameters: 
𝛽1 = 0.00675 
𝛽2 = 0.993 
Using the whole-exome sequencing data for the 207 Middle Eastern individuals, we estimated 
the parameters: 
𝛽1 = 0.0457 
𝛽2 = 0.954 
Using the whole-exome sequencing data for the combined Finn and NFE individuals to simulate 
a population with substructure, we estimated the parameters: 
𝛽1 = 0.0121 
𝛽2 = 0.988 
 
As a comparison, we compared the expected probabilities for homozygotes versus the calculated 
probabilities using the fitted models across the 3 populations (Table 3.5). 
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Table 3.5: Comparison of homozygosity by descent or population substructure 
The expected probabilities, as well as calculated probabilities after correcting for homozygosity 
by descent or population substructure across the non-Finnish European (NFE), Finnish and 
Middle Eastern populations across different allele frequency ranges. 
 
Allele 
Freq 
Expected NFE 
Calculated 
NFE 
Inflation 
(Calculated/ 
Expected) 
Finn 
Calculated 
Finn 
Inflation 
(Calculated/ 
Expected) 
Middle 
Eastern 
Calculated 
Middle 
Eastern 
Inflation 
(Calculated/ 
Expected) 
0.1% 1×10-6 9.97×10-6 9.97 7.74×10-6 7.74 4.67×10-5 46.65 
0.5% 2.5×10-5 6.97×10-5 2.79 5.86×10-5 2.34 2.52×10-4 10.09 
1% 1×10-4 1.89×10-4 1.89 1.67×10-4 1.67 5.52×10-4 5.52 
5% 2.5×10-3 2.92×10-3 1.17 2.82×10-3 1.13 4.67×10-3 1.87 
10% 0.01 0.011 1.08 0.011 1.06 0.014 1.41 
20% 0.04 0.041 1.04 0.041 1.03 0.047 1.18 
30% 0.09 0.092 1.02 0.091 1.02 0.1 1.11 
40% 0.16 0.16 1.01 0.16 1.01 0.17 1.07 
50% 0.25 0.25 1 0.25 1 0.26 1.05 
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Calculating significance for the 3 homozygous non-synonymous observations in BCKDK 
We assumed a non-synonymous composite allele frequency of 0.0024 for BCKDK in 207 control 
Middle Eastern individuals (1 non-synonymous heterozygote in 414 chromosomes), and that 
there was 1 heterozygote and 3 homozygotes observed in 208 Middle Eastern cases with autism. 
The probability of observing a homozygote adjusted for homozygosity by descent or population 
substructure is 0.00012, representing an inflation of 19.3 from the expected probability. The 
RAFT LOD score for these 3 homozygous observations is 4.99, P = 1.64×10-6. Given that there 
are 3 additional affected siblings who are homozygous and 9 unaffected siblings who are not 
homozygous across these families, the final p-value for this observation is 1.64×10-6 × (0.25)3 × 
(0.75)9 = 1.92×10-9. 
 
Calculating significance for 2 homozygous non-synonymous observations in DHCR24 in the 
Middle Eastern population 
For the 2 Middle Eastern homozygotes, we assumed a non-synonymous composite allele 
frequency of 0.0048 (2 heterozygotes in 414 chromosomes), and that there were 2 heterozygotes 
and 2 homozygotes observed in 207 Middle Eastern cases with autism or intellectual disability. 
The probability of observing a homozygote adjusted for homozygosity by descent or population 
substructure is 0.00025, representing an inflation of 10.7 from the expected probability. The 
RAFT LOD score for these 2 homozygous observations is 2.35, P = 1×10-3. Given that there are 
3 additional affected siblings who are homozygous and 9 unaffected siblings who are not 
homozygous, the final p-value for this observation is 1×10-3 × (0.25)3 × (0.75)9 = 1.18×10-6. 
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Calculating significance for 1 homozygous non-synonymous observations in DHCR24 in the 
European population 
For the 1 European homozygote, we assumed a non-synonymous composite allele frequency of 
0.00442 (38 heterozygotes in 8,600 chromosomes), and that there were 5 heterozygotes and 1 
homozygote observed in 1,063 European cases with autism. The probability of observing a 
homozygote adjusted for homozygosity by descent or population substructure is 5.22×10-5, 
representing an inflation of 2.7 from the expected probability. The RAFT LOD score for this 
homozygous observation is 0.84, P = 0.049. Given that there are 2 additional affected siblings 
who are homozygous, the final p-value for this observation is 0.049 × (0.25)2 = 3.08×10-3. 
 
Calculating significance for combined observations in DHCR24 using meta-analysis 
In order to obtain a chi-squared statistic with 1 degree of freedom, we performed meta-analysis 
across the Middle Eastern and European populations to evaluate the significance of the 3 
homozygotes in DHCR24 in both populations. We performed the expectation maximization step 
to obtain the genotype relative risk that maximizes the sum of the log likelihood function for 
both populations. That is: 
𝑅𝐴𝐹𝑇 =  𝑙𝑜𝑔10
⎣
⎢
⎢
⎢
⎡ 𝑃�𝑛𝑎𝑎_𝑀𝐸�𝑐𝑎𝑠𝑒, 𝛾 = 𝛾cases�𝑃�𝑛𝑎𝑎_𝑀𝐸�����������𝑐𝑎𝑠𝑒, 𝛾 = 𝛾𝑐𝑎𝑠𝑒𝑠�
𝑃�𝑛𝑎𝑎_𝐸𝐴�𝑐𝑎𝑠𝑒, 𝛾 = 𝛾cases�𝑃�𝑛𝑎𝑎_𝐸𝐴����������𝑐𝑎𝑠𝑒, 𝛾 = 𝛾𝑐𝑎𝑠𝑒𝑠�
𝑃�𝑛𝑎𝑎_𝑀𝐸�𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠�𝑃�𝑛𝑎𝑎_𝑀𝐸�����������𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠�
𝑃�𝑛𝑎𝑎_𝐸𝐴�𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠�𝑃�𝑛𝑎𝑎_𝐸𝐴����������𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠� ⎦⎥⎥
⎥
⎤
 
where  
𝑃�𝑛𝑎𝑎_𝑀𝐸�𝑐𝑎𝑠𝑒, 𝛾 = 𝛾cases� is the probability of homozygotes in the Middle Eastern (ME) cases, 
𝑃�𝑛𝑎𝑎_𝑀𝐸�����������𝑐𝑎𝑠𝑒, 𝛾 = 𝛾𝑐𝑎𝑠𝑒𝑠� is the probability of non-homozygotes in the Middle Eastern cases, 
𝑃�𝑛𝑎𝑎_𝐸𝐴�𝑐𝑎𝑠𝑒, 𝛾 = 𝛾cases� is the probability of homozygotes in the European (EA) cases, 
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𝑃�𝑛𝑎𝑎_𝐸𝐴����������𝑐𝑎𝑠𝑒, 𝛾 = 𝛾𝑐𝑎𝑠𝑒𝑠� is the probability of non-homozygotes in the European cases, 
𝑃�𝑛𝑎𝑎_𝑀𝐸�𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠� is the probability of homozygotes in the Middle Eastern 
controls, 
𝑃�𝑛𝑎𝑎_𝑀𝐸�����������𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠� is the probability of non-homozygotes in the Middle Eastern 
controls, 
𝑃�𝑛𝑎𝑎_𝐸𝐴�𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠� is the probability of homozygotes in the European controls, 
𝑃�𝑛𝑎𝑎_𝐸𝐴����������𝑐𝑜𝑛𝑡𝑟𝑜𝑙, 𝛾 = 𝛾𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠� is the probability of the non-homozygotes in the European 
controls. 
 
The allele frequencies and inflation correction factors used are the same as mentioned above for 
the Middle Eastern and European populations. The meta-analyzed RAFT LOD score for these 3 
homozygous observations is 4.22, P = 1.04×10-5. Given that there are 5 additional affected 
siblings who are homozygous and 9 unaffected siblings who are not homozygous, the final p-
value for this observation is 1.04×10-5 × (0.25)5 × (0.75)9 = 7.64×10-10. 
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ABSTRACT 
Exome sequencing studies in complex diseases are challenged by the allelic heterogeneity, large 
number and modest effect sizes of associated variants on disease risk and the presence of large 
numbers of neutral variants, even in phenotypically relevant genes. Isolated populations with 
recent bottlenecks offer advantages for studying rare variants in complex diseases as they have 
deleterious variants that are present at higher frequencies as well as a substantial reduction in 
rare neutral variation. To explore the potential of the Finnish founder population for studying 
low-frequency (0.5-5%) variants in complex diseases, we compared exome sequence data on 
3,000 Finns to the same number of non-Finnish Europeans (NFEs) and used several well-
characterized population cohorts in a reverse genetics approach to genotype 83 low-frequency 
loss-of-function variants in 36,262 Finns. Using a deep set of quantitative traits collected on 
these cohorts, we identified splice variants in LPA that lowered plasma lipoprotein(a) levels as 
well as novel associations with circulating D-dimer levels, galectin-3 levels, triglycerides and 
systolic blood pressure. Through accessing the national medical records of these participants, we 
could evaluate the LPA finding via Mendelian randomization and confirm that these splice 
variants confer protection from cardiovascular disease (OR = 0.84, P = 3×10-4), demonstrating 
for the first time that inhibition of LPA may have therapeutic efficacy. More generally, this study 
articulates substantial advantages for studying the role of rare variation in complex phenotypes in 
Finland - combining a unique population genetic history with data from large population cohorts 
and centralized research access to medical records and National Health Registers.  
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INTRODUCTION 
After widespread success with genome-wide association studies (GWAS) of common 
variants, several studies have recently begun to identify rare (with <0.5% allele frequency) and 
low-frequency (0.5-5%) variants in complex diseases and traits such as triglycerides [1], insulin 
processing [2], bone mineral density [3], Alzheimer’s disease [4], impulsivity [5], and prostate 
cancer [6], some of which confer protection from disease [4]. Protective loss of function variants 
that can be tolerated in a homozygote state in humans are of particular interest as potential safe 
targets for therapeutic inhibition. Interestingly, many of these studies that have discovered rare 
and low-frequency variants have benefited from the use of isolated populations that have 
undergone bottlenecks resulting in frequency enrichment of the associated variants. In contrast to 
the large number of extremely rare variants present in out-bred populations, such bottlenecked 
populations have greater genetic homogeneity with a simplified spectrum of rare variation: fewer 
total variable sites exist and those that do are more likely found in many more individuals. This 
observation has been borne out in numerous examples of Mendelian disease where, for example, 
Finns and Ashkenazi Jews have characteristic high incidence of recessive diseases because of the 
dramatic enrichment of specific mutations [7,8,9] – in the wider European population these same 
diseases are rarer and have mutational spectra involving a more diverse array of extremely rare 
mutations. It has not yet been assessed to which extent these population structures, so 
advantageous to Mendelian studies but of little importance to common variant GWAS, might 
generally improve the power to identify low-frequency and loss of function (LoF) variants in 
studies of complex disease.  
To explore this question, we used exome sequencing to characterize the allelic 
architecture of the Finnish population compared with a set of non-Finnish Europeans (NFEs) 
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from the United States, Great Britain, Germany and Sweden. We demonstrate that Finns carry a 
significant enrichment of low-frequency (0.5-5%) loss-of-function (LoF) variation, defined here 
as nonsense and essential splice sites that are rare in NFEs. In addition to the isolated population 
structure, Finland has nationwide health records that provide decades of follow-up data that can 
be linked to epidemiological studies. The combination of the population structure and nationwide 
health records provide exceptional opportunities to study the impact of low-frequency variants 
on risk factors and disease outcomes and their risk factors. These opportunities have stimulated 
an international collaboration, The Sequencing Initiative Suomi (The SISu project) that aims to 
combine these resources and build knowledge and tools for genome health initiatives. We then 
genotyped 83 LoF variants in several large well-phenotyped population-based cohorts comprised 
of 36,262 Finns and tested for association to 60 quantitative traits and used data from the 13 
disease outcomes assessed using the National Health Registers. We demonstrate that 5 of these 
variants have significant associations with clinically relevant phenotypes, demonstrating the 
general value of the Finnish population for the study of low-frequency variants studies in 
complex as well as Mendelian diseases. Using data from centralized medical records and 
national registries, we further confirm two LoF variants that significantly reduce Lp(a) levels are 
associated with protection from cardiovascular disease. 
 
RESULTS 
As part of the SISu Project, we assembled more than 5,000 whole-exome sequences from 
Finns in projects including GoT2D, ENGAGE, migraine, METSIM and the 1000 Genomes 
Project along with 3,000 whole exome-sequences of NFEs from GoT2D, ESP, NIMH and 1000 
Genomes project using the same data generation and processing pipelines (Table 4.1). The raw 
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BAM files from these projects were compressed and re-processed at the Broad Institute and 
variant calling was performed in a unified manner to minimize potential batch effects. To 
simplify the comparison of representation of the allele frequencies, we included exactly 3,000 
Finns and 3,000 NFEs in our analyses. 
We initially compared the number and frequency of variable sites in 3,000 Finns and 
3000 NFEs (Figure 4.1) and observed several expected hallmarks of the isolated bottlenecked 
Finnish population history. There was a marked depletion of ‘singletons’, or variants that were 
observed only once in 3,000 individuals, in Finns compared to NFEs – an average Finn had 3.7 
times fewer singleton variants in these data (binomial P < 1×10-6). On the other hand, there was a 
marked excess of low-frequency variants in Finns versus NFEs (binomial P < 1×10-6), 
collectively suggesting that while most rare variants did not survive the bottleneck, the variants 
that did were of substantially elevated frequency [10], while the rates of common variation were 
not different between Finns and NFEs. All these findings are consistent with an expected impact 
of the Finnish population bottleneck. 
We then stratified the variants according to their functional annotations – loss-of-function 
(LoF) variants, missense variants and synonymous variants. We found a higher proportion of 
LoF variants in Finns compared to NFEs across the rare and low-frequency allelic spectrum 
(Figure 4.1) and for missense variants predicted to be deleterious by PolyPhen2 (Figure 4.2). 
This is also a direct consequence of the bottleneck: alleles that are elevated in frequency through 
the bottleneck are drawn at random from extremely rare variants in the parental population, 
where there is a higher proportion of LoF variants that arose recently or were kept at low 
frequencies because of negative selection. This is clearly demonstrated with the decreasing 
proportions of LoF variants with increasing allele frequencies (Figure 4.1).  
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Table 4.1: Exomes collected from ongoing studies 
Finnish studies 
Project Number of exomes 
GoT2D (Botnia) 214 
GoT2D (FUSION) 960 
GoT2D (Scania Diabetes Registry) 9 
GoT2D (Helsinki-sib) 57 
GoT2D (METSIM) 962 
ENGAGE (Young Finns) 
717 ENGAGE (Health 2000) 
ENGAGE (FINRISK) 
1000 Genomes Project 81 
Total 3000 
 
NFE studies 
Project Number of exomes 
WTCCC 641 
ESP 1792 
NIMH 373 
1000 Genomes Project 
(GBR + TSI + CEU) 
194 
Total 3000 
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Figure 4.1: Ratio of variants and proportion of variants found in Finns versus NFEs 
(A) Ratio of the number of LoF, missense and synonymous variants found in Finns versus NFEs 
with the ratios for LoF variants highlighted in red text and the ratios for synonymous variants in 
black. The p-values represent the probabilities of the excess of variable sites in Finns occurring 
by chance. The p-values in red represent the probabilities for the LoF variants, the p-values in 
blue represent the probabilities for the missense variants and the p-values in black represent the 
probabilities for the synonymous variants. (B) Percentage of variants that are loss-of-function 
(LoF) across the allele frequency spectrum, with the numbers indicating the percentage of LoF 
variants in Finns versus NFEs. The p-values represent the p-values from the hypergeometric test 
of whether the ratio of LoF variants differ from the ratio of synonymous variants in Finns 
compared to NFEs.  
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Figure 4.1: Ratio of variants and proportion of variants found in Finns versus NFEs 
(Continued) 
A 
 
B 
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Figure 4.2: Ratio of variants and proportion of missense variants predicted by PolyPhen2 
found in Finns versus NFEs 
 (A) The ratios for probably damaging missense variants predicted by PolyPhen2 highlighted in 
red text and the ratios for benign missense variants in black. The p-values represent the binomial 
probabilities of the variants being enriched in Finns and similarly, the p-values in red represent 
the probabilities for the probably damaging missense variants and the p-values in black represent 
the probabilities for the benign missense variants. (B) Percentage of variants that are missense 
variants across the allele frequency spectrum. 
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Figure 4.2: Ratio of variants and proportion of missense variants predicted by PolyPhen2 
found in Finns versus NFEs (Continued) 
A 
 
B 
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The observation that LoF variants in the 0.5-5% range are enriched in Finns and our 
hypothesis that some of these variants might have strong phenotypic consequences, motivated 
the large targeted association study described below (Figure 4.3). Despite the reduced overall 
variation in the isolated population, the existence of a greater number of low frequency LoF 
variants results in an average Finn harboring 0.16 homozygous LoF variants compared to only 
0.095 in an average NFE, driven primarily by homozygosity in the 0.5 to 5% allele frequency 
range (Figure 4.4). These features of the Finnish population have already been well described as 
they pertain to Mendelian diseases: many characteristic “Finnish founder mutations” exist at 
unusually high frequencies, even up to 1%, for highly penetrant and reproductively lethal 
disorders while such variants are extremely rare or absent in NFEs [11]. We confirmed with 
simulations that while such variants are inevitably pushed to extremely low frequency after 1,000 
or more generations, they can easily persist at frequencies between 0.1 and 1% up to 100 
generations after a bottleneck (Figure 4.5). Table 4.2 shows a table of a set of Finnish Disease 
Heritage (www.findis.org) variants and their population frequencies. The extent to which such 
variants contribute to more common diseases, either through highly-penetrant recessive subtypes 
or modest risk to carriers, will correspond to advantages in rare and low-frequency association 
studies in isolated populations.  
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Figure 4.3: Study design figure illustrating the analysis 
We used an initial set of exome sequences from Finns and NFEs to perform the selection and 
survey of the 83 LoF variants across 60 quantitative traits and 13 disease categories. 
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Figure 4.4: Number of LoF variants per individual 
(A) Number of LoF variants in Finns vs NFEs per individual. (B) Number of homozygous LoF 
variants in Finns vs NFEs per individual. 
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Figure 4.5: Simulations for a set of variants (ranging from 1% to 5% allele frequencies) 
with complete recessive lethality 
The red line indicates the expected allele frequencies in present-day Finns (where the Finnish 
bottleneck occurred ~100 generations ago) and the blue line indicates the expected allele 
frequencies in Finns 1,000 generations after the Finnish bottleneck, similar to the out-of-Africa 
bottleneck which occurred >1,000 generations ago. 
170 
 
Table 4.2: Allele frequencies of variants discovered from the FinDis database 
Chr Pos Gene Type AA AA_Pos FInn_AF NFE_AF Disease 
9 6588403 GLDC NON_SYNONYMOUS_CODON A/T 569 0.02251 0.00583 Glycine encephalopathy 
9 6556242 GLDC NON_SYNONYMOUS_CODON V/M 705 0.01468 0.0025 Glycine encephalopathy 
11 125769895 HYLS1 NON_SYNONYMOUS_CODON D/G 211 0.00884 0.00017 Hydrolethalus syndrome 1 
9 131284937 GLE1 INTRON_VARIANT - - 0.00855 0 Lethal congenital contracture syndrome 
1;Arthrogryposis, lethal, with anterior horn 
cell disease 
2 49210264 FSHR NON_SYNONYMOUS_CODON A/V 189 0.00785 0 Ovarian dysgenesis 1 
13 77574606 CLN5 NON_SYNONYMOUS_CODON N/K 108 0.00784 0.01568 Ceroid lipofuscinosis, neuronal, 5 
1 40557070 PPT1 NON_SYNONYMOUS_CODON R/W 122 0.00736 0 Ceroid lipofuscinosis, neuronal, 1 
2 136564701 LCT STOP_GAINED Y/* 822 0.00717 0 Lactase deficiency, congenital 
17 57157240 TRIM37 SPLICE_ACCEPTOR_VARIANT - - 0.007 0 Mulibrey nanism 
3 150645894 CLRN1 STOP_GAINED Y/* 176 0.00684 0 Usher syndrome, type 3A 
10 17113456 CUBN NON_SYNONYMOUS_CODON S/N 865 0.00652 0.01084 Megaloblastic anemia-1, Finnish type 
4 178359918 AGA NON_SYNONYMOUS_CODON C/S 163 0.00567 0 Aspartylglucosaminuria 
4 178359924 AGA NON_SYNONYMOUS_CODON R/Q 161 0.00567 0 Aspartylglucosaminuria 
6 74354306 SLC17A5 NON_SYNONYMOUS_CODON R/C 39 0.00517 0.00067 Sialuria, Finnish type (Salla disease) 
13 77566147 CLN5 NON_SYNONYMOUS_CODON P/S 21 0.00412 0.00505 Ceroid lipofuscinosis, neuronal, 5 
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Table 4.2: Allele frequencies of variants discovered from the FinDis database (Continued) 
         Chr Pos Gene Type AA AA_Pos FInn_AF NFE_AF Disease 
10 17083159 CUBN NON_SYNONYMOUS_CODON P/L 1297 0.004 0 Megaloblastic anemia-1, Finnish type 
14 23245147 SLC7A7 SPLICE_ACCEPTOR_VARIANT - - 0.004 0 Lysinuric protein intolerance 
2 219525942 BCS1L NON_SYNONYMOUS_CODON S/G 78 0.00383 0.00017 GRACILE syndrome 
21 45709656 AIRE STOP_GAINED R/* 257 0.00353 0.00051 Autoimmune polyendocrinopathy 
syndrome , type I, with or without 
reversible metaphyseal dysplasia 
12 91449319 KERA NON_SYNONYMOUS_CODON N/S 247 0.0032 0 Cornea plana 2 
10 126086626 OAT NON_SYNONYMOUS_CODON L/P 264 0.003 0 Gyrate atrophy of choroid and retina with 
or without ornithinemia 
10 126086626 OAT NON_SYNONYMOUS_CODON L/P 264 0.003 0 Gyrate atrophy of choroid and retina with or 
without ornithinemia 
4 15538697 CC2D2A STOP_GAINED Q/* 31 0.00255 0 Meckel syndrome 6 
1 46657769 POMGNT1 SPLICE_DONOR_VARIANT - - 0.00234 0.00017 Muscular dystrophy-dystroglycanopathy 
(congenital with brain and eye anomalies), 
type A, 3 
1 46657769 POMGNT1 SPLICE_DONOR_VARIANT - - 0.00234 0.00017 Muscular dystrophy-dystroglycanopathy 
(congenital with brain and eye anomalies), 
type A, 3 
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Table 4.2: Allele frequencies of variants discovered from the FinDis database (Continued) 
         Chr Pos Gene Type AA AA_Pos FInn_AF NFE_AF Disease 
10 102750231 C10orf2 NON_SYNONYMOUS_CODON Y/C 508 0.00183 0 Mitochondrial DNA depletion syndrome 7 
(hepatocerebral type) 
17 56292121 MKS1 NON_SYNONYMOUS_CODON R/W 156 0.00137 0 Meckel syndrome 1 
8 100832259 VPS13B NON_SYNONYMOUS_CODON N/S 2993 0.00117 0.00717 Cohen syndrome 
16 53639522 RPGRIP1L NON_SYNONYMOUS_CODON R/C 1202 0.001 0.00067 Meckel syndrome 5 
1 40557075 PPT1 SPLICE_REGION_VARIANT - - 0.00084 0.00134 Ceroid lipofuscinosis, neuronal, 1 
9 6554703 GLDC NON_SYNONYMOUS_CODON G/R 761 0.00084 0 Glycine encephalopathy 
9 6588417 GLDC NON_SYNONYMOUS_CODON S/I 564 0.00083 0 Glycine encephalopathy 
5 149360691 SLC26A2 NON_SYNONYMOUS_CODON T/K 512 0.00067 0 Diastrophic dysplasia 
10 126094114 OAT NON_SYNONYMOUS_CODON R/T 42 0.00067 0 Gyrate atrophy of choroid and retina with or 
without ornithinemia 
19 36322260 NPHS1 STOP_GAINED R/* 1109 0.00067 0 Nephrotic syndrome, type 1 
9 131303403 GLE1 NON_SYNONYMOUS_CODON I/T 684 0.0005 0 Arthrogryposis, lethal, with anterior horn 
cell disease 
1 46655129 POMGNT1 SPLICE_DONOR_VARIANT - - 0.00034 0.00017 Muscular dystrophy-dystroglycanopathy 
(congenital with brain and eye anomalies), 
type A, 3 
1 46655129 POMGNT1 SPLICE_DONOR_VARIANT - - 0.00034 0.00017 Muscular dystrophy-dystroglycanopathy 
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Table 4.2: Allele frequencies of variants discovered from the FinDis database (Continued) 
         Chr Pos Gene Type AA AA_Pos FInn_AF NFE_AF Disease 
(congenital with brain and eye anomalies), 
type A, 3 
5 149359991 SLC26A2 NON_SYNONYMOUS_CODON R/W 279 0.00033 0.00133 Diastrophic dysplasia 
5 149357444 SLC26A2 NON_SYNONYMOUS_CODON N/H 77 0.00017 0.0005 Diastrophic dysplasia 
7 107423465 SLC26A3 NON_SYNONYMOUS_CODON S/F 398 0.00017 0 Chloride diarrhea, congenital, Finnish type 
8 94808198 TMEM67 NON_SYNONYMOUS_CODON C/R 534 0.00017 0 Meckel syndrome 3 
9 6605186 GLDC NON_SYNONYMOUS_CODON T/M 269 0.00017 0 Glycine encephalopathy 
9 131298693 GLE1 NON_SYNONYMOUS_CODON R/H 569 0.00017 0.00033 Lethal congenital contracture syndrome 1 
12 91445245 KERA STOP_GAINED R/* 313 0.00017 0 Cornea plana 2 
14 23282447 SLC7A7 NON_SYNONYMOUS_CODON G/V 54 0.00017 0 Lysinuric protein intolerance 
16 28493481 CLN3 NON_SYNONYMOUS_CODON R/H 234 0.00017 0 Ceroid lipofuscinosis, neuronal, 3 
1 40555089 PPT1 NON_SYNONYMOUS_CODON Q/E 177 0 0.00017 Ceroid lipofuscinosis, neuronal, 1 
1 40555167 PPT1 STOP_GAINED R/* 151 0 0.00067 Ceroid lipofuscinosis, neuronal, 1 
1 40562882 PPT1 STOP_GAINED L/* 10 0 0.00017 Ceroid lipofuscinosis, neuronal, 1 
1 46658068 POMGNT1 NON_SYNONYMOUS_CODON R/H 442 0 0.00033 Muscular dystrophy-dystroglycanopathy 
(congenital with brain and eye anomalies), 
type A, 3 
2 136558283 LCT NON_SYNONYMOUS_CODON R/H 1587 0 0.00017 Lactase deficiency, congenital 
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Table 4.2: Allele frequencies of variants discovered from the FinDis database (Continued) 
         Chr Pos Gene Type AA AA_Pos FInn_AF NFE_AF Disease 
2 219525876 BCS1L STOP_GAINED R/* 56 0 0.00017 GRACILE syndrome 
3 150690352 CLRN1 NON_SYNONYMOUS_CODON N/K 48 0 0.00017 Usher syndrome, type 3A 
4 15572069 CC2D2A NON_SYNONYMOUS_CODON W/R 625 0 0.00018 Meckel syndrome 6 
5 149357747 SLC26A2 STOP_GAINED R/* 69 0 0.00033 Diastrophic dysplasia 
5 149361150 SLC26A2 NON_SYNONYMOUS_CODON H/P 665 0 0.00017 Diastrophic dysplasia 
8 1719266 CLN8 NON_SYNONYMOUS_CODON L/M 16 0 0.00017 Ceroid lipofuscinosis, neuronal, 8 
8 1719594 CLN8 NON_SYNONYMOUS_CODON N/S 125 0 0.00133 Ceroid lipofuscinosis, neuronal, 8 
8 1728557 CLN8 NON_SYNONYMOUS_CODON P/A 229 0 0.00017 Ceroid lipofuscinosis, neuronal, 8 
8 94777876 TMEM67 SPLICE_DONOR_VARIANT - - 0 0.00017 Meckel syndrome 3 
8 94817024 TMEM67 NON_SYNONYMOUS_CODON G/E 705 0 0.00017 Meckel syndrome 3 
8 100155318 VPS13B NON_SYNONYMOUS_CODON A/T 590 0 0.00183 Cohen syndrome 
8 100729602 VPS13B SPLICE_DONOR_VARIANT - - 0 0.00033 Cohen syndrome 
8 100830757 VPS13B STOP_GAINED R/* 2839 0 0.00017 Cohen syndrome 
9 6553420 GLDC NON_SYNONYMOUS_CODON A/V 802 0 0.00017 Glycine encephalopathy 
9 6587141 GLDC NON_SYNONYMOUS_CODON S/T 617 0 0.00017 Glycine encephalopathy 
9 6595109 GLDC NON_SYNONYMOUS_CODON A/V 389 0 0.00018 Glycine encephalopathy 
9 6602147 GLDC NON_SYNONYMOUS_CODON R/W 373 0 0.00017 Glycine encephalopathy 
10 17152923 CUBN NON_SYNONYMOUS_CODON P/L 337 0 0.00017 Megaloblastic anemia-1, Finnish type 
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Table 4.2: Allele frequencies of variants discovered from the FinDis database (Continued) 
         Chr Pos Gene Type AA AA_Pos FInn_AF NFE_AF Disease 
10 102749544 C10orf2 NON_SYNONYMOUS_CODON R/W 463 0 0.00017 Mitochondrial DNA depletion syndrome 7 
(hepatocerebral type) 
10 126086581 OAT NON_SYNONYMOUS_CODON P/L 279 0 0.00017 Gyrate atrophy of choroid and retina with or 
without ornithinemia 
10 126086581 OAT NON_SYNONYMOUS_CODON P/L 279 0 0.00017 Gyrate atrophy of choroid and retina with or 
without ornithinemia 
10 126092416 OAT NON_SYNONYMOUS_CODON P/L 103 0 0.00033 Gyrate atrophy of choroid and retina with or 
without ornithinemia 
10 126100579 OAT NON_SYNONYMOUS_CODON N/K 54 0 0.00017 Gyrate atrophy of choroid and retina with or 
without ornithinemia 
13 77566309 CLN5 NON_SYNONYMOUS_CODON W/R 75 0 0.00144 Ceroid lipofuscinosis, neuronal, 5 
13 77570169 CLN5 NON_SYNONYMOUS_CODON W/R 73 0 0.00017 Ceroid lipofuscinosis, neuronal, 5 
13 77570221 CLN5 STOP_GAINED W/* 90 0 0.00017 Ceroid lipofuscinosis, neuronal, 5 
16 53679606 RPGRIP1L STOP_GAINED Q/* 872 0 0.00017 Meckel syndrome 5 
17 19251095 B9D1 SPLICE_DONOR_VARIANT - - 0 0.00017 Meckel syndrome 9 
17 56293449 MKS1 SPLICE_REGION_VARIANT E 129 0 0.00017 Meckel syndrome 1 
21 45194641 CSTB SPLICE_ACCEPTOR_VARIANT - - 0 0.00033 Epilepsy, progressive myoclonic 1A 
(Unverricht and Lundborg) 
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Given our empirical observations of proportionally more LoF variants in the 0.5-5% 
allele frequency range in Finns, we next conducted a pilot test of this hypothesis that some of the 
Finnish-enriched low-frequency LoF variants might have strong phenotypic effects. We 
successfully genotyped 83 LoF variants (protein-truncating nonsense, essential splice site 
variants and frameshift variants) that were enriched in Finns. Of these 83 variants, 76 variants 
were more than 2-fold enriched and 26 were more than 10-fold enriched, and 75 out of the 83 
LoF variants found at 0.5-5% allele frequency in Finns) using Sequenom MALDI-TOF 
genotyping assays (Table 4.3). Three genes (SERPINA10, LPA and FANCM) contained two LoF 
variants each; we combined these pairs and tested them as single composite LoF variants, 
resulting in a total of 80 independent LoF variants tested in this study. These 83 variants were 
genotyped in a total of 36.262 individuals from three population cohorts: FINRISK [12] (26,245 
individuals), Health2000 (7,363 individuals) and Young Finns [13] (2,654 individuals).  
As these three studies are population-based cohorts, we were able to assess whether any 
of the homozygous LoF variants might be lethal in fetal life or early infancy, or result in such a 
severe phenotype that these individuals would not be able to participate in a population survey. 
Study-wide, there was a modest excess of homozygotes of the variants (1.23-fold versus Hardy-
Weinberg expectation) arising from within population substructure. A nonsense variant in the 
Translation Elongation Factor, Mitochondrial gene (TSFM) that is present at 1.2% allele 
frequency in Finns and absent in NFEs, was not found in a homozygous state in >36,000 Finns 
(Hardy Weinberg Equilibrium (HWE) P = 0.0077). This suggests that complete loss of TSFM 
might result in embryonic lethality, severe childhood diseases in humans, or that the individuals 
might not have been ascertained by the studies employed, i.e. if the individuals are too sick to be 
included in the studies. A lookup of this variant in another 25,237 Finnish exome chip 
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genotyping data from the GoT2D studies confirmed that the variant is present at 1.2% in Finns, 
but again with no homozygotes observed (combined HWE P = 1.6×10-4). The fact that recessive 
missense variants in TSFM have been reported to result in mitochondrial translation deficiency 
[14,15] lends additional plausibility to the hypothesis that complete loss of this gene is not 
tolerated in humans.   
Several other LoF variants occur in genes where recessive mutations have been noted to 
cause severe Mendelian diseases from the Online Mendelian Inheritance in Man database 
(OMIM) [16]. For instance, the Fanconi anemia complementation group M gene (FANCM) was 
initially discovered in one family with Fanconi anemia [17], but we did not observe any deficit 
of homozygous LoFs in FANCM from our dataset (expected = 5, observed = 7), which we would 
typically observe for a disease causing recessive variant. However, examination of the hospital 
discharge records did not provide any evidence for blood diseases, increased cancer events or 
any other chronic diseases in these individuals with homozygous LoFs in FANCM. Singh et al. 
reported that the initial case that led to the association of FANCM with Fanconi anemia also 
harbor biallelic, functional mutations in FANCA, a well established Fanconi anemia gene [18]. 
Our findings in this study, combined with the findings by Singh et al. do not support the 
hypothesis that FANCM is a Fanconi anemia gene.  
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Table 4.3: Final list of variants from Sequenom genotyping in 36,262 Finns 
Chr Type Gene Annotation #Hom 
ref 
#Het #Hom 
nonref 
Genotyping 
Finn_AF 
Sequencing 
Finn_AF 
Sequencing 
NFE_AF 
Expected 
Het 
Expected 
Hom 
HWE 
1 frameshift PADI1 - 35238 519 3 0.00734 0.01131 9.00E-04 521 2 0.4465 
1 stop COL9A2 full 34981 798 4 0.01126 0.01105 0.00316 797 5 1.0000 
1 stop SLFNL1 full 33429 1617 29 0.02388 0.03517 0.00676 1635 20 0.0500 
1 frameshift GBP5 - 34496 641 4 0.00923 0.01010 0.00224 643 3 0.5485 
1 splice DPYD partial 33517 1465 20 0.02150 0.01659 0.00268 1473 16 0.3088 
1 splice AKNAD1 partial 33619 2124 36 0.03069 0.03762 0.00045 2129 34 0.6565 
1 frameshift C1orf56 - 33788 707 7 0.01045 0.01252 0.00179 713 4 0.1075 
1 stop SELP partial 34926 866 9 0.01235 0.01134 0 873 5 0.1253 
1 stop CFHR2 full 33171 1820 31 0.02687 0.03519 0.00671 1831 25 0.2592 
1 stop OBSCN partial 33419 2341 44 0.03392 0.02743 0.00305 2347 41 0.6282 
1 frameshift LGALS8 - 33104 1959 36 0.02893 0.03514 0 1972 29 0.2155 
2 stop GCA partial 34908 893 11 0.01278 0.01598 0.00179 903 6 0.0532 
2 frameshift PDE11A - 34222 898 7 0.01298 0.01616 0.00313 900 6 0.5351 
2 frameshift DNAH7 - 34936 801 8 0.01143 0.01051 0.00134 808 5 0.1498 
2 stop HTR2B partial 34613 1181 9 0.01674 0.01172 0 1179 10 0.8728 
3 stop CCDC37 partial 33549 2171 48 0.03169 0.02991 0.00514 2195 36 0.0467 
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Table 4.3: Final list of variants from Sequenom genotyping in 36,262 Finns (Continued) 
 
Chr Type Gene Annotation #Hom 
ref 
#Het #Hom 
nonref 
Genotyping 
Finn_AF 
Sequencing 
Finn_AF 
Sequencing 
NFE_AF 
Expected 
Het 
Expected 
Hom 
HWE 
3 stop A4GNT full 34472 569 4 0.00823 0.01132 0.00089 572 2 0.3057 
4 splice CDKL2 full 34251 1490 23 0.02147 0.01948 0.00492 1503 16 0.1015 
4 stop HERC6 partial 33345 1733 26 0.02542 0.02061 0.00089 1740 23 0.4503 
5 frameshift PCDHA3 - 33410 2344 47 0.03405 0.03110 0.00671 2355 42 0.3760 
5 frameshift FCHSD1 - 34150 941 14 0.01380 0.01494 0.00179 956 7 0.0091 
5 stop GPR151 full 34502 1256 15 0.01797 0.01940 0.00537 1263 12 0.2919 
5 splice ARHGEF37 full 34051 1056 10 0.01532 0.01617 0.0076 1060 8 0.4779 
5 stop ATP10B full 32747 2292 46 0.03397 0.02932 0.00045 2303 40 0.3701 
6 frameshift GPLD1 - 34388 1415 19 0.02028 0.01737 0.00492 1424 15 0.2322 
6 stop SLC17A4 partial 34014 1772 22 0.02536 0.02510 0.01565 1770 23 0.9150 
6 stop CRISP1 full 34293 855 8 0.01239 0.01262 0.00134 860 5 0.2673 
6 frameshift MYCT1 - 31828 3825 112 0.05661 0.06093 0.02507 3820 115 0.8430 
6 stop CLDN20 full 33768 2049 37 0.02961 0.02710 0 2060 31 0.3108 
6 splice LPA full 33712 1883 45 0.02768 0.02183 0.00492 1918 27 0.0011 
6 splice LPA full 32886 3294 82 0.04768 0.04689 0.03533 3293 82 1.0000 
6 - LPA - 31067 4968 227 0.07476 - - 5017 203 0.0683 
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Table 4.3: Final list of variants from Sequenom genotyping in 36,262 Finns (Continued) 
 
Chr Type Gene Annotation #Hom 
ref 
#Het #Hom 
nonref 
Genotyping 
Finn_AF 
Sequencing 
Finn_AF 
Sequencing 
NFE_AF 
Expected 
Het 
Expected 
Hom 
HWE 
6 splice WDR27 partial 34109 938 6 0.01355 0.01217 0.00586 937 6 1.0000 
7 frameshift TMEM195 - 34659 1114 17 0.01604 0.02102 0.00268 1130 9 0.0169 
7 frameshift PRPS1L1 - 32248 3386 101 0.05020 0.05335 0.02415 3408 90 0.2222 
7 splice ABCB5 partial 30082 5388 267 0.08286 0.06178 0.0083 5431 245 0.1344 
7 stop POM121L12 full 32808 2527 78 0.03788 0.02660 9.00E-04 2581 51 0.0002 
7 stop CCL26 full 34930 891 6 0.01260 0.02425 0.01342 892 6 0.8302 
7 stop C7orf64 partial 30517 4361 137 0.06619 0.06854 0.02816 4328 153 0.1664 
7 stop NDUFA5 partial 31994 2997 68 0.04468 0.04082 0.00568 2993 70 0.8512 
7 stop CLCN1 full 34632 1120 13 0.01602 0.01536 0.00045 1128 9 0.1805 
8 frameshift FGL1 - 32954 2514 63 0.03715 0.03877 0.00045 2542 49 0.0447 
8 frameshift HTRA4 - 34843 930 10 0.01327 0.01373 0.00313 937 6 0.1510 
8 frameshift EPPK1 - 34154 1619 21 0.02320 0.02060 0 1622 19 0.6406 
9 stop IFNA5 full 34211 1543 23 0.02221 0.01657 0.00581 1554 18 0.1806 
9 stop IFNE full 33924 1134 14 0.01657 0.01904 0.00134 1143 10 0.1408 
9 splice SOHLH1 full 34816 992 15 0.01426 0.01173 0 1007 7 0.0078 
9 splice PNPLA7 partial 34442 1333 16 0.01907 0.01909 0.00762 1339 13 0.3938 
180 
181 
 
Table 4.3: Final list of variants from Sequenom genotyping in 36,262 Finns (Continued) 
 
Chr Type Gene Annotation #Hom 
ref 
#Het #Hom 
nonref 
Genotyping 
Finn_AF 
Sequencing 
Finn_AF 
Sequencing 
NFE_AF 
Expected 
Het 
Expected 
Hom 
HWE 
10 frameshift PTCHD3 - 32838 2182 52 0.03259 0.04058 0.00493 2211 37 0.0173 
10 stop ZMYND17 full 34967 817 7 0.01161 0.01819 0.00179 821 5 0.3475 
10 stop LIPK full 34437 673 6 0.00975 0.01011 0.00224 678 3 0.1539 
10 frameshift CALHM2 - 33416 2293 48 0.03341 0.03796 0.00939 2309 40 0.1893 
11 splice MS4A2 full 33769 1307 15 0.01905 0.01377 0.00089 1312 13 0.4743 
11 stop P4HA3 partial 16564 15276 3795 0.32084 0.31727 0.15229 15530 3668 0.0021 
12 splice PRPH full 34170 1553 23 0.02237 0.01617 0.00539 1563 18 0.2242 
12 frameshift SPATS2 - 34419 726 7 0.01053 0.01212 0.00134 732 4 0.1169 
12 stop TSFM partial 34928 886 0 0.01237 0.01184 0 875 5 0.0077 
13 stop ZMYM5 full 34287 809 9 0.01178 0.01375 0.00134 817 5 0.0647 
13 stop CLYBL full 30879 2210 39 0.03453 0.03759 0.03491 2209 40 1.0000 
14 stop FANCM full 35122 636 5 0.00903 0.01293 0 640 3 0.2216 
14 stop FANCM full 36060 201 1 0.00280 0.00405 0.00089 202 0 0.2469 
14 - FANCM - 35422 833 7 0.01168 - - 837 5 0.3541 
14 stop TBPL2 full 34176 780 11 0.01147 0.01091 0 793 5 0.0070 
14 stop SERPINA10 full 34505 1199 11 0.01709 0.01659 0.00492 1200 10 0.7537 
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Table 4.3: Final list of variants from Sequenom genotyping in 36,262 Finns (Continued) 
 
Chr Type Gene Annotation #Hom 
ref 
#Het #Hom 
nonref 
Genotyping 
Finn_AF 
Sequencing 
Finn_AF 
Sequencing 
NFE_AF 
Expected 
Het 
Expected 
Hom 
HWE 
14 stop SERPINA10 full 36170 92 0 0.00127 0.00081 0.0076 92 0 1.0000 
14 - SERPINA10 - 34965 1283 14 0.01808 - - 1287 12 0.4604 
14 stop SERPINA12 full 34284 817 6 0.01181 0.01657 0.00716 819 5 0.4955 
15 frameshift PLCB2 - 34675 1014 8 0.01443 0.01292 0 1015 7 0.7110 
15 frameshift DUOX2 - 34415 664 6 0.00963 0.01334 0.00269 669 3 0.1469 
15 stop GCNT3 full 34994 744 9 0.01066 0.01496 0.00089 754 4 0.0218 
16 splice CCDC78 partial 35046 633 6 0.00904 0.01536 0.00089 639 3 0.0733 
16 stop PHKB partial 34739 1019 15 0.01466 0.01444 0.00048 1034 8 0.0150 
16 stop ELMO3 full 34047 1692 26 0.02438 0.01657 0.00268 1701 21 0.2670 
16 splice ATP2C2 full 34178 1563 28 0.02263 0.02061 0.0085 1582 18 0.0301 
17 splice EFCAB5 partial 34551 1217 13 0.01737 0.01602 0.00583 1221 11 0.4388 
17 stop EFCAB3 full 31576 2831 63 0.04289 0.03880 0.00626 2830 63 1.0000 
18 frameshift MRO - 33955 1154 19 0.01697 0.02342 0.00984 1172 10 0.0092 
19 stop ZNF763 full 33920 1073 14 0.01573 0.01334 0.00134 1084 9 0.0801 
19 stop ZNF571 full 32746 3003 77 0.04406 0.03930 0.00403 3018 70 0.3465 
19 splice SPHK2 partial 34249 1418 14 0.02026 0.01870 0.00328 1417 15 1.0000 
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Table 4.3: Final list of variants from Sequenom genotyping in 36,262 Finns (Continued) 
 
Chr Type Gene Annotation #Hom 
ref 
#Het #Hom 
nonref 
Genotyping 
Finn_AF 
Sequencing 
Finn_AF 
Sequencing 
NFE_AF 
Expected 
Het 
Expected 
Hom 
HWE 
19 stop FUT2 full 3393 12254 9256 0.61772 0.37662 0.47139 11761 9502 3.69E-
11 
19 frameshift NLRP13 - 35129 679 3 0.00956 0.01131 0.00179 678 3 1.0000 
19 stop ZNF772 partial 33489 1613 22 0.02359 0.01739 0.00894 1618 20 0.5610 
19 stop ZNF544 partial 32421 2632 69 0.03943 0.03597 0.01118 2661 55 0.0482 
20 frameshift FAM65C - 34242 1510 18 0.02161 0.01817 0 1513 17 0.7069 
22 frameshift DNAJB7 - 33281 1758 29 0.02589 0.01939 0.00492 1769 24 0.2430 
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Mutations in COL9A2 can cause autosomal dominant multiple epiphyseal dysplasia or 
autosomal recessive Stickler syndrome, diseases that affect the connective tissues and result in 
underdeveloped bones, among several other phenotypes. When surveying data from two major 
RNA sequencing studies [19,20], we observed the Q326X variant in the Collagen, Type IX, 
Alpha 2 gene (COL9A2) to be associated to decreased RNA levels in several tissues, including 
lung, liver and skin, from the RNA sequencing data (binomial P = 3.51×10-9). However, we did 
not detect any deviation from HWE for the COL9A2 Q326X variant and the hospital discharge 
records did not provide any evidence for connective tissue diseases with the 798 heterozygous 
carriers or the 4 homozygous carriers. Likewise, Dihydropyrimidine dehydrogenase (DPYD) 
deficiency causes intolerance to overload of pyrimidines, such as the chemotherapeutic agent 5-
fluorouracil [21]. Some reports suggest that DPYD deficient homozygotes might be associated 
with neurological abnormalities [22], whereas others do not find any specific phenotype 
associations [23]. In our study, the hospital discharge records did not indicate any enrichment of 
any disease categories among the 20 individuals with homozygous for LoFs in DPYD.   
 The FINRISK cohort had collected 60 biochemical and physiological quantitative 
measurements of cardiovascular or immunologic relevance (Table 4.4), some of which are highly 
correlated. We tested the 80 variants across the 60 traits and report from this initial screen all 
associations with p<2×10-4 – that is, a value where we would expect only one chance observation 
in the entire study. In total, we observed 41 associations that exceeded this significance threshold 
(Table 4.5), far beyond the expected. If the phenotype was available in the Young Finns and 
Health 2000 cohorts, replication was attempted for these initial scan  hits and significant 
associations are highlighted below when the combined p-value was smaller than a conservative 
study-wide Bonferroni-corrected threshold of 0.05/(80*60) = 1×10-5. 
185 
 
Table 4.4: List of 60 blood pressure measures and biochemical assays  
Trait Description 
Systolic bp Systolic blood pressure 
Diastolic bp Diastolic blood pressure 
HDL High density lipoprotein 
Triglycerides Triglycerides 
LDL Low density lipoprotein 
Lp(a) Lipoprotein (a) 
APOA1 Apolipoprotein A-I 
APOB Apolipoprotein B 
Galectin-3 Galectin-3 
LPS Lipopolysaccharide 
CRP C reactive protein 
HGF Hepatocyte growth factor 
SCF Stem cell factor 
SDF1 Stromal cell derived factor 1 (CXCL12) 
TNF-beta Tumor necrosis factor beta 
TRAIL TNF related apoptosis inducing ligand 
IL4 Interleukin 4 
IL6 Interleukin 6 
IL10 Interleukin 10 
IL12 Interleukin 12 
IL17 Interleukin 17 
Eotaxin Eotaxin (CCLL11) 
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Table 4.4: List of 60 blood pressure measures and biochemical assays (Continued)  
  
Trait Description 
FGF Fibroblast growth factor 
GCSF Granulocyte colony stimulating factor 
GM-CSF Granulocyte monocyte colony stimulating factor 
IFN-gamma Interferon_gamma 
MCP1 Monocyte chemoattractant protein 1 (CCL2) 
PDGF Platelet derived growth factor 
MIP1B Macrophage inflammatory protein 1 beta (CCL4) 
RANTES Regulated on Activation, Normal T cell Expressed and Secreted (CCL5) 
VEGF Vascular endothelial cell growth factor A 
Active-B12 Active vitamin B12 
Adiponectin Adiponectin 
BNP Brain_natriuretic_peptide 
CK_MB Creatine kinase isoenzyme MB 
Creatinine Creatinine 
Vasopressin C terminal pro vasopressin 
Endothelin1 C terminal pro endothelin 1 
Cystatin-C Cystatin C 
D-dimer D-dimer 
Ferritin Ferritin 
Homocysteine Homocysteine 
IL18 Interleukin 18 
IL1_RA Interleukin1 receptor antagonist 
Leptin Leptin 
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Table 4.4: List of 60 blood pressure measures and biochemical assays (Continued)  
  
Trait Description 
MPO Myeloperoxidase 
Adrenomedullin Mid regional pro adrenomedullin 
ANP Mid regional pro atrial natriuretic peptide 
Neopterin Neopterin 
BNP N terminal prohormone of brain natriuretic peptide 
PLA_A Phospholipase A2 activity 
PLA_M Phospholipase A2 mass 
PLGF Placental growth factor 
PON1 Paraoxonase 1 
TIMP1 Tissue inhibitor metalloproteinase 1 
Glucose Glucose corrected for fasting 
Insulin Insulin corrected for fasting 
Testerone Testerone 
Vitamin-B12 Vitamin B12 (Cobalamin) 
Vitamin-D Vitamin D 
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Table 4.5: All associations with discovery P<2e-04 
      
   Discovery Replication Combined 
Trait Gene Variant N Beta SE P-value N Beta SE P-value N Beta SE P-value 
Lp(a) LPA splice 6696 -0.608 0.031 2.17E-81 2200 -0.729 0.055 6.80E-39 8896 -0.637 0.027 1.53E-117 
Vitamin-B12 FUT2 stop 6087 0.199 0.019 3.68E-26         
Galectin-3 TBPL2 stop 6648 -0.460 0.080 9.37E-09         
GCSF ATP2C2 splice 6660 0.272 0.055 6.98E-07 2188 -0.037 0.105 7.25E-01 8848 0.206 0.049 2.27E-05 
IL4 ATP2C2 splice 6660 0.258 0.055 2.48E-06 2188 0.035 0.105 7.42E-01 8846 0.209 0.061 5.91E-04 
IFN-gamma ATP2C2 splice 6660 0.255 0.055 3.24E-06 2188 0.060 0.105 5.72E-01 8841 0.051 0.016 1.45E-03 
IL6 ATP2C2 splice 6660 0.251 0.055 4.58E-06 2188 0.073 0.105 4.88E-01 8848 0.213 0.049 1.16E-05 
Endothelin1 FUT2 stop 6146 0.086 0.019 5.63E-06         
D-dimer FGL1 frameshift 6582 0.210 0.046 6.12E-06         
IL12 ATP2C2 splice 6660 0.245 0.055 8.13E-06 2188 0.042 0.105 6.87E-01 8848 0.201 0.049 3.45E-05 
IL17 ATP2C2 splice 6660 0.241 0.055 1.12E-05 2188 -0.136 0.105 1.95E-01 8848 0.160 0.049 9.91E-04 
Systolic bp ATP2C2 splice 25764 0.125 0.029 1.25E-05 9355 0.113 0.054 3.65E-02 35119 0.122 0.025 1.31E-06 
IFN-gamma P4HA3 stop 6655 0.080 0.019 1.70E-05 2186 -0.036 0.032 2.70E-01 8841 0.051 0.016 1.45E-03 
IL17 P4HA3 stop 6655 0.080 0.019 1.72E-05 2186 0.015 0.033 6.34E-01 8841 0.064 0.016 7.27E-05 
Vitamin-B12 CLYBL stop 6600 -0.203 0.047 1.83E-05         
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Table 4.5: All associations with discovery P<2e-04 (Continued) 
 
   Discovery Replication Combined 
Trait Gene Variant N Beta SE P-value N Beta SE P-value N Beta SE P-value 
Lp(a) LPA splice 6696 -0.608 0.031 2.17E-81 2200 -0.729 0.055 6.80E-39 8896 -0.637 0.027 1.53E-117 
Vitamin-B12 FUT2 stop 6087 0.199 0.019 3.68E-26         
Galectin-3 TBPL2 stop 6648 -0.460 0.080 9.37E-09         
GCSF ATP2C2 splice 6660 0.272 0.055 6.98E-07 2188 -0.037 0.105 7.25E-01 8848 0.206 0.049 2.27E-05 
IL4 ATP2C2 splice 6660 0.258 0.055 2.48E-06 2188 0.035 0.105 7.42E-01 8846 0.209 0.061 5.91E-04 
IFN-gamma ATP2C2 splice 6660 0.255 0.055 3.24E-06 2188 0.060 0.105 5.72E-01 8841 0.051 0.016 1.45E-03 
IL6 ATP2C2 splice 6660 0.251 0.055 4.58E-06 2188 0.073 0.105 4.88E-01 8848 0.213 0.049 1.16E-05 
Endothelin1 FUT2 stop 6146 0.086 0.019 5.63E-06         
D-dimer FGL1 frameshift 6582 0.210 0.046 6.12E-06         
IL12 ATP2C2 splice 6660 0.245 0.055 8.13E-06 2188 0.042 0.105 6.87E-01 8848 0.201 0.049 3.45E-05 
IL17 ATP2C2 splice 6660 0.241 0.055 1.12E-05 2188 -0.136 0.105 1.95E-01 8848 0.160 0.049 9.91E-04 
Systolic bp ATP2C2 splice 25764 0.125 0.029 1.25E-05 9355 0.113 0.054 3.65E-02 35119 0.122 0.025 1.31E-06 
IFN-gamma P4HA3 stop 6655 0.080 0.019 1.70E-05 2186 -0.036 0.032 2.70E-01 8841 0.051 0.016 1.45E-03 
IL17 P4HA3 stop 6655 0.080 0.019 1.72E-05 2186 0.015 0.033 6.34E-01 8841 0.064 0.016 7.27E-05 
Vitamin-B12 CLYBL stop 6600 -0.203 0.047 1.83E-05         
TNF-beta HTRA4 frameshift 6669 -0.292 0.069 2.68E-05 2188 0.378 0.141 7.29E-03 8857 -0.172 0.062 5.54E-03 
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Table 4.5: All associations with discovery P<2e-04 (Continued) 
 
   Discovery Replication Combined 
Trait Gene Variant N Beta SE P-value N Beta SE P-value N Beta SE P-value 
IL4 ATP10B stop 6673 0.186 0.045 3.55E-05 2189 0.141 0.086 1.01E-01 8862 0.177 0.040 9.71E-06 
FGF P4HA3 stop 6655 0.076 0.019 4.58E-05 2186 0.006 0.032 8.49E-01 8841 0.059 0.016 2.81E-04 
TNF-beta ATP10B stop 6673 0.184 0.045 4.65E-05 2189 0.091 0.081 2.63E-01 8862 0.164 0.039 3.26E-05 
TNF-beta ATP2C2 splice 6660 0.223 0.055 4.69E-05 2188 -0.024 0.099 8.08E-01 8848 0.170 0.048 3.86E-04 
IFN-gamma ATP10B stop 6673 0.183 0.045 4.81E-05 2189 0.037 0.086 6.68E-01 8862 0.152 0.040 1.45E-04 
SDF1 ATP2C2 splice 6660 0.221 0.055 5.69E-05 2188 0.057 0.105 5.85E-01 8848 0.186 0.049 1.31E-04 
TNF-beta P4HA3 stop 6655 0.075 0.019 5.94E-05 2186 0.007 0.031 8.10E-01 8841 0.058 0.016 2.66E-04 
FGF ATP2C2 splice 6660 0.220 0.055 5.98E-05 2188 0.033 0.105 7.51E-01 8848 0.180 0.049 2.11E-04 
IL18 EPPK1 frameshift 6677 -0.232 0.058 6.20E-05 2160 -0.240 0.102 1.88E-02 8837 -0.234 0.050 3.42E-06 
PDGF ATP10B stop 6673 0.181 0.045 6.20E-05 2189 -0.011 0.086 9.02E-01 8862 0.139 0.040 4.84E-04 
SDF1 ATP10B stop 6673 0.178 0.045 7.62E-05 2189 -0.118 0.085 1.66E-01 8862 0.114 0.040 4.12E-03 
Triglycerides MS4A2 splice 25051 0.129 0.033 7.80E-05 9489 0.151 0.054 4.85E-03 34540 0.135 0.028 1.31E-06 
VEGF HTRA4 frameshift 6669 -0.274 0.069 7.86E-05 2188 -0.010 0.149 9.46E-01 8857 -0.227 0.063 3.10E-04 
IL17 CLYBL stop 6671 0.185 0.047 8.77E-05         
IL10 ATP2C2 splice 6660 0.214 0.055 9.33E-05 2188 0.134 0.105 2.04E-01 8848 0.197 0.049 5.08E-05 
IL6 P4HA3 stop 6655 0.072 0.019 9.70E-05 2186 -0.016 0.033 6.17E-01 8841 0.051 0.016 1.73E-03 
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Table 4.5: All associations with discovery P<2e-04 (Continued) 
 
   Discovery Replication Combined 
Trait Gene Variant N Beta SE P-value N Beta SE P-value N Beta SE P-value 
IL17 HTRA4 frameshift 6669 -0.270 0.069 1.03E-04 2188 -0.008 0.149 9.57E-01 8857 -0.223 0.063 3.97E-04 
IFN-gamma CCL26 stop 6663 -0.307 0.080 1.15E-04 2192 -0.183 0.133 1.69E-01 8855 -0.274 0.068 5.94E-05 
IL12 ATP10B stop 6673 0.174 0.045 1.20E-04 2189 0.010 0.086 9.09E-01 8862 0.138 0.040 5.41E-04 
IL6 ATP10B stop 6673 0.173 0.045 1.23E-04 2189 0.024 0.086 7.79E-01 8862 0.141 0.040 4.15E-04 
IL17 ATP10B stop 6673 0.173 0.045 1.24E-04 2189 -0.003 0.086 9.74E-01 8862 0.135 0.040 7.13E-04 
PDGF P4HA3 stop 6655 0.071 0.019 1.31E-04 2186 -0.022 0.032 4.99E-01 8841 0.048 0.016 2.86E-03 
GCSF CLYBL stop 6671 0.180 0.047 1.41E-04         
PDGF ATP2C2 splice 6660 0.209 0.055 1.43E-04 2188 0.048 0.105 6.49E-01 8848 0.174 0.049 3.40E-04 
GCSF EFCAB3 stop 6606 0.157 0.042 1.86E-04 2192 -0.157 0.079 4.62E-02 8798 0.087 0.037 1.84E-02 
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Three of these association have been previously reported and represent positive controls 
for our approach: a strong association for the 2 splice variants (c.4974-2A>G and c.4289+1G>A) 
in the Lipoprotein(a) gene (LPA) with lipoprotein(a) measurements in plasma (Pdiscovery = 
2.17×10-81, Pdiscovery+replication = 1.53×10-117, combined ?̂? = -0.64 or -8.77 mg/dL per allele), the 
W154X variant in Fucosyltransferase 2 (FUT2) with increased Vitamin B12 levels [24] (?̂? = 0.2, 
P = 3.7×10-26 or 43.38 pg/mL per allele) and the R225X variant in the Citrate Lyase Beta Like 
gene (CLYBL) with decreased Vitamin B12 levels [25] (?̂? = -0.2, P = 1.8×10-5 or -43.38 pg/mL 
per allele) [26]. The boxplots for these associations are shown in Figure 4.6.  
In addition to an extremely strong correlation between lipoprotein(a) levels and 
cardiovascular disease, it has been previously reported that genetic variants that elevate 
circulating lipoprotein(a) levels are cardiovascular risk factors [27,28]. The converse, critical for 
evaluation of the therapeutic hypothesis of inhibition, that lowering lipoprotein(a) levels can 
confer cardiovascular protection has not yet been evaluated. With access to centralized medical 
records available to research in Finland, we utilized the strong lipoprotein(a) lowering variants 
discovered here to evaluate the impact of lipoprotein(a) lowering via Mendelian randomization. 
Using a Cox proportional hazards model for incident cardiovascular disease in these cohorts 
(adjusted for age, gender and therapies), the composite LPA variant was found to protect against 
coronary heart disease (Hazard Ratio HR = 0.79, P = 6.7×10-3), demonstrating that lowering 
lipoprotein(a) levels are likely to confer protection for cardiovascular diseases. We confirmed 
this finding using three independent non-Finnish datasets: an early onset myocardial infarction 
dataset of 18,000 individuals and two studies from the Estonian Biobank (4,600 and 7,953 
individuals respectively), which collectively replicated the observation that the LPA variants 
confer cardioprotective effect (OR = 0.87, P = 0.016).  
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Figure 4.6: Boxplots for the known and novel associations 
The normalized Z-scores are shown for the homozygous alternates, heterozygous and 
homozygous reference individuals on the left, while the log of the unnormalized values are 
shown on the right for the 3 genotypes. 
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Figure 4.6: Boxplots for the known and novel associations (Continued) 
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Figure 4.6: Boxplots for the known and novel associations (Continued) 
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Figure 4.6: Boxplots for the known and novel associations (Continued) 
  
  
 
 
 
 
 
  
197 
 
After meta-analyzing all the datasets, the final odds ratio was found to be 0.84 (P = 3×10-
4, Figure 4.7). Similar to observations previously reported for PCSK9 (which induces 
cardioprotection through the lowering of low density lipoprotein levels) [29], we found 227 
individuals who are homozygous or compound heterozygous for the two LPA splice variants 
with no evidence for increased morbidity or mortality based on National Health Records. This 
suggests that reduction of lipoprotein(a) is well-tolerated and might constitute a potential drug 
target for cardiovascular diseases (Table 4.6). 
In addition, we observed novel associations were observed for the TBPL2, FGL1, MS4A2 
and ATP2C2 variants. The R331X variant in the TATA Box Binding Protein Like 2 gene (TBPL2) 
was associated to decreased levels of galectin-3 (?̂? = -0.46, P = 9.4×10-9 or -1.77 ng/dL per 
allele). Increased galectin-3 levels have previously been associated with increased risk for heart 
failure, chronic kidney disease and diabetes [30,31,32,33]. The TBPL2 gene encodes a widely 
expressed transcription factor that has been described to be involved in myoblast differentiation 
[34] and Tbpl2-/- mice and zebrafish have defects in reproduction and haematopoiesis [35,36]. 
We did not observe any association between TBPL2 R311X and cardiovascular or diabetes 
outcomes. 
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Figure 4.7: Forest plot for the LPA splice variants with cardiovascular diseases. 
The cardiovascular diseases are defined as coronary heart disease (CHD), ischemic heart disease 
(IHD), heart failure (HF) or myocardial infarction (MI). 
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Table 4.6: Correlations between the combined LPA variant and various disease states 
The rows with significant correlation between the levels of the biomarker and disease status (P<1e-03) are shaded in blue and the rows 
with significant association (P<=0.05) between the variant and disease status (allelic or homozygous tests) are highlighted in red text. 
 T-test 
Association of combined 
LPA variant with Lp(a) 
levels adjusted for disease 
Association of combined LPA variant 
with disease 
Association of combined LPA homozygotes with 
disease 
Disease 
Higher 
Lp(a) 
levels 
Lower 
Lp(a) 
levels 
N Beta P-value N cases 
N 
controls Beta P-value 
Case 
aa 
Case 
Aa 
Case 
AA OR P-value 
Cardio vascular 
disease 6.73E-04 9.99E-01 6696 -0.607 3.03E-81 2272 23508 -0.112 7.73E-02 12 302 1958 0.77 4.99E-01 
Coronary heart 
disease 8.19E-04 9.99E-01 6696 -0.607 2.81E-81 1645 24135 -0.153 3.86E-02 6 215 1424 0.53 1.56E-01 
Myocardial 
infarction 1.04E-02 9.90E-01 6696 -0.608 1.91E-81 953 24827 -0.148 1.18E-01 3 125 825 0.46 2.23E-01 
Acute coronary 
syndrome 1.23E-02 9.88E-01 6696 -0.608 2.20E-81 1286 24494 -0.111 1.70E-01 6 171 1109 0.69 4.81E-01 
Stroke 3.72E-02 9.63E-01 6696 -0.608 2.21E-81 1038 24742 -0.048 5.80E-01 8 140 890 1.16 6.94E-01 
Major adverse 
cardiac events 4.30E-02 9.57E-01 6696 -0.608 2.12E-81 3207 22573 -0.057 2.87E-01 20 442 2745 0.93 8.17E-01 
Ischemic heart 
disease 3.02E-01 6.98E-01 6696 -0.609 1.71E-81 2757 23023 -0.009 8.78E-01 19 391 2347 1.04 9.01E-01 
Cancer 6.43E-01 3.57E-01 6696 -0.608 2.33E-81 1934 23846 0.079 2.00E-01 14 296 1624 1.09 7.70E-01 
Rheumatoid 
arthritis 9.13E-01 8.68E-02 6696 -0.608 2.83E-81 1149 24631 0.015 8.53E-01 10 162 977 1.33 3.53E-01 
Asthma 9.40E-01 5.97E-02 6696 -0.608 2.40E-81 3137 22643 0.025 6.11E-01 19 460 2658 0.90 7.26E-01 
Heart failure 9.81E-01 1.92E-02 6696 -0.608 2.86E-81 1557 24223 0.044 5.26E-01 14 226 1317 1.38 2.58E-01 
High blood 
pressure 9.98E-01 2.00E-03 6696 -0.607 4.07E-81 5197 20583 0.070 9.71E-02 47 757 4393 1.49 2.20E-02 
Diabetes 1.00E+00 5.27E-07 6696 -0.607 2.12E-81 2866 22914 0.030 5.70E-01 22 414 2430 1.17 4.65E-01 
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The 1-bp c.545_546insA frameshift in the Fibrinogen-like 1 gene (FGL1) was associated 
with increased D-dimer levels (?̂? = 0.21, P = 6.1×10-6 or 52.23 ng/mL per allele). D-dimers are 
products of fibrin degradation and their concentration in the blood flow is clinically used to 
monitor thrombotic activity. The role of FGL1 in clot formation remains unclear: although FGL1 
is homologous with fibrinogen, it lacks the essential structures for fibrin formation, with one 
study suggesting its presence in fibrin clots [37]. In addition, given prior links between variants 
associated with D-dimer levels and stroke, we utilized the same Mendelian randomization 
approach as for LPA above and found a nominally significant association between FGL1 
c.545_546insA and increased risk of ischemic stroke (OR = 1.32, P = 0.024). If replicated, this 
would be consistent with modest risk increase for stroke that other variants associated to 
circulating D-dimer levels, such as reported for variants in coagulation Factor V, Factor III and 
FGA [38].  
We found suggestive associations for the c.637-1G>A splice variant in the membrane-
spanning 4-domains, subfamily A, member 2 gene (MS4A2) with triglycerides (Pdiscovery = 
7.80×10-5, Pdiscovery+replication = 1.31×10-6, ?̂? = 0.14 or 0.14 mmol/L per allele). This observation is 
consistent with our previously published study of 631 individuals in the DILGOM subset of 
FINRISK showing that whole blood expression of MS4A2 was strongly negatively associated 
with total triglycerides (?̂? = -1.62, P = 2.1×10-27) [39] and a wide range of systemic metabolic 
traits[40].  A similar but insignificant trend was observed in 15,696 individuals from the 
D2D2007, DPS, FUSION, METSIM and DRSEXTRA cohorts (?̂? = 0.04, P = 0.32). The MS4A2 
gene encodes the β-subunit of the high affinity IgE receptor, a key mediator of the acute phase 
inflammatory response.   
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The c.2482-2A>C splice variant in the ATPase Ca++ Transporting Type 2C Member 2 
gene (ATP2C2) was associated with increased systolic blood pressure (Pdiscovery = 1.25×10-5, 
Pdiscovery+replication = 1.3×10-6, ?̂? = 0.12 or 2.13 mmHg per allele (an association that is undisturbed 
by correction for lipid lowering medication (?̂? = 0.12, P = 1.75×10-5) or blood pressure lowering 
medication (?̂? = 0.13, P = 1.3×10-5)). Based on its structure, ATP2C2 is predicted to catalyze the 
hydrolysis of ATP coupled with calcium transport. Interestingly, the ATP2C2 c.2482-2A>C 
variant is also significantly associated to several highly correlated immune markers, such as 
granulocyte colony-stimulating factor (?̂? = 0.26, P = 6.98×10-7), interleukin-4 (?̂? = 0.27, P = 
2.48×10-6), interferon-γ (?̂? = 0.26, P = 3.24×10-6) and interleukin-6 (?̂? = 0.25, P = 4.58×10-6).   
 
DISCUSSION 
In this study, both replicated results and novel associations demonstrate the association of 
low-frequency LoF variants with various complex traits and diseases. In addition, we discovered 
a novel cardiovascular protective effect from splice variants in the LPA gene, suggesting that 
knocking down levels of circulating Lp(a) can confer a protection from cardiovascular diseases. 
Given that we detected numerous individuals in these adult population cohorts, healthy and in 
the expected Hardy-Weinberg proportions, carrying a complete knockout of LPA (homozygous 
or compound heterozygous for the 2 splice variants), this suggests that knocking out the gene in 
humans does not result in severe medical consequences. As such, this study provides a 
substantial body of human data that LPA may be an effective target for therapeutic purposes.  
As more Finnish samples are being sequenced, these enriched variants can also be 
imputed with high precision to the large number of existing samples with array-based GWAS 
genotypes. This advantage is likely to be more pronounced for the much larger pool of missense 
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variation – while one can presume all LoF variants in a gene might have a comparable effect on 
phenotype (and thereby burden tests of LoF variants in an out-bred sample is not at a great 
disadvantage compared to isolated populations), it is evident that many rare missense variants 
within the same gene will not all have the same impact on gene function. Thus the ability to 
assess single low-frequency variants conclusively, especially since they will include an excess of 
damaging variants enriched through a bottleneck, rather than perform burden tests on 
heterogeneous sets of extremely rare variants, will offer substantial ongoing advantage to 
isolated population studies as in recent findings. The Finnish population, with the concomitant 
advantage of existing genome-wide profiling of tens of thousands of individuals and numerous 
bio-repositories integrated with population-wide medical registry information, is well-positioned 
to be at the forefront of this new wave of discovery. 
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MATERIALS AND METHODS 
Exome sequencing quality control, annotation and filtering 
Raw Binary Sequence Alignment/Map (BAM) files from the various projects were 
jointly processed at the Broad Institute and joint variant calling was performed on all exomes to 
minimize batch differences. We annotated variants using a custom pipeline (MacArthur et al., 
unpublished) and we required all variants to pass the basic GATK filters and required all 
genotypes to have a quality score of ≥30, read depth of ≥10 and allele balance of between 0.3 
and 0.7 for heterozygous calls and <0.1 for homozygous calls. Allele counts and frequencies 
were calculated within the 3,000 individuals for Finns and NFEs respectively. 
 
Sequenom genotyping 
Genotyping was performed using the iPLEX™ Gold Assay (Sequenom® Inc.). Assays 
for all SNPs were designed using the eXTEND suite and MassARRAY Assay Design software 
version 3.1 (Sequenom® Inc.). Amplification was performed in a total volume of 5µL containing 
~10ng genomic DNA, 100nM of each PCR primer, 500µM of each dNTP, 1.25 x PCR buffer 
(Qiagen), 1.625mM MgCl₂and 1U HotStar Taq® (Qiagen). Reactions were heated to 94 °C for 
15 min followed by 45 cycles at 94 °C for 20 s, 56 °C for 30 s and 72 °C for 1 min, then a final 
extension at 72 °C for 3 min. Unincorporated dNTPs were SAP digested prior to iPLEX™ Gold 
allele specific extension with mass-modified ddNTPs using an iPLEX Gold reagent kit 
(Sequenom® Inc.). SAP digestion and extension were performed according to the 
manufacturer’s instructions with reaction extension primer concentrations adjusted to between 
0.7-1.8µM, dependent upon primer mass. Extension products were desalted and dispensed onto a 
SpectroCHIP using a MassARRAY Nanodispenser prior to MALDI-TOF analysis with a 
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MassARRAY Analyzer Compact mass spectrometer. Genotypes were automatically assigned 
and manually confirmed using MassARRAY TyperAnalyzer software version 4.0 (Sequenom® 
Inc.). The variants were then checked for concordance in allele frequencies with the exome 
sequencing data. 
 
Phenotyping 
Data on disease status from National Health registers (Hospital Discharged Registers 
maintained by THL (Institute for Health and Welfare, Finland), Cause of Death Register, 
Statistics Finland and Prescription Medication Register, THL) for FINRISK, Health2000 and the 
Young Finns Study participants of this study were collected and curated. A description of each 
cohort is provided in the Supplement. 
 
Analyses of RNA sequencing data 
To analyze the effects of the LoF variants on gene expression, we used RNA sequencing 
data from two major studies: the GEUVADIS project [19] with RNA sequencing data from 
lymphoblastoid cell lines of 462 individuals participants from the 1000 Genomes Project [41]), 
and the GTEx project with RNA-sequencing data from a total of 175 individuals with 1-30 
tissues each (http://www.broadinstitute.org/gtex/) [20]. The processing of the GEUVADIS data 
and the methods for allele-specific expression analysis are described in Lappalainen et al. [19] 
and the GTEx data were analyzed using similar methods. Allele-specific expression analysis was 
used primarily to capture nonsense-mediated decay. Additionally, to assess whether LoF variants 
lead to decreased exon expression levels overall or for individual exons, we calculated an 
empirical p-value for each exon of all the LoF genes with respect to all other exons genome-
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wide, denoting the proportion of all exons where carriers of the LoF variants are more extreme 
than in the each studied exon in LoF variant genes. The analyses were performed separately in 
each studied tissue: lymphoblastoid cell lines from the GEUVADIS data and nine tissues from 
the GTEx data. The significance threshold after correcting for the total number of tested exons 
across all tissues is 0.05/1070 = 4.67×10-5. 
 
Statistical analyses and methods 
Inverse rank-based normalization was performed on the quantitative measurements in 
males and females separately, with linear regression residuals using age and age2 as covariates. 
Linear regression was then performed on the normalized Z-scores using R to obtain the statistics 
for the associations. We tested the correlations between the quantitative measurements and 
disease outcomes using two one-tailed t-tests to assess the significance of observing higher levels 
of the quantitative measurements in cases (individuals with the disease outcomes) versus controls 
(individuals without the disease outcomes), as well as lower levels of the quantitative 
measurements in cases versus controls. To test the association of the variants with the prevalent 
disease outcomes, we performed a logistic regression in R to obtain the reported statistics. In 
addition, a Fisher’s Exact Test on the homozygous counts in cases and controls were performed 
to test for association with the homozygotes. The results for the LPA with cardiovascular disease 
association from MIGen ExA and the Estonian Biobank were meta-analyzed using METAL [42] 
and the combined results with FINRISK were obtained using the Fisher’s Combined P method 
with 4 degrees of freedom. 
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Associations between MS4A2 c.637-1G>A, gene expression and triglycerides 
We fit a linear model in which the log2-normalised gene probe expression of individual i 
was regressed on the LoF genotype, which was encoded as Xi = 0, 1 or 2 for the LoF genotypes -
/-, +/- or +/+ respectively and association analysis of MS4A2 gene expression and triglycerides 
was performed as previously reported [39]. Briefly, we used a multivariate linear regression 
adjusted for age, gender, and use of cholesterol or blood pressure lowering medication. We 
further tested for association between MS4A2 c.637-1G>A and triglycerides using a 2-sided t-
test. 
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CHAPTER 5 
Concluding Remarks 
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OVERVIEW 
 Whole-exome and whole-genome sequencing has revolutionized the way we map genes 
and variants in Mendelian and complex diseases in the past few years. In the near future, these 
technologies might be routinely used for both research as well as applied clinical diagnosis to 
identify, understand and treat genetic causes for various diseases. As approaches and methods for 
discovering causal or risk variants mature, we can expect the interpretation of these variants to 
remain an important challenge for human disease genetics. 
 
MAJOR FINDINGS 
Chapter 2 
 In this chapter, we discovered a small but significant 5% contribution to autism risk from 
rare recessively-acting variants on the autosomes and X-chromosome. The excess was mainly 
driven by genes that found to be expressed in the brain. While we found some genes that were 
previously implicated in Mendelian diseases, there was no evidence for specific genes. 
 
Chapter 3 
 In this chapter, we discovered 3 families with autism and intellectual disability with rare 
homozygous missense mutations in the DHCR24 gene. We developed a novel statistical method 
to evaluate the significance for such an observation in outbred and consanguineous populations. 
Finally, we adapted a yeast biochemical assay to evaluate the efficiency of desmosterol to 
cholesterol synthesis for these missense variants to understand the functionality and role of these 
rare missense variants in autism and intellectual disability. 
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Chapter 4 
 In this chapter, we explored the genetic architecture of the Finnish population versus 
other European populations and found that there are proportionally more deleterious rare and 
low-frequency variants in Finns. We genotyped 83 loss-of-function low-frequency variants in a 
large number of Finnish samples and associated these variants with 60 biochemical 
measurements and traits. In doing so, we discovered a strong association between splice variants 
in LPA with decreased circulating lipoprotein(a) levels and this translated to protection against 
cardiovascular heart disease. 
 
FUTURE DIRECTIONS 
 With the decreasing costs of whole-genome and whole-exome sequencing, genetic 
mapping in human diseases has been revolutionized since 2009. The interpretation of genetic 
variation in the human genome remains a challenge, even for an individual genome [1]. While 
the interpretation of predicted loss-of-function variants in the human exome is easier, such 
variation comprise of a tiny proportion of the whole human exome. The discovery of missense 
and synonymous variation from healthy and diseased human exomes will no doubt be the norm 
rather than abnormality. As such, it would seem that rapid functional assays to allow the 
assessment and interpretation of such variants with unknown significance will be increasingly 
important. In addition, as such whole-genome and whole-exome sequencing become the norm 
for clinical diagnoses, it will be extremely important to develop and adapt new technologies that 
can allow for a rapid and unbiased way of assessing the “functionality” of such variants. 
 
 
218 
 
Rapid assessment of functionality of human coding variation 
 As we have learnt from our DHCR24 project described in Chapter 3, such functionality 
assays are not necessarily straightforward or obvious, even for a cholesterol gene. For instance, 
although DHCR24 is involved in the synthesis of cholesterol from desmosterol, this might not be 
the best or most suitable assay for DHCR24 in some instances. The gene has also been 
demonstrated to play a role in regulating the oxidative stress response pathway by binding to p53 
and another “functionality” assay that might be suitable for studying the role of variation in 
DHCR24 can involve testing the strength of p53 binding rather than cholesterol synthesis.  
Moreover, a genome-wide “functionality” assay to probe all variation across all genes 
will be extremely difficult to design. One genomics approach that has been suggested is the use 
of high-throughput RNA sequencing to correlate the missense variations with gene expression. 
This approach might work in evaluating which loss-of-function variants result in reduced gene 
expression as a consequence of nonsense-mediated decay. However, if the missense variants 
result in decreased protein interaction, DNA binding or activation of a second messenger within 
the cell, this will not necessarily translate to an interpretable readout of the functionality of such 
missense variants. 
 
Non-coding variation in the human genome 
Understanding the role of non-coding variation in the human genome from whole-
genome sequencing will prove to be extremely difficult but potentially important. As discussed 
earlier, the yield of genetic discoveries in 250 clinical exomes is approximately 25% [2], 
suggesting that the remaining 75% have yet to be discovered, either from coding variants of 
unknown significance, non-coding variants or other unusual modes of inheritance. One of the 
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earliest papers that have explored this question is by Weedon et al. where the authors discovered 
6 recessive mutations in ten families with pancreatic agenesis in a ~400 bp enhancer region 
downstream of PTF1A [3]. Such studies are extremely difficult as they involve interrogating the 
99% non-coding regions of the human genome. However, we might expect human disease 
genetics to move rapidly into this area as we become more effective in understanding coding 
variation in the human genome. 
 
Unusual modes of inheritance 
As we become more efficient in our discovery of rare disease-causing or disease-
association variants in Mendelian and complex diseases, we can expect an increasing amount of 
research into unusual modes of inheritance that can aid in our understanding of disease 
etiologies. A recent paper described the discovery of a recessive allele (Arg229Gln) in the 
NPHS2 gene that results in disease only when it is associated with certain 3’ alleles in NPHS2 as 
a result of a dominant-negative effect [4]. As a result, the inheritance patterns in such affected 
families do not necessarily follow a classic recessive mode of inheritance. These unusual modes 
of inheritance are extremely exciting and provide novel insights into unusual genetic patterns 
that can result in disease manifestation. It is possible that such patterns of inheritance might 
prove to be the norm in disease genetics, given that there is still a vastly understood portion of 
causal or associated risk underlying Mendelian and complex diseases. 
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Founder populations 
 Other than the Finnish population described in Chapter 4, there are several other founder 
populations that can provide advantages for mapping genes and variants in Mendelian and 
complex diseases using whole-exome or whole-genome sequencing such as the Hutterites [5], 
Ashkenazi Jews [6] and French Canadians [7]. Even though there might be genes and variants 
that were lost as a result of bottlenecks in these populations, the unique genetic architecture of 
these populations can aid in the discovery of rare and low-frequency variants in Mendelian and 
complex diseases. 
 
A POSTSCRIPT 
 It is incredibly exciting that human genetics discovery has been revolutionized by 
improving technologies developed through decades of research. We are now in a new era of 
human disease genetic mapping as a result of the wide application of whole-exome and whole-
genome sequencing. With this come new challenges and opportunities for developing new 
methodologies and approaches to understand the coding variation in our exomes and how 
naturally occurring human variation can confer risk for diseases. Personally, I find it extremely 
challenging but exciting to be a human geneticist in this era where we can now rapidly identify 
and understand human variation in diseases. Hopefully these discoveries and knowledge can 
translate into treatment and drug discovery for various Mendelian and complex diseases at a 
much faster pace in the next decade. 
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